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Abstract 
Background 
Chronic rhinosinusitis without nasal polyps (CRSsNP) is a heterogeneous condition with 
common symptoms, clinical and radiological findings.  CRSsNP is typified by inflammation of 
the sinonasal epithelium and development of fibrosis, yet its precise pathophysiology 
remains elusive.    Recently stromal cells have been shown to act like immune effector cells 
in orchestrating chronic inflammation.  Histological analysis of tissue biopsies from patients 
with CRSsNP demonstrates recruitment of circulating inflammatory cells, though the precise 
role of structural cells such as epithelial and fibroblast cells in CRSsNP remains to be 
discovered.  
Aims 
1. (a) Recruit phenotyped cohorts of control & CRSsNP participants.   
(b) Characterise recruited CRSsNP participants’ tissue samples and isolated epithelial & 
fibroblast cells. 
2. Assay the sinonasal environment to determine any association between, infection, 
inflammation and remodelling. 
3.  Identify clusters of genes differentially expressed in CRSsNP & control participants. 
Methods 
Cohorts of healthy control and CRSsNP participants were recruited.  Matched tissue biopsy, 
epithelial and fibroblast cells were harvested together with clinical, radiological, 
microbiological and mucosal swab data.  Tissue and cellular samples were characterised to 
confirm their identity and disease status.  The sinonasal environment was characterised 
from mucosal swabs and analysed for a range of 40 human disease biomarkers.  
Transcriptome analysis was performed using microarrays and RNA sequencing with 
downstream bioinformatics investigation of the data.   
Results 
47 age and sex matched CRSsNP and control participants were recruited, differing 
significantly in symptom and radiological scores.  Histological analysis of tissue biopsy 
specimens was consistent with CRSsNP and control samples.  Matched epithelial and 
fibroblast cells were generated.  Assay of the sinonasal microenvironment identified 13 
discriminant mediators separating CRSsNP samples from controls using a novel, non-invasive 
technique.  Transcriptomics identified 239 differentially expressed genes in CRSsNP tissue 
biopsy samples.  Cellular samples differed significantly from their matched tissue biopsies. 
Conclusions 
This thesis characterises a cohort of tightly defined CRSsNP patients and healthy controls to 
investigate the potential role of epithelial and fibroblast cells in CRSsNP.  Transcriptomics has 
demonstrated clusters of genes upregulated in CRSsNP, however changes were not 
consistent in matched cellular samples questioning the validity of cellular models in CRSsNP.  
Additionally, a straightforward, non-invasive measure of the CRSsNP cytokine profile has 
been demonstrated.  The mediators identified in these assays could potentially be 
developed as biomarkers of sinonasal inflammation as an adjunct in patient management. 
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1 Background 
1.1 Anatomy of the paranasal sinuses 
The paranasal sinuses consist of three paired and one unpaired air filled spaces within the 
bones of the skull, namely the maxillary, frontal, ethmoid and sphenoid sinuses (Figure 1).  
All four sinuses are located around the nasal cavity into which they drain.  The sinuses are 
lined by pseudostratified ciliated epithelium with goblet cells, which produce mucus along 
with the sub-epithelial mucus glands to keep the sinuses clear (Figure 2).  The paranasal 
sinuses collectively humidify and warm inspired air on its passage to the lungs, increase the 
resonance of speech, reduce the weight of the skull and serve as protective crumple zones in 
facial and head trauma (Dalgorf and Harvey, 2013).  Human paranasal sinuses develop from 
the viscerocranium, the origins of the maxillary sinus are seen after the 10th week of 
embryonic life and the sinuses continue to develop into adolescence.  
 
 
Figure 1.  Anatomy of the paranasal sinuses.  (a)  Leonardo da Vinci’s depiction of a skull.  
The right side of the skull has been sectioned to demonstrate the frontal and maxillary 
sinuses.  The close proximity of the sinuses, orbit and dentition is shown as infections of 
these anatomical areas had significant morbidity and mortality in the pre-antibiotic era.  
Image taken from (Mavrodi and Paraskevas, 2013).  (b)  Schematic illustration of the 
paranasal sinuses.  Image adapted from (Drake, 2014). 
 
(a) (b) 
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Figure 2.  Mucociliary clearance of the paranasal sinuses.  Here the mucociliary pathway for 
the maxillary sinus is shown from its most inferior dependent part along the walls of the 
sinus to the nasal cavity via its ostium.  IT = inferior turbinate, MT = middle turbinate, NS = 
nasal septum.  Image taken from (Suh and Kennedy, 2011)  
 
1.2 Rhinosinusitis 
Rhinosinusitis refers to inflammation of the nose and paranasal sinuses resulting in the 
production of symptoms.  Rhinosinusitis is a more appropriate term than sinusitis as 
inflammation of the nose and paranasal sinuses coexist and are concurrent in most 
individuals (Fokkens et al., 2012).  Infection typically spreads from the nasal cavities to the 
sinuses and in the rare cases where infection may originate in the sinus, it will spread 
retrogradely into the nose.   
Rhinosinusitis is temporarily categorised into acute rhinosinusitis, with symptoms lasting less 
than four weeks and chronic rhinosinusitis with symptoms in excess of 12 weeks.  The 
overwhelming majority of rhinosinusitis episodes worldwide are short-lived acute viral 
infections, however the chronic form causes significant patient morbidity and as a result 
consumes vast amount of health resources (section 1.3.1.). 
Acute rhinosinusitis typically is caused by respiratory viruses such as Rhinovirus, Influenza A 
and B, Respiratory Syncytial Virus, Parainfluenza, Adenovirus and Human metapneumovirus.  
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An acute episode of viral rhinosinusitis usually has maximal symptoms after a few days and is 
resolved within a week.  Acute bacterial rhinosinusitis is much less common and typically 
follows a viral rhinosinusitis, with an initial reduction in symptoms and a second more severe 
peak of symptoms - referred to as a ‘double sickening’ with associated fever, mucopurulent 
secretions and raised serum inflammatory markers (Figure 3). 
 
Figure 3.  Acute viral versus bacterial rhinosinusitis.  A second peak in symptoms or ‘double 
sickening’ together with mucopurulent nasal secretions, fever and raised serum 
inflammatory markers is typical of an acute bacterial rhinosinusitis.  Image adapted from 
(Fokkens et al., 2012). 
1.3 Chronic rhinosinusitis 
The clinical and research definition of chronic rhinosinusitis (CRS) is an inflammation of the 
nose and paranasal sinuses that is present for more than 12 weeks (Fokkens et al., 2012).  
Chronic rhinosinusitis is not regarded simply as a prolonged episode of acute rhinosinusitis 
although its pathophysiology remains elusive.  However, it is currently best described as a 
dysfunctional host-environment interaction occurring in the nose and paranasal sinuses.  
CRS is presently phenotyped into chronic rhinosinusitis without nasal polyps (CRSsNP) and 
chronic rhinosinusitis with nasal polyps (CRSwNP).  Historically, CRSsNP was thought to be a 
result of a severe or incompletely treated acute rhinosinusitis and CRSwNP due to severe 
atopy, though these hypotheses have now been superseded by advances in our 
understanding of CRS pathophysiology (section 1.3.6). 
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1.3.1 Epidemiology 
The nose is the first point of contact between environmental microbes, pollutants, allergens 
and the respiratory system, and it is therefore not surprising that rhinosinusitis is so 
common.  Epidemiological data indicate that the prevalence of CRS in the general population 
is approximately 12% (Meltzer et al., 2004, Hastan et al., 2011) and greater than chronic 
back pain or diabetes (DiabetesUK, 2015) with annual healthcare costs in excess of $22 
billion  in the United States (Smith et al., 2015).  In 2014 the direct healthcare costs in the US 
were estimated to be between $6.9 and $9.9 billion, having risen from $5.8 billion in the late 
1990’s (Ray et al., 1999), with indirect costs of $13 billion.  The high cost of treatment 
reflects the vast number of affected individuals, chronicity of symptoms and the percentage 
of patients who are refractory to current maximal medical management (Lal et al., 2009) and 
thus require surgical intervention (Fokkens et al., 2012).  CRS is one of our commonest 
medical conditions and the fifth most common indication for antibiotic prescription (McCaig 
and Hughes, 1995).  Patients with CRS have been shown to have significantly impaired 
quality of life, with some patient reported outcome scores ranking as highly as COPD or 
angina (Soler et al., 2011).  
The current standard maximal medical therapy culminates in systemic antibiotics and 
steroids, yet failure rates remain high. Thus there are approximately 500,000 sinus surgical 
procedures per year (Owings and Kozak, 1998).  UK figures from clinical coding of hospital 
episode statistics HESONLINE (2015) shows in the order of 60,000 secondary care diagnoses 
and 15,000 associated sinus surgery procedures, meaning approximately one in four people 
elects to have surgical treatment.  Surgical intervention is effective in the short term, but 
often the disease process recurs (Hopkins et al., 2009b).  Such statistics for surgical therapy 
illustrate that our current medical therapies, either alone or combined with surgery are not 
effective.  This is not surprising, given that the basic disease mechanisms and pathogenesis 
of CRS are not understood (Van Crombruggen et al., 2011).  
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1.3.2 Diagnosis 
Diagnosis of CRS is currently made from patients symptoms with corroborative evidence 
identified from endoscopic sino-nasal assessment combined with computerised tomography 
(CT) scanning.  A pan-European consensus document has been published to standardise the 
diagnosis and management approach for CRS.  This collaborative, evidence based position 
paper is currently in its third revision (Fokkens et al., 2012) and seeks to standardise current 
clinical knowledge of CRS and help set the agenda for research based on the deficiencies in 
understanding of sinusitis.  
Diagnosis of CRS is currently defined as an inflammation of the nose and paranasal sinuses of 
at least 12 weeks duration of: 
1. two or more symptoms, one of which should be nasal blockage or nasal discharge 
2.  either facial pain/pressure or loss of smell 
3.  corroborative changes in the endoscopic assessment or CT scan  
 In addition there are a number of related general symptoms associated with CRS such as 
irritation of the larynx, pharynx and trachea - sometimes causing cough, ear pain and 
pressure and generalised fatigue, however at present these distant symptoms do not form 
part of the main diagnostic criteria and can be subject to other influences such as gender 
(Ference et al., 2015). 
The overall severity of CRS can be estimated using a variety of patient reported outcome 
measures, such as the well validated Sino-nasal Outcome Test-22 (SNOT-22) questionnaire 
(Hopkins et al., 2009a, Morley and Sharp, 2006, Piccirillo et al., 2002) which generates a 
severity score between 0-110 and can be stratified between mild (8-20), moderate (>20-50) 
and severe (>50) (Toma and Hopkins, 2016).  The Lund-Mackay radiological severity score 
(Lund and Mackay, 1993) is calculated based on the degree of sinus opacification on CT scan 
and gives a score between 0-24 (Table 1). 
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Anatomical sinus 
group/drainage pathway 
Right side Left side 
Frontal sinus 0/1/2 0/1/2 
Maxillary sinus 0/1/2 0/1/2 
Anterior ethmoid sinuses 0/1/2 0/1/2 
Posterior ethmoid sinuses 0/1/2 0/1/2 
Sphenoid sinuses 0/1/2 0/1/2 
Ostiomeatal complex 0/2 0/2 
Table 1.  Lund-Mackay scoring system for degree of sinus involvement.  Points are accrued 
for the degree of opacification of each sinus group (0 = normal, 1 = partly opacified, 2 = 
completely opacified) and the important drainage pathway of the ostiomeatal unit (0 = 
unaffected, 2 = opacified).  A combined score between 0-24 is generated from the sinus 
groups bilaterally. 
 
1.3.3 Classification 
The current literature defines CRS as a disease of the nasal and paranasal sinus mucosa 
present for more than 12 weeks with mucosal changes that vary from inflammatory 
remodelling to the formation of nasal polyps (Fokkens et al., 2012).  It represents a spectrum 
of diseases with a common end result of chronic sinonasal inflammation and fibrotic airway 
remodelling.  CRS is subtyped principally by the presence or absence of nasal polyps on 
examination of the nose either by direct inspection, endoscopic assessment and sometimes 
supplemented by CT imaging (Figure 4).  The aetiopathogenesis of CRS is, however, poorly 
understood.  It is classified as sinonasal inflammation, but is currently defined only by 
symptomatology rather than specific cellular or histological appearances.  The symptoms are 
often attributable to changes in sinonasal mucosa, mucus or mucociliary clearance leading to 
sinonasal ostial blockage and impaired function.   
Histological assessment of polypoid and non-polypoid tissue specimens demonstrates that 
they represent differing disease pathologies.  Chronic rhinosinusitis without nasal polyps 
(CRSsNP) is characterised by sinonasal fibrosis, basement membrane thickening, epithelial 
damage, mononuclear cell infiltration and goblet cell hyperplasia (Kou et al., 2012).  Chronic 
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rhinosinusitis with nasal polyps (CRSwNP) is characterised by basement membrane 
thickening, epithelial damage, stromal oedema and pseudocyst formation (Bachert et al., 
2000, Kou et al., 2012).  The basement membrane thickening is the end result of a dense 
fibrotic response typified by accumulation of fibronectin and type I, III and V collagens 
(Pawankar and Nonaka, 2007).  Both diseases also have a differing T helper cell profile and 
cytokine signature.  CRSsNP has been shown to be predominantly a Th1 inflammatory 
environment with type 1 interferon gamma (IFN-γ) as the predominant cytokine along with 
the pro-fibrotic transforming growth factor β (TGF- β).  In contrast CRSwNP is associated 
with a Th2 and IL-5 predominant inflammatory environment (Van Crombruggen et al., 2011).   
 
Figure 4.  Endoscopic photographs of normal nasal cavity mucosa. CRS without nasal polyps 
(CRSsNP) and CRS with polyps (CRSwNP). Accompanying each photograph, H&E stained 
sections illustrate differing disease histopathology.  CRSsNP demonstrates epithelial cell loss, 
fibrosis and immune cell chemotaxis. CRSwNP shows sub-epithelial oedema, pseudocyst 
formation and absence of fibrosis. Image adapted from (Kou et al., 2012). 
 
In addition to the well-established phenotypes of polypoid and non-polypoid CRS, various 
sub-phenotypes or endotypes have been proposed in an attempt to further sub-categorise 
the two heterogeneous polyp/non-polypoid groupings (Akdis et al., 2013, Tomassen et al., 
2016).  Such sub-classification is greatly needed to help our understanding of CRS, however 
no doubt due to their novelty their use is not yet widespread.  
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1.3.4 Current treatments 
Chronic rhinosinusitis is principally managed using medical therapy, with surgical procedures 
reserved for cases that fail to respond to pharmacological management.  A percentage of 
patients are not responsive to a combination of medical and surgical treatments and have 
been termed ‘difficult to treat’ rhinosinusitis (Fokkens et al., 2012). 
1.3.4.1 Medical 
Current maximal medical therapy comprises corticosteroids either intranasal, systemic or 
both in combination with antibiotics and nasal irrigation (Dubin et al., 2007).  Corticosteroids 
have been shown to reduce the amounts of chemotactic cytokines produced from the nasal 
mucosa (Mullol et al., 2000, Xaubet et al., 2001) and reduce eosinophil viability and 
activation (Mullol et al., 1997, Mullol et al., 1995).  Corticosteroids act via intracellular 
glucocorticoid receptors, promoting an increase in anti-inflammatory cytokines including 
interleukin 10 (IL-10) and negative regulation of pro-inflammatory cytokines such as tissue 
necrosis factor α (TNF-α) and interferon-γ (IFN-γ).  Corticosteroids can be delivered either 
systemically or topically, with the topical route preferred to minimise the side effect from 
systemic absorption.  The main drawback to the topical route is the varied penetration of 
drug delivery to the nose & sinuses in the presence of obstructive nasal disease (Harvey et 
al., 2008, Grobler et al., 2008), however their use is supported by level 1 evidence from 
multiple published randomised controlled trials (Fokkens et al., 2012).  Antibiotics are 
frequently used to treat CRS in both primary and secondary care.  Short term antibiotics 
currently do not have any substantial evidence to support their use, with the exception of 
proven, culture positive exacerbations.  The use of long term antibiotics attracted significant 
interest following the increased survival of patients with diffuse pan bronchiolitis treated 
with erythromycin who were observed to achieve CRS symptom resolution (Nagai et al., 
1991, Kudoh et al., 1998).  Macrolide antibiotics have been shown to possess anti-
inflammatory effects at lower dosage than conventionally used for their anti-infective 
properties.  Unfortunately, despite the initial promise, a recent Cochrane review has found 
little evidence of their efficacy in CRS (Head et al., 2016).  However, it is worth noting that 
only five randomised controlled trials could be included in this review, each with small 
cohorts between 43 to 79 participants therefore further evidence on the efficacy of 
antibiotics in CRS is required (Bewick et al., 2016).  Nasal irrigation with either iso or 
hypertonic saline solution can be topically applied and its use is widespread.  The lack of 
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drugs and hence side effects in saline irrigation, makes it a popular choice among patients 
and physicians, however a recent Cochrane review has questioned the evidence for its use 
(Chong et al., 2016).   
Due to the lack of medical treatment evidence base for efficacy in CRS, pharmacological 
treatment has remained essentially unchanged over a time that has seen significant 
developments in the surgical management of CRS.  Medical therapy has also been relatively 
static over the last couple of decades in which time other chronic inflammatory conditions 
such as inflammatory bowel disease and rheumatoid arthritis have seen biological therapies 
revolutionise their treatments and patient outcomes.   To improve CRS management, similar, 
contemporary medical advances are required and are currently in their infancy such as the 
biological therapies dupilumab (monoclonal anti IL-4 & IL-13 Th2 cytokine inhibitor) (Bachert 
et al., 2016), mepolizumab (monoclonal anti IL-5) (Gevaert et al., 2011) and omalizumab 
(monoclonal anti IgE) (Pauwels et al., 2015, Gevaert et al., 2013).  There is currently an 
unmet need for further clinical trials of medical therapy for CRS.  
1.3.4.2   Surgical 
Within secondary care CRS is often found to be refractory to current pharmacological 
treatment with antibiotics and corticosteroids, leaving many patients facing the choice of 
surgery or persistent symptoms.  Failure of medical therapy typically results in patients 
having functional endoscopic sinus surgery (FESS) to resect diseased tissue, ventilate 
affected sinus groups and provide access for topical medical therapy.  Since its original 
description by Messerklinger in the 1980s (Messerklinger) FESS has become a widely 
accepted treatment for CRS.  As with any surgical procedure it is not without complications; 
including bleeding, ocular complications or a leakage of cerebrospinal fluid.  FESS is a time 
consuming and expensive intervention whose high disease recurrence may require frequent 
re-operation (Hopkins et al., 2009b). 
Advances in endoscopic surgical equipment, image guidance systems, surgical procedures 
and anaesthesia have improved the surgical management of CRS - with robotic surgery on 
the horizon.  However effective surgery is in the short-term, there remains a relatively high 
disease recurrence rate (Hopkins et al., 2009b).  Patients with post-surgical CRS recurrence 
face a frustrating cycle of revisiting previously failed medical and surgical interventions.  A 
current evidence based summary of the management of CRS is shown in Figure 5.  The lack 
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of medical treatment options is, however, not surprising when we consider the pathogenesis 
of CRS is not understood. 
 
1.3.5 Physiology of the sinuses 
Mucociliary clearance is essential to the maintenance of normal paranasal sinus physiology 
and health.  Paranasal sinuses are lined with respiratory pseudostratified ciliated epithelium 
with goblet cells, which together produce the mucus and then transports it with any trapped 
material posteriorly to the pharynx where it is swallowed.  The rate of mucociliary clearance 
is controlled by a combination of anatomical factors of the sinuses, biochemical components 
of the constituent mucus and physiological parameters.  The physiological factors co-
ordinate the mucus volume produced and the rate of ciliary clearance.  In health there are 
between 50 to 200 cilia per epithelial cell, each measuring approximately 5µm long.  Under 
normal conditions ciliary beat frequency varies from 9 to 15Hz which propels the mucus to 
the nasopharynx at approximately 3 to 25mm/min (Cohen, 2006).  This can be measured by 
a saccharin transit test, placing sweet tasting saccharin at the tip of the nose and asking the 
subject how long it takes to taste.  Cilia consist of a typical ‘9+2’ axoneme of microtubules, 
that when stimulated by ATP cause the dynein arms of the microtubules to move against 
one another and produce ciliary movement.  Cilia insert into the basal membrane in an 
organised orientation so they all beat in the same direction and efficiently transport mucus.   
The ciliary beat frequency can be altered by both temperature, mechanical, hormonal and 
autonomic stimuli in an attempt to clear particulate matter trapped within the mucus.  
Unlike the lower airways where coughing can be used in combination with mucociliary 
clearance, the paranasal sinuses rely exclusively on mucociliary clearance to maintain their 
normal health. 
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1.3.6 Pathophysiology of chronic rhinosinusitis 
Globally, the majority of rhinitis or sinusitis episodes constitute acute disease, and as such 
are usually self-limiting or respond to simple medical intervention.  The pathophysiology of 
acute sinus inflammation is well documented.  However, it is not clear why CRS develops 
with its persistent inflammatory response, sinonasal airway remodelling and chronic disease 
symptoms.  Multiple studies have demonstrated that the CRS sino-nasal tract does not 
demonstrate a significantly altered microbial flora (section 1.3.6.1).  Similarly, it has been 
shown that CRS is not typically the result from a specific host immune deficiency.   
The first significant attempt to address the pathophysiology of CRS was the fungal 
hypothesis, suggesting CRS was due to a disproportionate immune response to Alternaria 
species of fungi (Ponikau et al., 1999, Sasama et al., 2005, Hamilos and Lund, 2004).  
Numerous trials of antifungal therapy failed to corroborate the fungal hypothesis and this 
hypothesis has now been rejected.  Similarly, alterations in the leukotriene/prostaglandin 
axis have been hypothesised, but are not substantiated by the lack of response to 
leukotriene inhibitors.  Specifically for CRSwNP a ‘staphylococcal superantigen hypothesis’ 
has been proposed suggesting staphylococcal exotoxins drive a Th2 inflammatory response 
in combination with eosinophil and mast cell recruitment (Bachert et al., 2003).  However, 
superantigen effects have only been demonstrated in fewer than half of all CRSwNP 
patients, suggesting that superantigens may potentiate nasal polyps rather than be a direct 
cause (Van Crombruggen et al., 2011).  The ‘innate immune barrier hypothesis’ suggested 
defects in the innate immune barriers such as Toll-like receptors (TLRs) permit increased 
microbial stimulation and an accentuated immune response resulting in the phenotype of 
CRS (Kern et al., 2008, Ooi et al., 2008, van Drunen et al., 2012, Lane, 2009, Zhang et al., 
2013).  However the ‘innate immune barrier hypothesis’ does not explain the different 
phenotypes of CRSsNP and CRSwNP and the observed differences in their T helper cytokines.  
Finally following the observations of biofilms in periodontal disease (Ohlrich et al., 2009), the 
‘biofilm hypothesis’ suggests that in CRS bacteria organise themselves within biofilms to 
evade host defence mechanisms and therefore promote persistent inflammation (Foreman 
et al., 2012, Boase et al., 2013b).   
Resection of diseased surgical specimens from appropriately consenting patients in FESS 
procedures provides a valuable source of tissue for further investigation.  Histological 
analysis of CRS specimens has so far identified inflammatory cells, inflammatory cytokine 
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signatures and airway remodelling, though the precise pathophysiological mechanisms that 
cause the persistent, exaggerated sinonasal inflammation remain unclear.  This lack of 
disease understanding may perhaps explain the high proportion of patients refractory to 
current conventional pharmacological therapy.  The position of the sinonasal tract makes it 
highly accessible to the delivery of topical medical therapy.  As a result there are 
tremendous translational research opportunities to develop better topical nasal anti-
inflammatory approaches to treat this large patient population and hence reduce the 
number of operative procedures. 
Considerable, organised, international effort has gone into investigating the pathophysiology 
of CRS and our understanding of local sinonasal and upper airway immune mechanisms has 
greatly increased.  However, no one unifying molecular mechanism or pathway has been 
identified.  Therefore, CRS is still considered to be multifactorial, reflecting the numerous 
hypotheses and disease associations which have so far been described. 
1.3.6.1 Microbiology 
Historically the paranasal sinuses were thought to represent a sterile environment until 
Brook’s landmark publication (Brook, 1981), the first of many on the microbiology of the 
paranasal sinuses.   Early hypotheses from conventional, culture based assays suggested that 
CRS was due to the colonisation of the sinuses of CRS patients with more isolates of bacterial 
strains and possibly more pathogenic species including anaerobes than in healthy sinuses 
(Brook et al., 1996, Aral et al., 2003) (Brook, 2005).  More recent molecular techniques to 
study the microbiome (all of the microbial genes present) have allowed a more definitive 
understanding of the microbiology of the sinonasal cavities than traditional culture methods.  
Microbiome studies from a number of authors have not shown significant differences in the 
microbial environment of CRS patients compared to healthy controls (Aurora et al., 2013) 
(Ramakrishnan et al., 2016, Ramakrishnan et al., 2013, Wilson and Hamilos, 2014). As a 
result there is nowadays less emphasis on a ‘pathogen driven hypothesis’. 
Current literature suggests that CRS may be the result of activation of abnormal pro-
inflammatory and fibrotic responses to numerous inhaled particles and ubiquitous 
pathogens that may constitute normal sinonasal flora (Van Crombruggen et al., 2011).  In 
health, epithelia of the sinonasal airway are able to clear inhaled particles and organisms 
and to produce appropriate defensive immune responses to pathogens, yet maintain 
immunological tolerance of commensal flora.  The epithelium of the sinonasal airway has a 
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series of membrane bound and intracellular Pathogen Recognition Receptors (PRRs) 
including the Toll-like receptor (TLR), Nucleotide-binding oligomerization domain (NOD) 
receptors, RIG-I-like receptors (RLRs) and C-type lectin receptors (CLRs) (Takeuchi and Akira, 
2010) capable of recognising conserved universal microbial motifs including Pathogen 
Associated Molecular Patterns (PAMPs) and endogenous Damage Associated Molecular 
Patterns (DAMPs) or alarmins (see below).  A number of reports of the expression of TLRs in 
sinonasal mucosa in general agree that all TLRs are expressed in both healthy controls 
CRSwNP patients and CRSsNP patients (Ramanathan et al., 2007, Vandermeer et al., 2004).  
In both CRSsNP and CRSwNP, receptor for advanced glycation end-products (RAGE) 
receptors have been reported to be expressed at lower levels than in healthy sinonasal and 
upper airway mucosa (Van Crombruggen et al., 2012).  
 
1.3.6.2  Alarmins 
Alarmins or DAMPs constitute a variety of intracellular molecules and extra cellular matrix 
elements released following cellular injury that cause inflammation.  Their release from cells 
undergoing non-programmed cell death has the ultimate aim of restoring cellular and tissue 
architecture by inflammatory and reparative mechanisms.  Alarmins typically signal through 
activation of TLRs, RAGE and related PRRs (Piccinini and Midwood, 2010).  Sino-nasal cells 
are subject to a whole variety of different stimuli that may result in cellular injury and 
release of alarmins due to their location at the entrance to the respiratory tract and the 
many thousands of litres of air per day that pass over their surface. 
Numerous DAMPs have been studied in the sinonasal passages. Altered protein amounts or 
RNA expression have been summarised in Van Crombruggen’s review (2013), Table 2. 
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DAMP CRSsNP CRSwNP Receptors 
S100A8/A9   TLR4, CD36, RAGE 
S100A7   RAGE 
Surfactant protein A & D ↑ ↑ TLR2 & TLR4 
Eosinophil-derived neurotoxin ↑  TLR2 
Fibronectin  ↑ TLR4 
Galectins  ↑ TLR2 
Tenascin-C  ↑ TLR4 & CD36 
Β-defensins 2 & 3 ↔  TLR1, TLR2 & TLR4 
Table 2.  Summary of known altered expression of damage associated molecular pattern 
(DAMPs) in CRSsNP and CRSwNP.  Adapted from (Van Crombruggen et al., 2013). 
 
 
1.3.6.3 Airway remodelling 
Irreversible airway remodelling and a progression from normal to disease is accepted in 
lower airways disease pathophysiology, for example asthma (Lazarus, 2006).  Similar 
mechanisms are gaining popularity in understanding CRS (Bassiouni et al., 2013, Bassiouni et 
al., 2012).  The end result of CRS airway remodelling is shown, with typical clinical and 
histological appearances (Figure 4), however the precise mechanisms underpinning these 
changes remain unknown.  From the published literature to date it is clear that CRS 
represents a spectrum of diseases with similar clinical symptoms, but differing 
pathophysiology (Van Crombruggen et al., 2012).  The mechanisms of CRS without polyps 
(CRSsNP) and CRS with nasal polyps (CRSwNP) represent differing diseases within the overall 
umbrella of CRS (Figure 6).   
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Figure 6. CRS phenotypes and their proposed pathophysiologies.  Different inflammatory T-
cell signatures and remodelling patterns are suggested.  CRS without nasal polyps (CRSsNP) 
and with polyps (CRSwNP).  Th1 = TH1 predominant cytokine pattern.  Th2+ =IL-5 positive, 
TH2 predominant signature; Th2- =IL-5 negative, TH2 predominant signature. SE-IgE =IgE 
antibodies to S. aureus enterotoxins.  Figure adapted from (Van Crombruggen et al., 2011). 
 
 
1.3.6.3.1 Early fibrosis  
Pivotal to the development of this thesis was the observation of early fibrosis and airway 
remodelling in the development of CRS (Van Bruaene et al., 2012).  Van Bruaene et al. 
compared sinonasal mucosal samples from nine patients with early CRSsNP, defined as 
symptomatic bilateral endoscopic disease with persistent changes on CT scanning refractory 
to maximal medical therapy (Fokkens et al., 2012).  Sinonasal mucosa from the maxillary 
sinus, ethmoid sinus, uncinate process, inferior and middle turbinate was compared 
between CRSsNP and healthy controls.  The mucosal samples were analysed for Th1 
inflammatory cytokines, neutrophil activity and fibrotic airway remodelling by collagen 
deposition, Tissue Growth Factor-β (TGF-β) and its receptors at both the RNA and protein 
level.  Sinonasal fibrotic mucosal remodelling was observed, with significantly upregulated 
TGF-β throughout CRSsNP sinus biopsies compared to those of healthy controls, whilst no 
differences in inflammatory cytokines or neutrophil activity were seen.  This novel 
observation suggested that fibrotic airway remodelling preceded the inflammatory response 
typical of CRSsNP.  Although contrary to the then prevailing consensus of the of CRSsNP 
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natural history, subsequent clinical evidence has shown that a window of opportunity exists 
for effective surgical treatment of CRS following failure of medical therapy (Hopkins et al., 
2015b, Hopkins et al., 2015a).  A combination of these observations together with relevant 
observations in the fibrosis literature (section 1.3.7) led me to study the fibroblast in CRSsNP 
in more detail for this thesis.   
 
The sinonasal airway epithelium has a unique position in the upper airway, sampling and 
filtering all the inhaled particles and microorganisms.  Consequently the epithelial cells are 
subject to a variety of environmental and infective stimuli that can cause damage, release of 
intracellular alarmins and potentiate the inflammatory load.  The epithelial cells sit directly 
upon a network of fibroblasts within the lamina propria, yet the roles of the sensing nasal 
epithelium and underlying fibroblast cells have not been conclusively investigated, 
regardless of the fact that sinonasal airway fibrosis may precede overt inflammation and 
forms an end stage of the disease process.   
 
1.3.7 Fibroblasts role in inflammation 
The body is not afflicted with generalised inflammation in CRS sufferers.  Thus it is evident 
that the mal-regulation of inflammatory pathways is local rather than systemic.  Indeed, 
chronic inflammation has two defining features; chronicity and tissue specificity e.g. 
dermatitis, colitis, nephritis and so on.  What is it then that could be orchestrating such 
specific, tissue-tropic inflammation within the sinonasal tract?  Recent research highlights 
the role of stromal cells in the generation and persistence of chronic inflammation (Naylor et 
al., 2013).  Rather than simply being scaffolding or matrix generating cells on which organs 
are built, stromal cells such as fibroblasts and osteocytes have their own immunological 
function.  Also, stromal cells from various tissues are significantly different, for example 
fibroblasts from inflamed skin have a completely different appearance, immunological 
profile and function to fibroblasts from arthritic joints.  These epigenetic changes have been 
shown stable through generations both in vivo and in vitro (Polyak and Weinberg, 2009).  It is 
suggested that rather than being innocent bystanders, stromal cells actually co-ordinate 
tissue-specific chronic inflammation, directing immune cell activation (Figure 7).  This 
hypothesis could readily apply to the paranasal sinuses, where epithelial cells reside 
alongside fibroblasts within a complex bony honeycomb.  Recent early-CRS publications 
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suggest an increase in sinonasal fibroblasts and of collagen deposition precedes local 
inflammation (Van Bruaene et al., 2012) rather than the other way round.  The initiator of 
fibroblast recruitment and expansion is suggested to be due to upregulation of tissue growth 
factor β (TGF-β), a key cytokine in wound healing and repair.   This novel concept opposes 
the traditional concept that fibrosis and airway remodelling result from epithelial injury. 
 
 
Figure 7.  Control of immune cell accumulation.  (a) Normal health; division and recruitment 
are balanced by emigration and death.  (b) Chronic inflammation; an imbalance of 
recruitment, death and emigration of immune cells.  Stromal cells can influence this via the 
production of cytokines and chemokines e.g. interferons (IFN), interleukins (IL), B cell 
activating-factor (BAFF), and chemokines (CCl and CXC).  Image adapted from (Naylor et al., 
2013) 
  
(b) (a) 
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1.3.8 Fibroblasts in chronic rhinosinusitis 
Examination of sinonasal tissue sections from CRS patients and healthy controls 
demonstrates a marked difference in their tissue architecture.  CRS patients undergo airway 
remodelling with epithelial damage and an influx of multiple immune cell types including 
neutrophils, eosinophils, T-cells and macrophages.  This inflammatory infiltrate is localised 
alongside fibroblasts in the lamina propria underneath the epithelial surface.  At present 
there no therapeutic approaches to target the fibroblast in upper airway pathology.  Within 
this section I will present the results of a review article (Ball et al., 2016) of the current 
understanding of the role of the fibroblast in sinonasal disease with and without nasal 
polyposis (Figure 8) and how it could potentially be a focus for development of future CRS-
specific therapeutics. 
1.3.8.1 Chronic rhinosinusitis without nasal polyps 
Due to the plentiful supply of excised nasal polyp tissue, most sinonasal fibroblast 
investigations have been performed on cells from nasal polyps.  However, nasal fibroblasts 
can also be readily isolated from non-polypoid tissue, a feature that has been successfully 
exploited in a variety of investigations.  Thus far the clear distinction between the clinical 
phenotypes of polypoid and non-polypoid CRS has not been mirrored by distinct cellular 
differences in phenotype and function of their respective CRS fibroblasts.  This is no doubt 
due to the novelty of the fibroblast driven upper airway inflammation hypothesis, however 
we do know fibroblasts have a number of roles in both CRS with and without polyps.  The 
sections below review the current understanding of fibroblast involvement in non-polypoid 
CRS. 
1.3.8.1.1 Cell receptors and inflammatory signalling in nasal fibroblasts 
The sinonasal mucosa is exposed to a great range of pathogens, especially respiratory 
viruses.  Fibroblasts compose a dense sub-mucosal layer of the sinonasal passages and no 
doubt convey an important protective role from the many common viral infections.  
Takahashi et al (2006) investigated the effects of a synthetic dsRNA viral analogue, Poly I:C, 
on chemokines, type 1 interferons, Th1 cytokines and pro-inflammatory cytokines in nasal 
mucosal fibroblasts.  They first confirmed the presence of TLRs on nasal fibroblasts, 
identifying high levels of TLR 3, 4 and 9.  TLRs 1, 2, 5 and 6 were also detected but only at 
low levels whilst TLR 7, 8 and 10 were found not to be expressed.  Poly I:C signals via TLR-3 
and expression of this receptor was increased fivefold following Poly I:C treatment.  A 
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significant release of the chemokines IL-8 and RANTES and small amounts of type I 
interferon IFN-β were also observed following poly I:C treatment.  RANTES is a potent chemo 
attractant for a number of immune cells including monocytes, eosinophils, lymphocytes and 
basophils.  In the sinonasal environment it has been shown that fibroblasts and not epithelial 
cells are the source of RANTES (Maune et al., 1996).  Release of eotaxin, IL-1β, TNF-α, IFN-α, 
IFN-γ and IL-12 was assessed by ELISA but could not be detected following nasal fibroblast 
stimulation.  Maune et al. also confirmed the signalling pathway for production of nasal 
fibroblast derived IL-8 and RANTES was by JNK and PI3 kinase.  In addition, p38 MAP kinase 
was important for IL-8 production.  Therefore Takahashi et al propose Poly I:C, like viruses 
clinically, are potent and selective stimuli for nasal fibroblast derived IL-8 and RANTES, but 
not Th1 cytokines, pro-inflammatory cytokines or eotaxin.  Therefore more precise profiling 
of sinonasal viral infection associated chemokines may offer new pharmacological targets to 
block cellular inflammation in the nasal and sinus cavities. 
1.3.8.1.2 Nasal fibroblast derived cytokines & chemokines 
Kouzaki et al investigated the role in CRS of platelet-derived growth factor (PDGF) (2009), a 
proliferative and pro-fibrotic cytokine with emerging roles in renal, hepatic, respiratory and 
other inflammatory and fibrotic organ pathologies.  Using immunohistochemical techniques 
they localised PDGF in CRS patients to inflammatory, epithelial, glandular and vascular 
endothelial cells.  Increased expression of PDGF receptors was found in CRS submucosal 
fibroblasts.  The authors suggest that in CRS, local PDGF production may be important in 
promoting sinonasal fibrosis. 
Nonaka et al. (2010b) analysed the ability of nasal and respiratory tract fibroblasts to amplify 
inflammatory cell infiltration via chemokine production.  They measured the ability of 
fibroblasts to produce thymus and activation-regulated chemokine (TARC), a Th2 chemokine.  
Co-stimulation with either TNF-α and poly I:C or Th2 cytokines was found to induce a 
substantial TARC release.  Nasal fibroblasts may therefore be an additional source of 
chemokines, amplifying viral and Th2 induced airway disease. 
Oyer et al. (2013) studied the role of leukocyte adhesion molecules VCAM and ICAM to 
attract neutrophils and eosinophils by nasal fibroblasts.  Levels of nasal fibroblast VCAM and 
ICAM were measured by flow cytometry.  They found that both ICAM and VCAM nasal 
fibroblast expression were elevated in CRS.  Additionally, in vitro treatment with TNF-α and 
IFN-γ further increased ICAM, while treatment with TNF-α and IL-4 increased VCAM.  From 
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these observations they suggest that CRS has higher levels of leukocyte adhesion molecules, 
and the effect is amplified by the CRS inflammatory cytokine environment. 
In summary fibroblasts in chronic rhinosinusitis without nasal polyps emerge as important 
sensors of the sinonasal environment, able to monitor and respond to the upper airway 
environment through expression of a variety of pattern recognition receptors.  Dependent 
on their precise environmental milieu, nasal fibroblasts are able to produce a variety of pro-
inflammatory cytokines and chemokines to amplify the local inflammatory response. 
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Figure 8.  Summary of the current inflammatory and fibrotic roles of the fibroblast in CRS 
with polyposis (CRSwNP) and without (CRSsNP). Sinonasal fibroblasts have a wide range of 
chemotactic, inflammatory, and pro-fibrotic roles in the pathophysiology of chronic 
rhinosinusitis.  
BLyS, B-lymphocyte stimulator; CCL-11, C-C motif chemokine-11; DC, dendritic cell; GCP-2, 
granulocyte chemotactic protein-2; GRO-a, growth related oncogene a; ICAM, intercellular 
adhesion molecule; IFN, interferon; MCP-4, monocyte chemotactic protein-4; MIP-3a, 
macrophage inflammatory protein-3a; NK, natural killer; PDGF, platelet-derived growth 
factor; PDGFR, platelet derived growth factor receptor; PI, phosphatidylinositol; TGF, 
transforming growth factor; TLR, Toll-like receptor; TNF, tumour necrosis factor; VEGF, 
vascular endothelial growth factor.  Image taken from (Ball et al., 2016). 
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1.3.8.2 Chronic rhinosinusitis with nasal polyps 
Fibroblasts have been shown to contribute to the development of nasal polyps, providing 
extracellular matrix proteins including collagens, fibronectin and vimentin to the nasal polyp 
architecture.  In addition to a pro-fibrotic role fibroblasts have additionally been suggested 
to have inflammatory actions which may be important in the development and persistence 
of nasal polyps.  Most CRS fibroblast investigations to date have been based around in vitro 
cellular cultures of primary human nasal fibroblasts, since animal models of sinonasal 
disease do not presently sufficiently resemble CRS (Kara, 2004). 
1.3.8.2.1 Hypoxia driven inflammation 
Mucosal inflammation and swelling cause ostial sinus blockage in CRSwNP, reducing sinuses’ 
capacity to ventilate normally.  Such processes may create an environment with reduced 
oxygen tension.  In hepatic fibrosis and many similar conditions hypoxia results in an 
infiltration of inflammatory cells and subsequent cytokine release.  Early et al. (2007) 
investigated the role of reduced oxygen concentrations on fibroblasts isolated from nasal 
polyps.  Nasal polyp fibroblast hypoxia increased vascular endothelial growth factor (VEGF), 
transforming growth factor β (TGF-β), interleukin 8 (IL-8) and C-C motif chemokine-11 (CCL-
11) involved in eosinophil recruitment.  Importantly, hypoxia also resulted in airway 
remodelling with a significant up-regulation of fibroblast derived intracellular pro-collagen 
and fibronectin.  Shun et al. (2011) and Sun et al. (2005) replicated the stimulation of IL-8 
and VEGF by nasal polyp fibroblast hypoxia, suggesting they prime the sinonasal 
environment for neutrophil infiltration and angiogenesis. 
1.3.8.2.2 Fibroblast – osteitis crosstalk  
Inflammation and remodelling of the bony paranasal sinus cavities or osteitis has been 
observed as a factor in CRS pathophysiology.  In CRS the histological and radiological 
appearances of the ethmoid sinus bone demonstrate fibrosis, new bone formation, 
inflammatory infiltrates and increased bone turnover, similar to skeletal osteomyelitis 
(Kennedy et al., 1998).  Park & colleagues (2007) investigated whether CRS inflammation 
stimulates nasal fibroblasts to function in a manner similar to osteoblasts and disrupt the 
normal paranasal sinus bone homeostasis.  They found that the pro-inflammatory cytokine 
interleukin-1β (IL-1β) stimulated nasal polyp fibroblasts to express receptor activator of 
nuclear factor κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), key 
regulators of osteoclastogenesis.  Paranasal fibroblasts reside in a densely packed lamina 
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propria directly in contact with paranasal sinus bone and periosteum.  Through this close 
anatomical relationship it appears that fibroblasts can influence the environment of the 
paranasal sinus bony labyrinth.  Whether or not inflammation/osteitis of the sinus bony 
architecture acts as a reservoir to drive persistence of chronic mucosal inflammation is 
currently a subject of much debate (Georgalas et al., 2010, Sacks et al., 2013, Videler et al., 
2011, Leung et al., 2016, Snidvongs et al., 2014). 
1.3.8.2.3 Nasal polyp fibroblasts as a source of cytokines 
Nasal polyposis is characterised by a chronic Th2 cytokine dominant environment.  Nasal and 
airway fibroblasts may be a major source of such Th2 cytokines (Tremblay GM, 1995, Nonaka 
et al., 1999, Nonaka et al., 2010b).  Nonaka et al. investigated whether either the Th2 
cytokine IL-4 or microbial breakdown products stimulated nasal polyp fibroblasts to produce 
the C-C chemokine MCP-4 (Nonaka et al., 2007).  MCP-4 is a potent chemokine for 
eosinophils, monocytes and lymphocytes which are important immune cells in the nasal 
polyp (Cauna et al., 1972, Nonaka et al., 1995).  They assessed the contribution of IL-4 to 
fibroblast mediated inflammation in nasal polyposis by evaluating the presence of IL-4 and 
pro-inflammatory lipid receptors on nasal polyp fibroblasts.  From this they identified IL-4 
receptors are present on nasal fibroblasts and that fibroblasts stimulated by IL-4 up regulate 
amounts of IL-6, CCL-11, MCP-4 & TGF-β1.  The authors suggest that nasal fibroblasts 
contribute to ongoing inflammatory processes in nasal polyps, producing an environment to 
drive nasal polyp growth by releasing pro inflammatory IL-6 and pro fibrotic TGF-β which 
may work together in an autocrine fashion (Steinke et al., 2004).   
1.3.8.2.4 Nasal polyp fibroblast chemotaxis of airway immune cells 
Neutrophilic infiltrate of nasal mucosa in CRS is readily identified histologically.  Presence of 
neutrophils suggests that during the development of CRS, neutrophil chemokines are 
generated.  Rudack & colleagues (2002) isolated nasal polyp fibroblasts and treated them 
with TNF-α.  Neutrophil chemokines were measured by ELISA and mRNA expression with 
biological chemotactic activity identified by three step high performance liquid 
chromatography.  They identified that IL-8, Granulocyte chemotactic protein-2 (GCP-2) and 
growth-related oncogene α (GRO-α) were induced by pro-inflammatory stimuli, with the 
most significant neutrophil chemotactic activity resulting from IL-8.  GRO-α contributed to 
neutrophil chemotaxis and GCP-2 represented a co-stimulatory chemokine from human 
nasal polyp fibroblasts.  The secretion of IL-8 from CRS sinonasal fibroblasts also suggests 
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that once neutrophils have been attracted, they will themselves produce further IL-8 
amplifying the inflammatory process.  Subsequently, neutrophils will release further 
interleukins 1 and 6, interferon-γ (IFN-γ) and TNF-α to contribute to the chemotaxis and 
activation of additional immune cells. 
Dendritic cells are critical mediators of antigen surveillance and presentation and can help to 
amplify adaptive immune responses.  They are present in upper airway diseases including 
CRSwNP, though their regulation in CRS is not yet clear.  Nonaka et al (2010c) investigated 
the role of Macrophage inflammatory protein-3α (MIP-3α), a known migratory factor for 
immature dendritic cells in nasal polyp fibroblasts.  Nasal polyp fibroblasts cultured with Toll-
like receptor (TLR) 2, 3, 4, 5 ligands, IL-1β, and TNF-α induced MIP-3α expression, as 
quantified by mRNA on real time RT-PCR and ELISA measurement of protein levels.  They 
discuss the fact that fibroblasts make up 47% of the cells present in nasal polyps (Jordana M, 
1995), and since the proportion of activated fibroblasts is higher in nasal polyps, they may 
well represent a critical source of inflammatory mediators. The researchers further propose 
that nasal polyp fibroblasts may contribute to dendritic cell recruitment by TLR and pro 
inflammatory cytokine induced production of MIP-3α. 
1.3.8.2.5 Nasal polyp fibroblast interactions with the adaptive immune system 
Recruitment and activation of B cells to sites of upper airway inflammation will engage the 
humoral immunity of the adaptive immune system.  B lymphocyte stimulator (BLyS) has 
potent stimulatory activity on B cells and their subsequent immune responses.  Yamada & 
colleagues (2010) examined BLyS expression in human nasal polyp fibroblasts.  They 
identified that BLyS was present in nasal polyp fibroblasts and its expression was markedly 
induced by the viral TLR analogue Poly I:C in a dose dependent manner.  BLyS is an important 
survival factor for lymphocytes - increasing B-cell, CD4 positive T-cell and natural killer cell 
activity (Shan et al., 2006).  BLyS is targeted therapeutically in patients with systemic lupus 
erythematosus with the monoclonal antibody belimumab.  The finding that BLyS is 
overexpressed in nasal polyp tissue may allow future therapeutic trials of similar agents in 
nasal polyposis. 
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1.3.8.2.6 Intracellular nasal polyp fibroblast Staphylococcus aureus 
Staphylococcus aureus is one of the major pathogens in CRS with nasal polyps, and is 
thought to produce exotoxins that act as superantigens in polyp formation (Bachert et al., 
2007).  Persistence of Staphylococcus aureus may be a factor in the chronicity of nasal polyp 
inflammation.  The potential for S. aureus to reside intracellularly, thus being protected from 
extracellular host defence mechanisms is likely to promote nasal persistence.  It has been 
established that fibronectin binding proteins on the fibroblast surface facilitate intracellular 
human S. aureus invasion via its associated receptor integrin α5β1 (Alexander and Hudson, 
2001).  Following internalisation, S. aureus is capable of inducing pro-inflammatory cytokines 
to exacerbate the disease microenvironment.  Clement et al. (2005) identified invasion of S. 
aureus into fibroblast and myofibroblastic cells of CRS patients nasal mucosa by confocal 
scanning microscopy.  Clusters of greater than ten intracellular Staphylococcus aureus 
organisms were frequently seen intracellularly encapsulated within a ring of α smooth 
muscle actin. 
In summary, the fibroblast in chronic sinusitis with nasal polyposis appears to have multiple 
roles, especially in regard to airway remodelling, immune cell chemotaxis and contributing 
directly to the inflammatory milieu, all hallmarks of nasal polyp formation. 
The understanding of chronic rhinosinusitis disease pathophysiology is certainly increasing 
following concerted international effort, though is by no means complete.  The large burden 
of CRS disease requires more effective therapy and only by understanding the disease 
mechanisms can progress with new therapies become a reality.  The potentially paradigm 
changing role for fibrosis early in the disease appears to be somewhat supported by 
investigation of registries of clinical patient outcome data for patients who have had delayed 
surgery for CRS after medical therapy has failed.  The role of fibrosis and the fibroblast in CRS 
therefore merits further study. 
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1.4 Approaches to investigating nasal cells in chronic rhinosinusitis 
A number of different techniques will be employed in this thesis to investigate nasal cells 
including fibroblasts and will be described in the following sections.  The use of 
transcriptome analysis within chapter 5 is introduced here. 
1.4.1 Transcriptome analysis 
The transcriptome is the sum of all RNA within cells, tissues or an organism.  It differs from 
the genome (DNA) which remains fairly static.  The transcriptome reflects all the genes that 
are actively being expressed at a point in time, therefore will vary with environment or 
disease conditions.  Knowledge of the transcriptome is a very useful way to analyse the 
molecular make up of cells and tissues, to interpret functional elements of the genome and 
to help understand disease.  Study of the transcriptome has been made possible with 
advances in powerful nucleic acid sequencing technology, in part driven by the Human 
Genome Project.  High throughput sequencing technology dramatically reduced the time, 
and hence cost, resulting in the phrase ‘next generation sequencing’.  Within this thesis I will 
use both microarrays and next generation RNA sequencing to investigate the transcriptome 
of sinonasal tissue biopsies and isolated cells from CRS patients and healthy controls. 
1.4.1.1 Microarrays 
Microarrays have been available for transcriptome research for a few decades, with evolving 
complexity and range of targets.  Microarrays utilise a series of known single stranded DNA 
probes hybridised onto a solid chip surface.  The DNA being investigated is labelled with a 
fluorophore and if it hybridises with one of the known complementary probes it fluoresces a 
specific colour which can be measured following stimulation with a laser (Figure 9).  The raw 
data produced consist of the fluorescence intensities for all the hybridised probes, which are 
then background corrected and normalised.  This is facilitated by a number of in built control 
probes within the array.  The background corrected, normalised data is then suitable for 
further downstream bioinformatics analysis.  Microarrays often contain many tens of 
thousands of DNA probes so a single sample can be interrogated for many genes at a time.  
However, samples can only be investigated for the known DNA probes on the chip rather 
than all the possible nucleic acids within the sample. 
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Figure 9.  Schematic illustration of a microarray.  Known DNA probes are attached to a 
microarray chip (green DNA strand).  Complementary DNA labelled with a fluorophore 
within the sample can hybridise to the probes (red strand).  Following a series of washing 
steps hybridised probes can be stimulated with a laser and the fluorescence measured for 
down stream bioinformatics analysis.  Image adapted from (Goodwin et al., 2016). 
 
1.4.1.2 RNA sequencing 
RNA sequencing is a more recent and sophisticated form of transcriptome analysis.  In 
comparison to microarray technology, RNA sequencing directly determines all the 
complementary DNA sequences in a sample.  Historically this was performed by the much 
slower, more expensive and non-quantitative Sanger dideoxy sequencing method developed 
in the 1970s which was the mainstay of sequencing technology for nearly 40 years (Sanger et 
al., 1977).  RNA sequencing first involves the generation or libraries from the RNA by 
fragmenting into short read segments with adaptors attached to each end.  The fragments 
are then amplified many times and bound to a template with adaptors.  The template 
concentration and localisation are directed by patterned flow cells to control and increase 
the cluster density of amplified fragments.  The sequencing is then determined by synthesis; 
complementary fluorophore labelled nucleotides then bind to the fragments which are read 
following excitation with lasers.  The fluorophores are then cleaved from the newly 
synthesised DNA strand and the process is repeated sequentially until all of the fragments 
have been synthesised and read (Figure 10).  Once sequencing has been completed, all the 
reads are aligned to a reference genome with information provided about the genes present 
and their expression level available for further bioinformatics analysis. 
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Figure 10.  Schematic illustration of RNA sequencing.  RNA samples are first fragmented into 
short read segments with adaptors attached to either end, amplified and bound to a flow 
cell.  The short fragments are synthesised with fluorophore labelled nucleotides which are 
read sequentialy following stimulation with a laser.  The process is repeated till the sequence 
and amounts of all the fragments is known.  Image adapted from (Goodwin et al., 2016)
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1.5 Hypothesis, aims and objectives 
1.5.1 Hypotheses 
The pathophysiology of chronic rhinosinusitis without nasal polyps (CRSsNP) is in part due to 
key differences in tissue structural cells such as epithelial and fibroblast cells.  Further, 
epithelial and fibroblast cells contribute to the pathophysiology of CRSsNP by driving the 
inflammatory and fibrotic environment of CRSsNP.  Nasal epithelial cells and fibroblasts will 
be significantly different between healthy control and CRSsNP participants in terms of their 
cytological appearance, behaviour and transcriptome and be useful models representative 
of their parent tissues for the study of CRSsNP.   
1.5.2 Aims 
1(a). Recruit phenotyped cohorts of control & CRSsNP participants.   
1(b). Characterise recruited CRSsNP participants’ tissue samples and isolated epithelial &          
fibroblast cells. 
2. Assay the sinonasal environment to determine any associations among infection, 
inflammation and remodelling. 
3. Identify clusters of genes differentially expressed in CRSsNP & control participants. 
1.5.3 Objectives 
1.  Recruit a cohort of well phenotyped CRSsNP patients and controls from the Newcastle 
Hospitals.  Patients will be phenotyped on the basis of a) quantification of symptoms by 
patient reported outcome measures, b) radiologically by CT scans and c) histologically. 
2. Isolate and characterise patient derived primary nasal epithelial cells and primary nasal 
fibroblasts by tinctorial, immunohistochemical and electron microscopy and compare these 
cellular observations to their associated participant tissue biopsies.   
3. Characterise the environment of the sino-nasal cavities by measurement of inflammatory 
cytokines, known human disease biomarkers and microbial species present by mucosal lining 
fluid analysis, sandwich and multiplex ELISA and quantitative RT-PCR. 
4. Characterise the transcriptome of CRSsNP tissue biopsies and isolated primary epithelial 
and fibroblast cells using microarrays and RNA sequencing. 
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2 General laboratory methods 
2.1 Tissue culture 
2.1.1 Primary cell culture 
All tissue culture work was performed within sterile class II laminar flow hoods in a 
dedicated tissue culture lab.  Harvested primary nasal epithelial cells (PNECs) were isolated 
from their cytology brushes and centrifuged at 400g for 4 minutes to pellet cells.  PNECs 
were then re-suspended in 15ml of Lonza basal epithelial growth (BEGM) media (BEGM 
BulletKit CC-3171 & CC-4175) at 37˚C.  PNECs were then placed into 75ml submerged tissue 
culture flasks (Greiner Bio-One, Germany) that had been coated with 0.5% collagen I 
(Nutacon Purecol, Netherlands) to facilitate adherence.  Once in tissue culture flasks, PNECs 
were viewed with a phase contrast microscope (Nikon, Japan) and motile cilia could be seen 
for 72 hours until ciliated cells were lost and adherent basal cells were seen confirming 
harvest of viable epithelial cells.   Cells were grown in a tissue culture incubator enriched 
with 5% CO2 at 37˚C until confluent at passage zero (P0).  Once confluent, PNECs were 
trypsinised with 2ml 0.25% trypsin EDTA (T4049, Sigma UK) for approximately 5 minutes 
then re-suspended in cell culture media prior to use in experiments or frozen down to build 
up an archive of primary patient-derived PNECs.  All samples were stored in a biobank in 
accordance with the Human Tissue Act (HTA reference: 12195) 
Primary nasal fibroblasts (PNFs) were directly isolated from sinonasal biopsy samples using 
an outgrowth technique.  Resected biopsy specimens were dissected into 1-2mm tissue 
fragments whilst still in media and then placed in a scored 10cm vented petri dish to aid cell 
adherence.  On top of each 1-2mm tissue fragment one drop of Sigma high glucose 
Dulbecco′s Modified Eagle′s Medium (DMEM) media (DMEM 5671, Sigma)  with 100iu/ml 
penicillin/streptomycin (P0781, Sigma), 50ml foetal calf serum (FCS) (F9665, Sigma), 2mM L-
Glutamine (G7513, Sigma) and 5ml Amphotericin B (A2942, Sigma) was added for 24 hours.  
Following the first 24 hour incubation with minimal media to aid adherence, a further 10ml 
of media was added to the petri dish.  As soon as islands of fibroblast cells were observed to 
be proliferating out from the tissue fragments, PNFs were trypsinised and seeded in 75ml 
tissue culture flasks and grown to passage 1 (P1).  Once confluent, cells were trypsinised for 
either experimentation or freezing as part of the study archive.  
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Cells in culture were maintained with media changes every 2-3 days.  In addition to growth 
in culture flasks, cells were cultured for microscopy on 13mm coverslips (collagen coated for 
PNECs) inserted into a 24 well culture plate using the same culture conditions. 
Primary human lung fibroblasts were isolated and cultured using the same methodology as 
described for nasal fibroblasts.  Primary human lung fibroblasts were kindly donated via a 
related lung transplantation project within our group’s laboratories, with appropriate 
research governance approvals co-ordinated by my supervisor Professor Fisher. 
2.1.2 Cell line culture 
Searches for commercially available cell lines were performed using the online catalogues of 
the American Type Culture Collection (ATCC) and European Collection of Cell Cultures 
(ECACC) using the search terms nose, sinus and human.  Searches identified only one 
appropriate cell line, RPMI 2650 which was purchased and grown in standard laboratory cell 
culture conditions as detailed above.  A vial of 2x106 cells was cultured as per the supplier’s 
instructions (ATCC) in Sigma Eagle’s Minimum Essential Medium (EMEM) (M2279, Sigma) 
with supplemental 1% non-essential amino acids (7145, Sigma), 100iu/ml 
penicillin/streptomycin (P0781, Sigma), 50ml foetal calf serum (FCS) (F9665, Sigma) and 
2mM L-Glutamine (G7513, Sigma).  Cells were supplied at P26 and were amplified in T175 
tissue culture flasks to generate sufficient cell numbers for the required experiments.  Cells 
were grown as submerged monolayer cultures in tissue culture flasks for stimulation 
experiments and on 13mm circular coverslips for imaging.   
2.1.3 Cell viability 
Cell viability was assessed either by propidium iodide (P4170, Sigma, UK) flow cytometry or 
automated cell counting of trypan blue (T8154, Sigma) stained cells with an EVE cell counter 
(NanoEnTek, USA).  For flow cytometry cells were washed in phosphate buffered saline (PBS) 
(D8537, Sigma), re-suspended in phenol free minimum essential medium (MEM) (51145, 
Sigma) with 10µl propidium iodide added prior to running samples on a 3 laser BD FACS 
CantoII instrument as per manufacturer’s instructions. 
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2.1.4 Freezing & archiving cultured cells 
Cells were trypsinised with 0.25% primary cell trypsin-EDTA and re-suspended in their 
respective media.  Cells were then centrifuged at 400g for 4 minutes and the supernatant 
was removed.  The cells were then re-suspended in cell freezing medium (C6164, Sigma UK) 
at 1x106 cells/ml as determined by cell counting with an automated cell counter (EVE, 
NanoEnTek, USA).  Cells were cooled at 1˚C per minute to -80˚C in a Mr. Frosty cell freezer 
(C1562, Sigma UK) and then transferred to archived liquid nitrogen storage. 
2.2 Epithelial cell treatments 
Confluent monolayers of cultured PNECs were stimulated with a number of CRS disease 
relevant stimuli.  Cells were grown in 24 well tissue culture plates and stimuli were applied 
for 24 hours at which point cells were harvested and their viability was measured using 
propidium iodide (P4170, Sigma, UK) flow cytometry.  The media was collected to determine 
the relative amounts of inflammatory cytokine & alarmin release from the stimulated cells.  
Cells were cultured with a six -point dose range of stimulants; diesel exhaust particles from 
0-100µg/ml, cigarette smoke extract 0-100% solution (see below for protocol), hydrogen 
peroxide solution 0-10mM (16911, Sigma UK), whole cell lysates of laboratory reference 
strains of Pseudomonas aeruginosa and patient derived Haemophilus influenza 0-100µl/ml 
and thapsigargin 0-100µM (T9033, Sigma, UK).  Dose ranges were identified from previous 
work on airway epithelial cells within our laboratory (Suwara et al., 2014). 
2.2.1 Cigarette smoke extract preparation 
Cigarette smoke produced from one University of Kentucky reference research grade 
cigarette was drawn through 25ml of Lonza BEGM basal epithelial growth media over 2-3 
minutes with a vacuum pump in a fume hood.  The media containing cigarette smoke extract 
(CSE) was then sterile filtered using a 0.2 μm pore size Minisart filter and designated 100% 
CSE.  CSE was diluted to concentrations as required for stimulation experiments, with Lonza 
BEGM basal epithelial growth media.  Once prepared, CSE was immediately used for cell 
treatments to prevent degradation. 
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2.2.2 Bacterial whole cell lysates 
Whole cell lysates of Pseudomonas aeruginosa lab reference strain PA01 and a patient 
derived Haemophilus influenza (kindly supplied by Dr Liz Moisey) were generated by 
streaking out bacteria on to brain, heart infusion (BHI) media (LM1135, Oxoid, UK) agar 
plates and incubated at 37˚C overnight to form colonies.  Colonies were then scraped off the 
agar and re-suspended to an even solution in PBS to a bacterial optical density standard of 
0.2 at 600nm.  The suspension was sonicated for 3 cycles on ice using a Branson Sonifier 150 
(Sigma) and placed on ice.  A one hour incubation with 200µg/ml of DNase II at 37˚C, then 
1mg/ml proteinase K incubation for 2 hours at 60˚C was performed, followed by boiling at 
100˚C for 20 minutes to inactivate proteinase K.  Lysates were confirmed rather than live 
bacteria by re-streaking on BHI agar plates overnight to demonstrate the absence of colony 
formation. 
2.3 Fibroblast treatments 
Confluent monolayers of cultured PNFs were stimulated with a range of recombinant human 
alarmin proteins to determine their inflammatory response.  PNFs were cultured in 6-well 
tissue culture plates and, once confluent, serum starved for 24 hours in modified Eagle’s 
medium (M4526, Sigma UK).  Human recombinant alarmins were added for 24 hours’ 
incubation using doses determined from previous work within our laboratory (Suwara et al., 
2014);  IL-1α (200-LA, R&D Systems) and IL-1β (201-LB, R&D Systems)  125pg/ml & 
500pg/ml, HMGB-1 50ng/ml & 200ng/ml (1690-HM, R&D Systems), LPS (L2630, Sigma) and 
Poly I:C (P1530, Sigma) 5µg/ml & 20µg/ml.  After 24 hours in culture, the media was 
harvested, centrifuged at 600g for 5 minutes to pellet any debris and the supernatants 
stored at -80oC prior to analysis by ELISA.  Adherent PNFs were trypsinised and their RNA 
was extracted using a NucleoSpin RNA extraction kit (Machery-Nagel, Germany) as described 
below. 
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2.4 RPMI 2650 cell line treatments 
Monolayers of PNECs and RPMI 2650 cells approaching confluence were stimulated with 
CRSsNP disease relevant pro-inflammatory ligands: TNF-α 1ng/ml, 5ng/ml, 10 ng/ml (T0157, 
Sigma), Lipopolysaccharide (LPS) 0.1µg/ml, 1 µg/ml, 10 µg/ml (L2630, Sigma), 
Polyinosinic:polycytidylic acid (Poly I:C) 50 µg/ml, a synthetic viral analogue (P9582, Sigma) 
and TGF-β 5ng/ml (T7924, Sigma) for 3 and 24 hours to determine if the cells were able to 
mount appropriate inflammatory responses.  Untreated control cells without inflammatory 
ligands were cultured in parallel.  Standard curves were performed as internal controls to 
ensure reproducibility between experiments.  All cells were treated with identical conditions 
in triplicate repeats from the same batch of inflammatory ligands.  Following stimulation, the 
conditioned media was harvested and the inflammatory response measured by the amount 
of IL-8 released into the culture media. Quantification was by sandwich ELISA for IL-8 protein 
as per manufacturer’s instructions (DY208, R&D systems).   
2.5 Macrophage conditioned media 
Conditioned media from cultured macrophages (THP-1 cell line and peripheral blood 
mononuclear cell isolation) were kindly provided by Dr Lee Borthwick & David Dixon.  Briefly, 
THP-1 cells were cultured in complete RPMI 1640 media till confluence, then polarised for 48 
hours in RPMI 1640 with 10ng/ml IFN‐γ (R&D Systems, 285‐IF‐100) and 1μg/ml LPS (Sigma, 
L2880) for M1 macrophages or 2ng/ml of IL‐13 (R&D systems, 213‐ILB‐025) and 2ng/ml IL‐4 
(R&D systems, 204‐IL‐010) for M2 macrophages.  After 8 hours, polarised cells were then 
washed and RPMI 1640 media was incubated for 24 hours to generate conditioned media.  
Peripheral blood mononuclear cells were isolated from consenting volunteers (NRES REC 
reference: 12/NE/0121) using gradient centrifugation with Percoll (17-5445-01, GE 
Healthcare).  Monocytes were separated from peripheral blood mononuclear cells by CD14 
MicroBead magnetic separation (Miltenyi Biotec) following manufacturer’s instructions.  
Primary human monocytes were subsequently cultured in Lonza X-Vivo-10 primary media 
(BE04-743Q, Lonza) and polarised as for THP-1 cells, with the appropriate X-Vivo-10 primary 
cell media. 
Conditioned media from M0, M1 and M2 polarised macrophages as above was incubated 
with cultures of primary nasal fibroblasts to investigate the effect of interleukin (IL) 1α and 
IL-1β blockage with blocking antibodies; IL-1 α (R&D systems, AF-280-NA), IL-1β (R&D 
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systems, AF-201-NA) and IL-1 receptor antagonist (R&D systems, 280-RA) following the 
protocol developed in our laboratory by Suwara et al. (2014).   
2.6 Reverse transcription polymerase chain reaction 
2.6.1 RNA extraction from cultured cells 
RNA was extracted from confluent cells using a NucleoSpin RNA extraction kit (Machery-
Nagel, Germany) as per manufacturer’s instructions.  The optional DNase I digestion step 
was included.  The concentration in ng/µl and purity by absorbance at 260/280nm and 
260/230nm of isolated RNA were determined using a nanodrop 2000 spectrophotometer 
(Thermoscientific, USA).  Samples were kept on ice throughout and stored at -80˚C. 
2.6.2 RNA extraction from tissue biopsies 
RNA extraction from tissue biopsy samples was performed with Life technologies RecoverAll 
Total Nucleic Acid Isolation Kit (Ambion, USA) as per manufacturer’s instructions. Tissue 
biopsy samples were homogenised in a bead homogeniser (Qiagen TissueLyser II, 
Netherlands) for two cycles of 2 minutes at 30Hz.  Both the protease digestion and DNase I 
digestion step were performed.  The quality and concentration of isolated RNA was assessed 
with a nanodrop 2000 spectrophotometer as above.    
 
2.6.3 qRT-PCR 
Quantitative RT-PCR was used to measure relative levels of gene expression using the 
standard  ΔΔCt (cycle threshold) method; ΔΔCt= 2^(Ct of reference gene – Ct of candidate 
gene).  cDNA was reverse transcribed from  isolated RNA samples using the BIORAD iScript 
cDNA synthesis kit as per manufacturer’s instructions.  10ng of cDNA template was used per 
qRT-PCR reaction using SYBR Green JumpStart Taq Ready Mix on an Applied Biosystems 
7500 Real-Time PCR System for 35 cycles.  1µl of forward and reverse primers were supplied 
by Eurofins per reaction.  PCRs were performed in triplicate repeats with a no template or 
mRNA negative control.  Expression levels of mRNA were normalised to those of healthy 
controls for relative mRNA expression data.  Products formed in the qRT-PCR reactions were 
verified by 2% agarose gel electrophoresis and compared to a 100 base pair ladder. 
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2.6.3.1 Primers 
Gene Forward primer Reverse primer 
GAPDH GAGTCAACGGATTTGGTCGT GACAAGCTTCCCGTTCTCAG 
SAA CAGACAAATACTTCCATGCT ATTGTGTACCCTCCCCC 
TARC ACTGCTCCAGGGATGCCATCGTTTTT ACAAGGGGATGGGATCTCCCTCACTG 
VCAM1 GGCAGAGTACGCAAACACTT GGCTGTAGCTCCCCGTTAG 
Eotaxin-3 AACTCCGAAACAATTGTACTCAGCTG GTAACTCTGGGAGGAAACACCCTCTCC 
CCL2 GGCTAAACTCATCCATACTGT GCACTGAGATCTTCCTATTGGTGAA 
CCL4 CCAAACCAAAAGAAGCAAGC AGAAACAGTGACAGTGGACC 
CCL17 ACTGCTCCAGGGATGCCATCGTTTTT ACAAGGGGATGGGATCTCCCTCACTG 
IL-6 TACCCCCAGGAGAAGATT AAGGTTCAGGTTGTTTTC 
PlGF CAGAGGTGGAAGTGGTACCCTTCC CGGATCTTTAGGAGCTGCATGGTGAC 
sFLT-1 ACAATCAGAGGTGAGCACTGCAA TCCGAGCCTGAAAGTTAGCAA 
SFRP4 GCCAACTTTGGCAACGTATC GTGGACACTGGCAAGAAGAA 
IFI27 TGCCTCGGGCAGCCT TTGGTCAATCCGGAGAGTCC 
TNFRSF19 TTGGTCAATCCGGAGAGTCC GCCACATTCCTTAGACAACTCC 
LOX AAAACCAAGGGACATCAGA GGCTAAACTCATCCATACTGT 
SULF1 AACATTGCTAAGCGTCAT CACTCGGACAGTGGTAGG 
ITGB1 CACTCGGACAGTGGTAGG CCCCTGATCTTAATCGCAAA 
GAGE5 CCCCTGATCTTAATCGCAAA TTCACCTCCTCTGGATTTGG 
NFE2L3 TCCCAGCATGAGGAAAATGA TTCTGCCTCCCAGTCAGGTTT 
Table 3.  RT-PCR primers. 
 
2.7 Cell staining 
Cells grown on 13mm coverslips were washed twice in PBS, fixed in 4% paraformaldehyde 
for 10 minutes and then washed with PBS.  Glycine (100mM) was added to quench any 
remaining paraformaldehyde.  Cells were permeabilised in 0.1% Triton-X100 (T8787, Sigma) 
in PBS for 30 minutes, washed twice in PBS 0.2% Tween 20 (P1379, Sigma) and once further 
in PBS.  Cells were then either stained with H&E to assess cellular morphology or using 
immunocytochemical techniques for epithelial and mesenchymal markers.  Primary 
antibodies were incubated at 4oC overnight as follows: rabbit anti-human cytokeratin 17 
(Abcam ab53707), mouse anti-human cytokeratin 19 (Abcam ab52625), mouse anti-human 
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pancytokeratin (ab6401) mouse anti-human E-cadherin (ab15148), rabbit anti-human 
vimentin (Abcam ab92547), rabbit anti-human α smooth muscle actin (Abcam ab5694) and 
rabbit anti-human fibronectin (Sigma F3648).  Fluorophore-conjugated secondary antibodies 
at 1:100 dilution in 5% bovine serum albumin PBS-0.2% Tween 20 were incubated for 90 
minutes in the dark: goat anti-mouse FITC conjugated (Sigma F2012) and goat anti-rabbit 
TRITC conjugated (Sigma T6778).  Negative controls were performed with secondary only 
antibodies and matched IgG isotype negative controls to identify if there was non-specific 
binding or background auto fluorescence.   Coverslips were mounted on slides with DAPI 
Vectashield (H1200, Vector USA) and images were captured with a Nikon A1 confocal 
microscope on a Nikon Eclipse NI-E upright stand running Nikon Elements 4.30.02, with a x20 
0.75Na Plan Apo lens. 
2.8 Enzyme linked immunosorbent assay (ELISA) 
Sandwich ELISA kits were used to quantify amounts of cytokines released from stimulated 
cultures of PNECs & PNFs. A 96 well format ELISA kit was used to measure the amount of 
cytokines as per manufacturer’s instructions (R&D systems).  The amount of cytokine 
present was read by the optical densities at 450nm and calculated relative to a known 
standard curve on a Multiskan FC spectrophotometer (Thermoscientific, USA).   
2.9 Statistical analysis 
Statistical analysis of experimental results was mainly performed using the non-parametric 
Mann Whitney U test with a significance level of p<0.05 unless otherwise stated, since due 
to the relatively small sample sizes a normal distribution could not be assumed.  Statistical 
analysis of the bioinformatics data is presented in their respective results chapters.  
Graphical data are presented visually as the mean, with standard error of the mean. 
  
 39 
3 Results - Participant recruitment & sample characterisation 
3.1 Specific aims & objectives 
The specific aims & objectives for this phase of research were to recruit a well phenotyped 
cohort of research patient participants with non-polypoid chronic rhinosinusitis (CRSsNP) 
and a cohort of healthy control volunteers as sources for appropriate tissue and cells for 
further study.  I aimed to establish matched patient and control epithelial and fibroblast cells 
with functional data on their differential responses to disease relevant stimuli.  The samples 
were further used in studies to analyse the sinonasal environment in CRSsNP and 
comprehensively characterise the RNA transcriptome. 
3.2 Scientific rationale for experimental approach 
Chronic rhinosinusitis is a heterogeneous condition with an as yet unknown 
pathophysiology.  There are two distinct subtypes, those with and those without nasal 
polyps and it has been postulated that there will be an as yet undefined emerging number of 
endotypes or sub-phenotypes.  Analysis of patients with CRS requires careful prior 
phenotyping to ensure similar patients are being studied to draw meaningful conclusions.  I 
triangulated my participant phenotyping according to  
1. Endoscopic appearance in terms of presence/absence of nasal polyps 
2. Symptom severity from patient reported outcome measure score 
3. Radiological appearance on cross sectional CT scanning scores.   
Data concerning the microbiological environment were also collected as the resident flora 
has an impact on the local sinonasal tissues. The tissue biopsies collected and cells isolated 
underwent confirmatory histological and electron microscopic examination.  Isolated cells 
were also stimulated with a number of disease relevant stimuli to confirm their viability and 
functional responsiveness. 
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3.3 Methods 
3.3.1 Research Governance approvals 
A research protocol, patient information sheets, patient invitation letters & consent forms 
were produced and submitted to the Sunderland office of the National Research Ethics 
Service (NRES) together with the standard accompanying documents.   National Institute of 
Health Research (NIHR) Good Clinical Practice (GCP) training and assessment for consenting 
research participants was completed. 
Ethical approval for the project was granted from the Sunderland office of the NRES, REC 
reference 13/NE/0099.  Newcastle Hospitals NHS Foundation Trust R&D project approval 
was given, reference 6487.  Caldicott approval was granted from the Newcastle Hospitals 
Information Governance Officer, reference 6487 (2520).  Research participants were 
successfully recruited to the study to allow investigation of human tissue biopsies, primary 
sinonasal cells and mucosal samples with the required research governance details stored in 
the study master file.  The project is registered on the NIHR Clinical Research Network 
UKCRN ID: 14335. 
 
3.3.2 Participant recruitment 
Participants undergoing elective operations for chronic rhinosinusitis according to the EPOS 
2012 international consensus document (Fokkens et al., 2012) were invited to participate in 
the study.  Control participants undergoing elective operations that use the nose as an 
access route, for example for non-functioning pituitary gland surgery, in the absence of 
sinusitis symptoms or clinical findings were also invited to participate.  Participants were 
non-allergic based on their clinical history, were invited for definitive skin prick testing and 
free of corticosteroids via all routes for the preceding two weeks.  Standardised patient 
letters of invitation and participant information sheets were sent in advance of admission for 
operation to the Freeman Hospital ENT surgery department.  On the day of admission I 
discussed the study and addressed any questions raised by potential participants.  Those 
who agreed to participate in the study signed a consent form. The original was inserted into 
the study master file, with a copy given to the participant and one filed in the patient’s 
hospital notes.  Recruited participants completed the well validated patient reported 
outcome measure to quantify their sinonasal symptoms; Sinonasal outcome test 22 (SNOT-
22 - see appendix for questionnaires) (Hopkins et al., 2009a).   Once collected, participants’ 
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cells, samples and data were given a unique study identifier to preserve confidentiality & 
anonymity prior to transport to the laboratory.  All samples were stored in a HTA approved 
biobank reference: 12195.  The same participant samples were used for each of the results 
chapters presented in the thesis. 
3.3.3 Microbiological samples 
Once enrolled in the study, patient participants proceeded to surgery as per the routine 
clinical practice.  Following induction of general anaesthesia and prior to their operative 
procedure, a conventional microbiological swab was taken of the middle meatus, an 
anatomically important and constant landmark of the paranasal sinuses for standard culture 
and sensitivity.  A viral swab was also taken from a cohort of twenty of the recruited 
participants to collect viral nucleic acids for molecular detection of respiratory viruses; 
Influenza A, Influenza B, Rhinovirus, Respiratory Syncytial Virus, Parainfluenza 1-4, 
Adenovirus and Human metapneumovirus.  Using the same swab sample, molecular 
detection of common respiratory pathogens Streptococcus pneumoniae, Chlamydia 
pneumoniae, Bordetella pertussis, Haemophilus influenza and Mycoplasma pneumoniae was 
performed.  Unfortunately it was not possible as part of this assay to investigate for the 
presence of Staphylococcus aureus at this stage.  Samples were analysed by quantitative real 
time PCR and processed by the clinical diagnostic standard Public Health England Molecular 
laboratory, Royal Victoria Infirmary, Newcastle upon Tyne.     
3.3.4 Primary cell harvesting 
Having obtained microbiological and mucosal lining fluid analysis samples, I harvested 
primary nasal epithelial cells (PNECs).  This was performed by gentle passage of a 
multipurpose cytology brush as in (Figure 11)  (CellPath UK, M467).  Cells were harvested 
from the middle meatus, the principal drainage area of the most commonly affected CRS 
sinuses and an anatomically consistent landmark.  Cytology brushings were then placed in 
15ml Falcon tubes containing Lonza BEGM cell culture media (Lonza UK, CC-3171 & 
CC-4175) and transported to the research laboratory.  
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Primary nasal fibroblasts (PNFs) were harvested from small (2-5mm) research tissue biopsies 
from the uncinate process, a consistent anatomical landmark within the middle meatus.  The 
uncinate process is usually resected and discarded as clinical waste during functional 
endoscopic surgery (FESS) for CRS.  The resected uncinate processes were kept in 
physiological saline until the operation was complete (approximately 45 minutes).  Once the 
surgeon was satisfied that they could be disposed of and not required for clinical histological 
examination they were collected for research.  Samples were transported to the laboratory 
in Sigma high glucose DMEM media (DMEM 5671, Sigma UK) with 100iu/ml 
penicillin/streptomycin (P0781, Sigma UK), 50ml fetal calf serum (FCS) (F9665, Sigma UK), 
2mM L-Glutamine (G7513, Sigma UK) and 5ml Amphotericin B (A2942, Sigma UK).   
3.3.5 Biopsy sample processing and archiving  
Surgically resected tissue biopsy specimens were processed to yield multiple sample types 
from the each patient with matched clinical and symptom data.  A portion of tissue was fixed 
in formaldehyde to allow generation of paraffin embedded tissue sections for histology.  A 
portion was stored in RNAlater and stored at -80oC to allow RNA isolation from tissue 
biopsies.  A further portion of tissue was frozen to allow the subsequent extraction and 
analysis of protein content. 
(a) (b) 
Figure 11.  (a) Cytology brush for harvesting primary nasal epithelial cells. (b) Tissue 
biopsy fragments cut into 1-2mm size pieces on a cross-scored petri dish with a drop 
of media for the first 24 hours to generate primary nasal fibroblasts. 
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3.3.6 Electron microscopy 
3.3.6.1 Scanning electron microscopy 
Samples were fixed overnight in 2% glutaraldehyde in Sorenson’s phosphate buffer at 4oC, 
rinsed in several changes of phosphate buffered saline then dehydrated through a graded 
series of ethanol from 25% to 100% ethanol for a minimum of 30 minutes. Once in 100% 
ethanol, final dehydration was carried out by critical-point drying with carbon dioxide using a 
Baltec Critical Point Dryer. Samples were mounted on an aluminium stub with Achesons Silver 
ElectroDag.  Mounted samples were coated with 15nm gold using a Polaron SEM Coating Unit 
and examined with a Tescan Vega LMU scanning electron microscope. 
3.3.6.2 Transmission electron microscopy 
Samples were fixed in 2% glutaraldehyde in 0.1M sodium cacodylate buffer at 4oC overnight, 
rinsed in several changes of phosphate buffered saline then a secondary fixation was 
completed with 1% osmium tetroxide in water for 1 hour. Samples were then dehydrated 
using graded acetone - 25%, 50%, 75% 100% acetone for a minimum of 30 minutes.  
Dehydrated samples were processed by impregnating with 25% resin in acetone, 50% resin 
in acetone, 75% resin in acetone then 100% resin for minimum of 3 changes over 24hrs.  
Samples were then embedded in 100% resin at 60oC for 24-36 hrs. 
Semi-thin survey sections of 0.5µm were cut and stained with 1% toluidine blue in 1% borax 
to check for an appropriate region of interest.  Relevant ultrathin sections (70 nm) were then 
cut using a diamond knife on a Reichert ultra microtome or a Leica EM UC7 ultra microtome. 
The sections were stretched with chloroform to eliminate compression and picked up on 
Pioloform-filmed copper grids.  Grids were stained on a Leica EM AC20 automatic staining 
machine using 2% aqueous Uranyl Acetate and 3% Lead Citrate.  Sections were examined 
using a Philips CM 100 Compustage (FEI) Transmission Electron Microscope and digital 
images are collected using an AMT CCD camera (Deben), Electron Microscopy Research 
Services, Newcastle University. 
44 
3.3.7 Tinctorial staining of biopsy samples 
Paraffin embedded tissue sections of biopsy specimens were stained using haematoxylin and 
eosin staining to demonstrate tissue architecture.  Sections were dewaxed in xylene for 5 
minutes, rehydrated through graded alcohols and washed in water until slides were clear.  
Sections were then stained with freshly filtered Harris Haematoxylin for 1-2 min and washed 
in running tap water for 2- 3 minutes.  Eosin Y was applied as a counterstain for 2 minutes 
and slides were washed to remove excess eosin then dehydrated through graduated xylene 
and mounted in DPX (06522, Sigma, UK). 
Picro Sirius red staining was used to determine the histological visualization of collagen I and 
III fibres within the tissue biopsies.  Paraffin sections were dewaxed in xylene then 
rehydrated and washed with water. Sections were treated with 0.2% phosphor molybdic 
acid, washed in distilled water and incubated with Picro Sirius red in the dark for two hours.  
They were then washed in 0.01% hydrochloric acid, dehydrated in increasing concentrations 
of ethanol followed by xylene and mounted in pertex mounting medium. 
Sections were also stained with picro Mallory trichrome to demonstrate the presence of 
collagen deposition within tissue biopsies.  Paraffin sections were dewaxed in xylene then 
rehydrated and washed with water.  Nuclei were stained in Celestine Blue for 10 minutes 
followed by Haematoxylin for 10 minutes and washed in tap water. Picro orange staining 
was applied for 1 - 2 minutes, washed in tap water then stained with acid fuchsin for 2 
minutes.  Sections were rinsed in 2% acetic acid, differentiated in red differentiator and 
washed in tap water.  Aniline blue stain was applied for 2 minutes, followed by a further 2% 
acetic acid rinse, dehydrated through graduated alcohols and mounted in DPX. 
3.3.8 Immunohistochemical staining of biopsy samples 
Paraffin embedded tissue sections were stained using antibodies to determine the 
composition of the resident immune cells.  Neutrophils were stained with anti-neutrophil 
elastase, T-cells with anti CD3, monocytes and macrophages with anti CD68 and eosinophils 
with Sirius red carried out by the department of cellular pathology, Royal Victoria Infirmary, 
Newcastle upon Tyne. 
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3.3.9 Fluorescent immunohistochemical staining of biopsies and cells 
Paraffin embedded tissue sections were dewaxed in xylene twice for 5 minutes, followed by 
two 5 minute incubations in 100% and 70% alcohol.  Antigen retrieval was performed in 
10mM EDTA at pH8 in a microwave at 700W for 15 minutes.  Samples were allowed to cool 
and then non-specific binding was blocked with 5% BSA in PBS-0.2% Tween 20 (P1379, Sigma 
UK).  Sections were incubated overnight with primary antibodies at 4oC and then washed 
three times in PBS-Tween 20.  Fluorophore secondary antibodies were then incubated for 90 
minutes in the dark alongside a series of secondary only controls.  Following three further 
PBS-Tween 20 washes sections were mounted with DAPI Vectashield (H1200, Vector USA).  
Images were captured with a Nikon A1 confocal microscope on a Nikon Eclipse NI-E upright 
stand running Nikon Elements 4.30.02, with a x20 0.75Na Plan Apo lens. 
Cells grown on coverslips were fixed in 4% paraformaldehyde for 10 minutes and then 
washed with 1x phosphate buffered saline (PBS).  500µl 100mM glycine was added to 
quench any remaining paraformaldehyde.  Cells were then permeabilised in 0.1% Triton-
X100 (T8787, Sigma UK) in 1x PBS for 30 minutes and washed twice in PBS-0.2% Tween 20 
(P1379, Sigma UK) and once further in 1xPBS.  Cells were blocked with 5% bovine serum 
albumin (BSA) (A7906, Sigma UK) for 60 minutes to reduce non-specific binding.  Primary 
antibodies were incubated at 4oC overnight and then washed three times in PBS-Tween20. 
Fluorophore-conjugated secondary antibodies at 1:100 dilution were incubated for 90 
minutes in the dark.  The negative controls were incubated only with secondary antibodies 
to identify any non-specific binding or background auto fluorescence.   After five washes 
with PBS-Tween20 cells were mounted on slides in DAPI Vectashield and images captured.  
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3.4 Results 
3.4.1 Participant recruitment and clinical data 
A cohort of 47 age and sex matched patient participants were recruited to enter the study 
(Table 4).  Twenty five of the participants had a diagnosis of chronic rhinosinusitis without 
nasal polyps refractory to maximal medical management, defined as at least 3 months 
treatment with topical +/- systemic corticosteroids and antibiotics. Twenty two were healthy 
control volunteers having no sinusitis symptoms, radiological CT scan or endoscopic findings 
of sinonasal disease having had no previous surgical treatment.  All patients had no specific 
history of allergy and were invited for skin prick testing.  Assessment with transmission 
electron microscopy excluded a diagnosis of primary ciliary dyskinesia base on the typical 
‘9+2’ axoneme.  The sinonasal patient reported outcome measure symptom scores of the 
two groups were significantly different (p<0.0001) as illustrated in Figure 12(a).  The 
calculated Lund Mackay radiological CT scan scores were also significantly different 
(p<0.0001) between the control and chronic sinusitis cohorts as shown in Figure 12(b). 
Figure 12. (a) Patient reported outcome measures of sinonasal symptoms (SNOT-22 
questionnaire) in healthy control volunteers and chronic sinusitis patient participants 
without nasal polyps (CRSsNP). **** = p<0.0001. 
(b) Lund Mackay CT scan scores in healthy control volunteers and chronic sinusitis patient 
participants without nasal polyps (CRSsNP). **** =  p<0.0001 (n=47). 
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Patient ID CRS / 
Control 
Age Sex 
6487#1 Control 35 F 
6487#2 CRS 48 F 
6487#3 Control 65 M 
6487#4 CRS 64 F 
6487#5 Control 68 F 
6487#6 Control 52 M 
6487#7 CRS 71 M 
6487#8 Control 71 M 
6487#9 CRS 62 F 
6487#10 CRS 44 F 
6487#11 CRS 59 M 
6487#12 CRS 63 M 
6487#13 Control 64 M 
6487#14 CRS 68 M 
6487#15 CRS 37 F 
6487#16 Control 59 M 
6487#17 CRS 40 M 
6487#18 control 36 M 
6487#19 CRS 53 M 
6487#20 CRS 43 F 
6487#21 control 68 F 
6487#22 CRS 69 M 
6487#23 CRS 40 F 
6487#24 CRS 66 M 
6487#25 control 43 F 
6487#26 CRS 69 F 
6487#27 control 43 F 
6487#28 CRS 73 F 
6487#29 Control 73 F 
6487#30 Control 60 F 
6487#31 Control 43 M 
6487#32 CRS 41 M 
6487#33 Control 90 F 
6487#34 Control 26 F 
6487#35 CRS 48 F 
6487#36 Control 31 M 
6487#37 Control 63 M 
6487#38 Control 67 M 
6487#39 CRS 73 M 
6487#40 Control 77 M 
6487#41 CRS 46 F 
6487#42 Control 73 M 
6487#43 CRS 57 M 
6487#44 CRS 64 F 
6487#45 CRS 63 F 
6487#46 CRS 25 F 
6487#47 Control 69 M 
 
Table 4.  Table detailing recruited participant’s demographic data  
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3.4.2 Microbiological data 
Analysis of recruited control participants’ sinonasal microbiological environment by 
conventional culture identified clinically significant growth (Staphylococcus aureus) in only 
one.  Staphylococcus aureus was identified from three of the chronic rhinosinusitis patient 
participants.  There were no polymicrobial isolates on conventional culture.  A molecular 
analysis was performed on 20 of the participants.  This included multiplex RT-PCR for both 
bacterial and viral pathogens.    Streptococcus pneumoniae and Haemophilus influenza were 
found in seven individuals, six in the rhinosinusitis cohort. There was no evidence of 
Influenza A, Influenza B, Rhinovirus, Respiratory Syncytial Virus, Parainfluenza 1-4, 
Adenovirus and Human metapneumovirus. 
 
3.4.3 Histological characterisation 
Haematoxylin and eosin staining of healthy control samples confirmed the typical healthy 
appearance of ciliated sinonasal pseudostratified epithelium (Figure 13ii(a)).  Serial sections 
immunostained for the presence of inflammatory cells (Figure 13ii (b-e)) show minimal 
evidence of either neutrophils with neutrophil elastase, T-cells with CD3, macrophages and 
monocytes with CD68 or eosinophils with Sirius red.  
Sections from participants with CRSsNP appeared markedly different.  Figure 13i(a) shows 
the typical non-polypoid appearances of epithelial cell damage and loss of cilia, combined 
with inflammatory cell recruitment and basement membrane thickening.  
Immunohistochemical analysis of the recruited immune cells demonstrates a mixed 
inflammatory infiltrate of neutrophils, T-cells, macrophages and monocytes and eosinophils. 
Sections were also stained for fibrosis with Picro Sirius. CRSsNP participants showed a dense 
thick band of staining at the level of the basement membrane consistent with increased 
deposition of a matrix of collagens 1 and 3 (Figure 14 (a+b)).  The increased deposition of 
collagen 1 and 3 is visible immediately below an epithelial layer with the typical disease 
appearances of epithelial and cilial loss.  Healthy control patient participants in contrast 
show much less mucosal basement membrane collagen deposition and an intact ciliated 
pseudostratified epithelial layer (Figure 14 (c+d)). 
  
 49 
Tinctorial staining with Picro Mallory trichrome highlights the CRSsNP appearances of 
connective tissue deposition and immune cell recruitment.  Figure 14(e) shows a low power 
view through the uncinate process with the bony component stained clear red.  The 
overlying mucosa is better visualised in higher magnification in Figure 14(f+g) where  the 
typical features of epithelial and cilial loss are again demonstrated, combined with basement 
membrane thickening and immune cell recruitment.
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Figure 14.  Tinctorial staining of chronic rhinosinusitis without nasal polyposis (CRSsNP) and 
healthy control participant tissue biopsies. (a+b) Picro Sirius red staining of CRSsNP 
participant sections (c+d) Picro Sirius red staining of healthy control participant tissue 
sections.  Magnification x20. (e-g) Picro Mallory trichrome staining of CRSsNP participant 
tissue section.  Magnification x10(e) x20 (f) x40 (g) (n=10) 
a b 
c d 
e 
f 
g 
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3.4.4 Tissue biopsy electron microscopy 
The ultrastructural epithelial health and integrity was first investigated with scanning 
electron microscopy.  Control samples (Figure 15 (a+c)) show low power images of a healthy 
pseudostratified epithelium with a dense network of intact cilia.  CRSsNP samples (Figure 15 
(b+d)) show the predicted marked epithelial and cilial loss, together with airway remodelling 
and deposition of fibrotic matrix.  When viewed in higher power magnification such as Figure 
15(d) x10 000 or Figure 16(b) x35 100, a few remaining epithelial cells with damaged, 
shortened cilia are visible in stark contrast to the high power views of healthy ciliated 
epithelial cells (Figure 16 (a)). 
Transmission electron microscopy was also performed.  Figure 17(a) shows the intact 
epithelium of a healthy control participant with the notable features of a continuous 
epithelial layer and abundant cilia, some of which are cut in longitudinal section and others 
in cross section.  Below the apical epithelial layer mitochondria can be seen to supply the 
large amounts of energy required by the motile cilia.  Figure 17(b) demonstrates a high 
power magnification (x64 000) through a cross section of healthy control participant cilia 
with the distinctive ‘9+2’ axoneme.  Figure 18(a+b) shows the dense epithelial covering of 
cilia and abundant mitochondria below the apical membrane for their supply of energy.  
When the transmission electron microscopy images are compared to the chronic 
rhinosinusitis without nasal polyposis participants there are quite significant differences.  
Figure 19 demonstrates the loss of epithelial cells and cilia.  Figure 20 shows that there are 
still some isolated clusters of cilia, which is best demonstrated in Figure 20b, however the 
epithelium has an unhealthy looking appearance with formation of multiple vesicles and 
unhealthy looking mitochondria. 
Figure 21 compares the mucosal glands between healthy control participants and those with 
non-polypoid chronic rhinosinusitis. The healthy control tissue mucosal glands in Figure 21(a) 
show regular healthy columnar epithelial cells.  The mucosal glands from diseased tissue in 
Figure 21(b) do not share the same regular, healthy appearance with increased vesicle 
formation and abundant mucous typical of chronic rhinosinusitis.
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(a)       (b) 
(c)       (d) 
 
 
 
 
 
Figure 15.  Scanning electron microscopy images of study participants healthy sinonasal mucosal 
tissue biopsy samples and chronic rhinosinusitis without nasal polyps (CRSsNP) samples.  
Compared to healthy control mucosa CRSsNP samples demonstrate the typical appearances of 
loss of cilia and epithelial cells and airway remodelling.   Magnifications; panels (a+b) 1500x, 
panels (c+d) 10 000x (n=6). 
Control CRS 
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Figure 16.  High power scanning electron microscopy images show (a) healthy sinonasal mucosa 
with cilia arising from their associated epithelial cells.  (b) Chronic rhinosinusitis images 
demonstrate epithelial remodelling with loss of cilia.  Magnification 35 100x (n=6). 
(a) 
(b) 
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(b) 
Figure 17.  Transmission electron microscopy images acquired from healthy control 
volunteers.  (a) shows longitudinal sections of the sinonasal cilia arising from the epithelial 
surface.  Magnification 19 000x.  There are also some areas within the image where the cilia 
have been cut in cross section.  (b) shows cross sections through the healthy cilia with the 
distinctive 9+2 axoneme pattern.  Magnification 64 000x (n=6). 
(a)
) 
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Figure 18.  Transmission electron microscopy images acquired from healthy control participants 
demonstrating abundant cilia arising from the epithelial surface (a+b).  Note the numerous 
mitochondria to provide the energy for the dynein motor domains for motion.  Magnification 
5800x (a) 19 000x (b) (n=6) 
(b) 
(a) 
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(b) 
Figure 19.  Transmission electron microscopy images captured from chronic rhinosinusitis 
without nasal polyposis patient participants.  Micrographs detail the loss of epithelial 
cells and cilia present in the tissue biopsies (a+b).  Magnification 620x (a) 1950x (b).(n=6) 
(a) 
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(b) 
Figure 20.  Transmission electron micrograph images acquired from chronic 
rhinosinusitis without nasal polyposis patient participants.  Images show some areas of 
preserved cilia on a pseudostratified epithelium.  Surrounding this there is marked loss 
of cilia upon an unhealthy epithelial layer.  Magnification 1950x (a) 5800x (b) (n=6) 
(a) 
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Figure 21   Transmission electron micrograph images captured of mucosal glands from 
healthy control volunteers (a) magnification 3400x and chronic rhinosinusitis without 
nasal polyposis (CRSsNP) patient participants (b) magnification 1450x. (a) shows a 
normal healthy glandular appearance in contrast to the images in CRSsNP (b).(n=6) 
(b) 
(a) 
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3.4.5 Tissue biopsy immunohistochemistry 
Antibody staining methods were optimised prior to fluorescent immunohistochemistry. A 
range of epithelial and mesenchymal markers was used to complement the previous 
observations.  A combination of epithelial marker antibodies is shown on healthy control 
samples in Figure 22 with their associated control samples.  Figure 22(b-d) shows strong 
staining of the epithelial layer of the mucosal biopsy with cytokeratin 17 as identified by the 
TRITC red.  There is an intact pseudostratified epithelial layer with nuclei counterstained in 
blue with DAPI. Figure 22(d) is dual stained for β-tubulin conjugated with FITC green and 
demonstrates an intact cilial layer to the epithelium.  The cilial staining is also demonstrated 
with FITC green in isolation in Figure 22(g).  The integrity of the epithelial layer is further 
confirmed by the presence of E-cadherin in Figure 22(e+f) where there is strong staining of 
the epithelial cells.  The presence of E-cadherin confirms it is a healthy pseudostratified 
epithelium with the formation of tight junctions.  There is also staining of E-cadherin below 
the epithelial layer in the lamina propria which is consistent with the columnar epithelial 
cells which line the sinonasal mucous glands.  
Staining of tissue sections using mesenchymal antibodies as markers of fibroblasts is shown 
in Figure 23.  Figure 23(a) is a control image and (b-d) are triple stained with FITC green for E-
cadherin, TRITC red for vimentin, fibronectin and α-smooth muscle actin respectively and all 
sections have a blue DAPI as a nuclear counterstain.  Sections show strong TRITC red staining 
for the mesenchymal markers in the lamina propria where fibroblasts typically reside 
underneath the basement membrane of the epithelial layer. Sitting within the areas of TRITC 
red conjugated mesenchymal staining are the mucous glands staining green from the E-
cadherin proteins within the columnar epithelium. 
The combination of epithelial and mesenchymal markers shown can be used to characterise 
the differences between mucosal tissue biopsies in health and CRSsNP.  Figure 24 compares 
the epithelial staining in health and disease, the intact ciliated pseudostratified epithelium 
seen in health is not seen in CRSsNP.  The epithelial stains seen in CRSsNP tissue sections 
highlight the epithelial damage, loss of tight junctions and loss of cilia.  Figure 25 compares 
the mesenchymal marker expression between healthy control biopsy sections and those 
from chronic rhinosinusitis without nasal polyposis.  In CRSsNP there is an increased staining 
of TRITC red conjugated mesenchymal markers vimentin, fibronectin and α-smooth muscle 
actin when compared to healthy control participant biopsies.  Tissue sections have been 
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counterstained with FITC green conjugated E-cadherin and blue DAPI nuclear stain to aid 
orientation and comparison.   
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e 
f 
g 
Figure 22.  Epithelial marker staining of normal healthy sinonasal tissue (a) no primary 
antibody control with FITC & TRITC secondary antibodies. (b) Cytokeratin 17 TRITC red x40 
magnification (c) x80 magnification (d) x80 magnification with cilial β-tubulin FITC green 
staining.  (e) Epithelial cadherin FITC green x 40 magnification (f) x 80 magnification. (g) β-
tubulin FITC green staining x 80 magnification.  All images counterstained with blue DAPI 
nuclear stain (n=12). 
a a 
b 
c 
d 
e 
f 
g 
a a 
b 
c
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e 
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g 
e 
f 
g 
b 
c 
d 
Figure 23.  Fibroblast marker staining of sinonasal tissue sections (a) no primary antibody control 
with FITC & TRITC secondary antibodies. (b) vimentin TRITC red magnification x40 (c) fibronectin 
TRITC red magnification x40 (d) α-smooth muscle actin TRITC red magnification x40.  All images 
counterstained with green FITC epithelial cadherin and blue DAPI nuclear stain (n=12). 
 
a 
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Control CRS 
a 
b 
c 
d 
c 
d 
b 
a 
Figure 24.  Epithelial marker staining of CRS & normal healthy sinonasal tissue (a) Epithelial 
cadherin FITC green x 40 magnification (b) x 80 magnification. (c) Cytokeratin 17 TRITC red x80 
magnification (d) Cilial β-tubulin FITC green staining x 40 magnification. All images counterstained 
with blue DAPI nuclear stain (n=12). 
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Control CRS 
a 
b 
c c 
b 
a 
Figure 25.  Fibroblast marker staining of CRS & normal healthy sinonasal tissue (a) 
Vimentin TRITC red x40, epithelial cadherin FITC green magnification x40 (b) 
fibronectin TRITC red , epithelial cadherin FITC green magnification x40 (c) α-smooth 
muscle actin TRITC red x40, epithelial cadherin FITC green magnification x40.  All 
images counterstained with green FITC epithelial cadherin and blue DAPI nuclear stain 
(n=12). 
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3.4.6 Cytology 
Patient derived primary cells were isolated from all participants’ tissue biopsies and 
cytological brushings.  The cells were then characterised by H+E and immunocytochemistry. 
Upon taking a cytological brushing for epithelial cells a smear was prepared and fixed for 
immediate analysis (Figure 26).  Haematoxylin and eosin staining of these cells confirms 
ciliated nasal epithelial cells as Figure 26(a).  Immunocytochemical staining was performed 
using the conjugated fluorescent antibody panel described in Section 3.3.9.  Figure 26(b+c) 
show examples of individual and clustered pseudostratified ciliated epithelial cells.  Figure 
26(d) shows a phase contrast microscopy image of the same fluorescent 
immunocytochemically stained epithelial cell.   
When epithelial cells were grown in culture they were further characterised as in Figure 27.  
The H+E sections show a confluent monolayer of cells with an epithelial appearance.  These 
cells were then characterised with a panel of epithelial stains (Figure 27 (b-d)).  Positive 
staining for the epithelial markers TRITC conjugated cytokeratin 17 red, FITC conjugated 
cytokeratin 19 green, FITC conjugated pan-cytokeratin green and FITC conjugated E-cadherin is 
shown.  The strongest staining for E-cadherin is seen where cells are confluent in small 
clusters and forming adherent junctions as would be expected.  The panel in Figure 27(g-i) 
shows a negative control and negative staining for the mesenchymal markers TRITC 
conjugated vimentin red, TRITC conjugated Fibronectin red, TRITC conjugated αSMA red 
with blue DAPI nuclear counterstain. 
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a 
b 
c 
b 
Figure 26. Epithelial sinonasal cells stained after brush harvesting with (a) haematoxylin 
and eosin, magnification x 20. (b+c) cells immunostained with FITC conjugated β-tubulin 
to stain cilia green and TRITC conjugated cytokeratin 17 red stain, sections 
counterstained with DAPI showing the nuclei in blue. (d) phase contrast image of the 
same view of (b) magnification x63 (n=5). 
 
d 
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Figure 27. Cultured PNECs stained with (a) H&E, magnification x40.  (b) TRITC conjugated cytokeratin 
17 red, (c) FITC conjugated cytokeratin 19 green (d) FITC conjugated pan-cytokeratin green (e) FITC 
conjugated E-cadherin (f) secondary antibody only negative control (g) TRITC conjugated vimentin 
red, (h) TRITC conjugated Fibronectin red (i) TRITC conjugated αSMA red (b-i) magnification x63 with 
blue DAPI nuclear stain (n=12).   
  
a 
b 
f 
 69 
3.4.7 Primary epithelial cell electron microscopy 
In addition to the tinctorial and immunocytochemical characterisation, isolated primary 
nasal epithelial cells (PNECs) were further analysed using scanning and transmission electron 
microscopy.  Scanning electron microscopy images acquired from cultures of PNECs 
demonstrated monolayers of cells with an epithelial like appearance and the formation of 
cilial structures (Figure 28).   
The same cells were visualised in culture with transmission electron microscopy.  To image 
cells with transmission electron microscopy they have to be grown on transwell filter inserts 
to allow the supporting medium to be cut in cross section for processing.  This explains the 
appearance of a white/grey membrane under the cells basolateral surface.  Figure 29 
demonstrates the transmission electron microscopy images between chronic sinusitis 
without nasal polyp participant derived primary cells and those from healthy control 
participants.  The most striking differences between the cells are the presence of cilial like 
structures on the healthy control cells in Figure 29(a) and their relative absence in panel (b).  
In addition to this the healthy control cells would form pseudostratified epithelial cultures as 
in Figure 30 with a covering of cilial like structures, whereas the cells derived from CRSsNP 
participants would not. 
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Figure 28.  Scanning electron microscopy images acquired from cultured primary nasal 
epithelial cells.  Magnification x1490 (a) x3380 (b) (n=6) 
 
(a) 
(b) 
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Figure 29. Transmission electron microscopy images acquired from (a) healthy control 
cultures of primary nasal epithelial cells and (b) chronic rhinosinusitis without nasal 
polyposis.  Magnification x5800 (a) x3400 (b) (n=6).  
(b) 
(a) 
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 Figure 30.  Transmission electron microscopy images captured from healthy control cultures of 
primary nasal epithelial cells showing formation of a pseudostratified epithelium and presence 
of cilia.  Magnification x1950 (a) x3400(b) (n=6). 
(b) 
(a) 
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3.4.8 RPMI 2650 commercial cell line 
The isolated primary nasal epithelial cells were compared with a commercially available 
sinonasal epithelial cell line, RPMI 2650, purchased from the American Type Culture 
Collection (ATCC) www.atcc.org/.  The morphological appearance of RPMI 2650 cells and 
response to some common cytokines and inflammatory ligands was compared to the 
isolated patient-derived primary cells to see if they could be used as substitutes in certain 
experiments due to their ready availability and inherent reproducibility. 
When grown in culture the RPMI 2650 cell line did not grow in confluent monolayers, but 
instead in isolated stacked clusters (Figure 31 (a)).  Using the same panel of fluorescent 
conjugated antibodies as the primary cells and tissue biopsies demonstrated a low 
expression of epithelial cytokeratin 17, an atypical staining pattern for E-cadherin and 
positive mesenchymal staining with vimentin.  Taken together these immunocytochemical 
appearances are not consistent with a pure epithelial cell line. 
To characterise RPMI 2650 cells their response to common inflammatory ligands, cytokines 
and growth factors was compared to primary epithelial cells as a screen.  I then measured 
the IL-8 inflammatory response to co-culture for three and twenty four hours with 
lipopolysaccharide (LPS) as a bacterial ligand, tumour necrosis factor-α (TNF-α) as an 
inflammatory cytokine, Polyinosinic:polycytidylic acid (Poly I:C) as a viral ligand and tissue 
growth factor –β (TGF-β) as a pro-fibrotic growth factor  As shown in Figure 31(e-h) primary 
nasal epithelial cells produced a statistically significant (p<0.05 - p<0.0001) dose dependent 
response, whereas RPMI 2650 cell lines did not show any response at either 3 or 24 hours.  
Following these results it was decided not to pursue the epithelial cell line any further and 
the results were published to alert other researchers in the field (Ball et al., 2015). 
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Figure 31.  Cultured RPMI 2650 cells stained with (a) haematoxylin & eosin (b) pan-cytokeratin 
TRITC (c) vimentin TRITC (d) E-cadherin FITC.  Magnification x63.  Response of RPMI 2650 and 
PNEC cells to stimulation with inflammatory ligands (e-h). (e+f) 3 hour treatment (g+h) 24 hour 
treatment with inflammatory ligands (UT – untreated control cells).  n=3 participants with 
triplicate repeats.  **** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05. 
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3.4.9 Primary fibroblast histological characterisation 
Primary cultures of nasal fibroblasts were characterised using the same systematic approach 
as for tissue biopsy sections and primary epithelial cells.  The primary nasal fibroblasts were 
isolated using an outgrowth technique directly from the matched parent tissue biopsies to 
validate their source.  Figure 32 shows the haematoxylin and eosin staining appearances 
alongside the immunocytochemical microscopy results.  Primary nasal fibroblasts in culture 
demonstrated their typical spindle like appearance in confluent monolayers.  They showed 
strong staining for the mesenchymal markers TRITC conjugated vimentin and TRITC 
conjugated fibronectin together with positive staining for FITC conjugated collagen 1.  
Negative staining for the epithelial markers was also observed in staining for TRITC 
conjugated cytokeratin 17 and FITC conjugated E-cadherin. 
Primary nasal fibroblast cells were also investigated with scanning and transmission electron 
microscopy (Figure 33).  Scanning electron microscopy showed the typical fibroblast 
appearances of elongated spindle like cells in contrast to the isolated primary nasal epithelial 
cells.  Transmission electron microscopy showed a single confluent monolayer of adherent 
cells.  There were no gross morphological differences between the primary nasal fibroblasts 
from healthy controls compared with CRSsNP participants. 
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a 
b 
c 
d 
e 
f 
g 
Figure 32.  Cultured primary nasal fibroblasts (PNFs) stained with (a) haematoxylin 
and eosin, magnification x40.  (b) secondary antibody only negative control (c) FITC 
conjugated E-cadherin (d) TRITC conjugated cytokeratin 17 red, (e) TRITC conjugated 
vimentin red  (f) TRITC conjugated Fibronectin red (g) TRITC conjugated collagen 1 (b-
g) magnification x63 with blue DAPI nuclear stain (n=12).   
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f 
Figure 33. (a) Scanning electron microscopy image of primary nasal fibroblasts (PNFs).  
Magnification x1490.  (b) Transmission electron microscopy of PNFs grown on a Transwell 
filter insert.  Magnification x4600 (n=6). 
(b) 
(a) 
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3.4.10 Characterisation of primary nasal epithelial and fibroblast cell responses 
3.4.10.1 Primary nasal epithelial cell viability following disease specific stimuli 
Confluent primary cultures of nasal epithelial (PNEC) and fibroblast (PNF) cells were 
investigated in tissue culture conditions.  Initially the cellular viability of PNECs in response 
to culture with a range of disease specific stimuli was assessed by flow cytometry with 
propidium iodide staining as shown in Figure 34.  The baseline viability of unstimulated cells 
was consistent across all treatment groups and confirms that the cells characterised in the 
previous sections are both the correct cell type and viable.  Interestingly, co-culture for 24 
hours with either increasing doses of whole cell lysates of laboratory reference strains of 
Pseudomonas aeruginosa, Haemophilus influenzae or diesel exhaust particles did not have 
any effect on PNEC viability.  Co-culture with increasing doses of cigarette smoke extract 
(CSE) and hydrogen peroxide (H2O2) did, however, produce a statistically significant (p<0.01) 
dose dependent effect on PNEC viability.  Co-culture with the endoplasmic reticulum (ER) 
stress inducing agent thapsigargin appears to have a statistically significant (p<0.001) 
threshold effect from concentrations of 10µM or greater. 
 
3.4.10.2 Epithelial alarmin release following disease specific stimuli 
Using identical co-culture conditions the release of the alarmin IL-1α was measured by ELISA 
(Figure 35).  Interestingly the greatest IL-1α release was triggered by co-culture with agents 
that promote either oxidative or endoplasmic reticulum stress rather than whole cell lysates 
of respiratory bacteria.  Co-culture with increasing concentrations of standardised diesel 
exhaust particles did not affect alarmin release.  
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Figure 34.  Primary nasal epithelial cell (PNEC) viability following 24 hour stimulation with 
relevant disease specific stimuli. (H2O2- hydrogen peroxide, CSE – cigarette smoke extract, TG – 
thapsigargin).  Viability assessed by propidium iodide flow cytometry. n=3 participants with 
triplicate repeat.  **** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05. 
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Figure 35.  Primary nasal epithelial cell (PNEC) IL-1α alarmin release following 24 hour stimulation 
with relevant disease specific stimuli.  (H2O2- hydrogen peroxide, CSE – cigarette smoke extract, TG – 
thapsigargin, DP – diesel particles, HI – Haemophilus influenzae, PA – Pseudomonas aeruginosa).  IL-
1α release quantified by ELISA. n=3 participants, triplicate repeats for each participant. **** = 
p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05. 
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3.4.10.3 Fibroblast responses to human recombinant alarmin proteins 
Cultures of primary nasal fibroblast cells were stimulated with a range of recombinant 
human alarmin proteins to stimulate an inflammatory response.  The most significant 
responses to the panel of alarmins tested were seen with IL-1α (p<0.05, Figure 36).   
Importantly, the physiological response to challenge with an alarmin confirms that the 
fibroblasts characterised from the last section are also able to produce appropriate 
inflammatory responses.  The next most marked response was seen to co-culture with IL-1β, 
though the responses were not always statistically significant which is interesting given the 
two ligands share a common receptor.  The viral analogue poly I:C produced the next most 
potent response. The variation on the magnitude of response precluded statistical 
significance.  The bacterial ligand LPS generated a similar inflammatory response from 
cultured fibroblasts (p<0.01 - p<0.05) with very minimal response from HMGB-1.  In 
response to co-culture with the alarmin proteins detailed, a similar reproducible amount of 
the pro-inflammatory cytokines IL-6 and IL-8 were produced, approximately 3-400ng/ml.  
The amount of TNF-α released was very minimal, essentially on the limit of detection of the 
ELISA kit. 
 
I selected 500pg/ml IL-1α as a reference ligand to screen for a range of cytokine responses 
from stimulated PNFs on the basis of maximal primary nasal fibroblast stimulation with the 
alarmins IL-1α and IL-1β. The strongest and only statistically significant response (p<0.01, 
Figure 37) in cytokine production from stimulated PNFs was seen in the amounts of IL-6 and 
IL-8, with small but measurable amounts of monocyte chemotactic protein 1 (MCP-1) and 
Granulocyte-macrophage colony-stimulating factor (GM-CSF). 
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 Figure 36.  Primary nasal fibroblast (PNF) IL-6, IL-8 and TNF-α inflammatory cytokine release following 
stimulation with human recombinant alarmin proteins as detailed along the x-axis.  Protein levels 
determined by ELISA.  n=3 participants per group, triplicate repeats for each participant.  ** = p<0.01, 
* = p<0.05. 
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Figure 37.  Primary nasal fibroblast (PNF) cytokine release following stimulation with the human 
recombinant alarmin protein IL-1α.  (C = media only control, T = 500pg/ml IL-1α treatment).    
Protein levels determined by ELISA.  n=3 participants per group, with triplicate repeats for each 
participant. ** = p<0.01, * = p<0.05. 
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3.4.10.4 Fibroblast responses to stimulation with synergistic human recombinant 
alarmin proteins 
To determine if there was any synergy in alarmin mediated PNF inflammatory responses, 
combinations of recombinant alarmin proteins were co-cultured with primary nasal 
fibroblasts.  Of the panel of alarmin proteins used, the greatest response by far was found in 
response to stimulation of the IL-1 receptor by either IL-1α or IL-1β proteins.  The 
combination of additional alarmin proteins produced no additional effect greater than either 
IL-1α or IL-1β proteins alone. 
 
3.4.10.5 Comparison of upper and lower airway fibroblast alarmin responses 
Primary lung fibroblasts (PLFs) were co-cultured with identical conditions to the primary 
nasal fibroblast challenge experiments, to determine if airway fibroblasts from different 
positions of the respiratory tract have differing responses to alarmins. 
When PLF co-cultures with the same panel of alarmin proteins were compared to PNF 
responses, there are a number of similarities but the responses are by no means identical 
(Figure 39).  PLFs also show the greatest response to the IL-1R ligands IL-1α and IL-1β, 
though the overall response is less marked.  Also similar to PNFs was the negligible response 
to HMGB-1 co-culture.  The pattern of relative amounts of IL-6, IL-8 and negligible TNF-α 
release is also similar.  Of note however, the PLFs do show statistically significant responses 
to the viral ligand Poly I:C (p<0.01 - p<0.05) , although the potency is much less.  Similarly the 
response to LPS as a bacterial ligand is much less potent and also not statistically significant. 
A similar pattern is observed when comparing PLFs with PNFs looking to see if any synergy 
between alarmins is affected, with the major effect solely in response to either IL-1α or IL-
1β. 
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 Figure 39.  Primary lung fibroblast (PLF) IL-6, IL-8 and TNF-α inflammatory cytokine release following 
stimulation with human recombinant alarmin proteins as detailed along the x-axis.  Protein levels 
determined by ELISA.  n=3 participants per group, with triplicate repeats for each participant.  ** = 
p<0.01, * = p<0.05. 
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3.4.10.6 Fibroblast response to alarmins 
Primary cultures of fibroblasts isolated from healthy control and chronic rhinosinusitis 
participants were compared in their responses to the same range of human recombinant 
alarmin proteins as shown in Figure 40.  While all fibroblasts were able to mount an 
inflammatory response there was no significantly different response between healthy 
control and chronic rhinosinusitis without nasal polyp fibroblasts 
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Figure 40.  IL-8 response in stimulated fibroblasts isolated from CRSsNP and control 
participants.  Fibroblasts stimulated with human recombinant alarmin proteins as detailed 
along the x-axis.  Protein levels determined by ELISA.  n=3 participants per group, with 
triplicate repeats for each participant. 
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3.4.10.7 Primary nasal fibroblast responses to co-culture with conditioned 
macrophage media 
The inflammatory IL-6 and IL-8 cytokine responses from primary nasal fibroblasts were also 
measured in response to co-culture with conditioned media from macrophages (Figure 41).  
Primary nasal fibroblasts, n=4 plus triplicate technical repeats, were co-cultured with 
conditioned media from macrophages that were either quiescent (M0), classically activated 
(M1) or alternatively activated (M2).  The experiments were performed with macrophages 
derived from the THP-1 cell line, n=3 plus triplicate technical repeats and also peripheral 
blood mononuclear cells (PBMCs) from n=3 healthy human volunteers in triplicate technical 
repeats.   THP-1 cells showed a small but significantly greater IL-6 and IL-8 response (p 
p<0.001 - p<0.01) when primary nasal fibroblasts were cultured with conditioned media 
from M0 and M2 macrophages than with only culture media.  In comparison primary nasal 
fibroblasts co-cultured with conditioned media from classically activated M1 macrophages 
produced a potent response of both IL-6 and IL-8.  Both the IL-6 and IL-8 responses were 
statistically significant (p<0.01 – p<0.0001 respectively), though the IL-8 released was one 
order of magnitude greater at approximately 150ng/ml detected in the cell culture 
supernatants. 
Attempts at modulating the inflammatory response were made using IL-1α and IL-1β 
blocking antibodies and an IL-1α receptor antagonist.  Used separately IL-1α and IL-1β 
blocking antibodies significantly reduced the IL-6 and IL-8 responses (p<0.05 – p<0.001), 
though their effect size was much greater in combination (p<0.01 – p<0.0001 respectively).  
The downregulation of the IL-6 and IL-8 response seen when the IL-1α receptor antagonist 
was used was of similar magnitude to the combination of IL-1α and IL-1β blocking 
antibodies. 
Following the initial success with the immortalised THP-1 cell line similar experiments were 
repeated using macrophages derived from peripheral blood mononuclear cells (PBMCs) 
isolated from healthy volunteers.  Neither M0 nor M2 macrophages showed a significant 
release of IL-6 or IL-8 from nasal fibroblasts in co-culture experiments with conditioned 
media.  Similar to the THP-1 cell line experiments a potent IL-6 and IL-8 release was seen in 
response to co-culture with classically activated M1 macrophages.  Both IL-6 and IL-8 release 
from conditioned M1 macrophage media co-culture demonstrated a highly significant 
response (p<0.0001), with approximately 40ng/ml IL-6 and 200ng/ml IL-8 measured.  The 
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effect of the conditioned M1 macrophage media could also be significantly (p<0.05 – 0.001) 
reduced by blockage of the IL-1 receptor.   Due to the limited supply of patient derived 
macrophages compared to THP-1 cell line derived macrophages, there were not enough cells 
to repeat the IL-1α blockage using IL-1α and IL-1β neutralising antibodies either 
independently or in combination.  Instead the IL-1α receptor was blocked directly, with a 
similar effect size. 
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(a) 
(b) 
(c) (d) 
Figure 41.  Histograms of IL-6 and IL-8 cytokine released following primary nasal fibroblast co-
culture with conditioned media from resting macrophages (M0), classically activated 
macrophages (M1) and alternatively activated macrophages (M2). Panels (a+b) macrophages 
derived from THP-1 cell line, (c+d) macrophages obtained from peripheral blood 
mononuclear cells (PBMCs) from healthy human volunteers.  PNFs n=4, THP-1 n=3, PBMCs 
n=3 plus triplicate repeat. Nab – neutralising antibody, Ra –receptor antagonist. **** = 
p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.05. 
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3.5 Discussion 
Chronic rhinosinusitis is a very common condition yet our understanding of its 
pathophysiology of is incomplete.  The disease causes a large personal (Hastan et al., 2011, 
Meltzer et al., 2004) and societal (Ray et al., 1999, Smith et al., 2015) burden.  A better 
understanding of the disease mechanisms involved in producing the persistent, exaggerated 
upper airway responses will no doubt translate into more modern anti-inflammatory 
medications.  Chronic rhinosinusitis represents a heterogeneous group of conditions with 
similar nasal symptoms.  It is characterised principally by the presence or absence of nasal 
polyps, though a number of emerging endotypes or sub-phenotypes have been hypothesised 
that may well demonstrate differing disease mechanisms (Akdis et al., 2013, Tomassen et al., 
2016).  To further study the condition requires careful phenotyping of recruited participants 
to draw meaningful conclusions.  Within this chapter the results of a carefully phenotyped 
cohort of age and sex matched participants has been detailed.  Patient participants have 
been selected based on a combination of their validated patient reported outcome measure 
symptom scores (Hopkins et al., 2009a), endoscopic appearance and radiological imaging 
scores (Lund and Mackay, 1993) for both CRSsNP and healthy control volunteers.  All 
participants followed the pan-European consensus document for surgical treatment of their 
chronic sinusitis having failed maximal medical therapy (Fokkens et al., 2012).  Once 
recruited into the study participants were characterised histologically with a biopsy to look 
for evidence of normal healthy mucosa or features consistent with chronic rhinosinusitis.  
The histological appearances of tissue biopsies from healthy control and chronic 
rhinosinusitis without nasal polyp participants included in the study are comparable with 
histological appearances in the published literature (Kou et al., 2012) and hence appropriate 
for further detailed CRSsNP studies. 
The microbiological environment of the recruited participants was studied using 
conventional culture and sensitivity techniques as well as a molecular based approach with 
multiplex quantitative RT-PCR.  With the exception of one study participant healthy control 
volunteers did not grow any pathogens typical of sinusitis or respiratory tract infection.  Only 
three of the CRSsNP patient participants grew clinically significant cultures with a 
conventional technique and there were no polymicrobial infections demonstrated.  This 
perhaps under represents the bacterial load in the sinonasal cavities of such participants and 
may be a reflection of the sensitivity of conventional culture to detect relevant microbes, 
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especially if they are encompassed in a biofilm.  A serious challenge of treating patients with 
chronic infective and inflammatory conditions is that a significant proportion of patients with 
clinical and laboratory signs of infection do not have organisms detected by traditional 
culture methods (Ramakrishnan et al., 2016, Tande and Patel, 2014).  This can be due to the 
recalcitrance of biofilm-encased bacteria, which are often present as dormant forms within 
the biofilms.  As a result increasingly molecular techniques are being used to identify the 
microbiome of the sinonasal cavities more accurately (Boase et al., 2013a, Aurora et al., 
2013).  To study the whole microbiome of the sinonasal cavity samples is a large and 
ultimately expensive study beyond the scope of this thesis, however, here I have employed 
molecular techniques to look for the common upper respiratory tract viruses and bacteria 
present in a cohort of the recruited patient participants. Initially a screen was performed for 
viral nucleic acids for molecular detection of ten common respiratory viruses; Influenza A, 
Influenza B, Rhinovirus, Respiratory Syncytial Virus, Parainfluenza 1-4, Adenovirus and 
Human metapneumovirus.  Surprisingly the swab results from all participants came back 
negative for viral nucleic acids.  This is especially surprising in the chronic rhinosinusitis 
participants as chronic rhinosinusitis patients have previously been shown to have high rates 
of detection of respiratory viruses in nasal lavage and mucosa (Cho et al., 2013), being 
implicated as triggers of disease flare up.  Samples of microbial nucleic acids were collected 
using the Public Health Laboratory England standardised nucleic acid swab technique, plus 
samples were taken from both sides of the sinonasal passages to increase the chance of 
detection.  On reviewing the literature it would appear that viral nucleic acids are potentially 
best detected with tissue biopsies or scraping of the mucosa (Jang et al., 2006), although this 
does not always yield positive results for viral infection of the sinuses and one study from 
New Zealand, like the results presented here also could not identify any similar respiratory 
viruses (Wood et al., 2011).  The same mucosal swabs were analysed using RT-PCR to detect 
nucleic acid from common respiratory pathogens.  Unlike the negative results for viral 
nucleic acids, bacterial pathogens showed seven positive results, six of which were from 
CRSsNP.  Positive molecular detection of Streptococcus pneumoniae and Haemophilus 
influenza were shown and in two chronic rhinosinusitis participants both were detected.  
Despite only using a limited panel of five respiratory bacterial pathogens, the fact that two 
were detected and polymicrobial pathogens were identified suggests that conventional 
microbial culture is not as sensitive in analysing the microbial environment of the sinonasal 
cavities.  Such a finding would justify the use of molecular microbiome analysis in future 
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work once the cost is more reasonable with its increased adoption.  It is likely that increased 
use of microbiome analysis in standard clinical microbiological diagnostic work up is not far 
from adoption on discussing with colleagues in the local Public Health England Laboratory. 
 
Since I am especially interested in the role of structural epithelial and fibroblast sinonasal 
cells in CRSsNP, biopsies were characterised to detail the presence and distribution of these 
particular cells within the tissue samples.  Knowledge of the composition of the tissue biopsy 
facilitated the generation of isolated matched primary cells for culture.  Once matched 
primary cells were isolated they were themselves characterised to ensure the appropriate 
cells had been isolated and cultured.  Epithelial cells were harvested under direct vision from 
the middle meatus, an anatomically consistent landmark and key sinus drainage point within 
the paranasal sinus complex.  Cytological brushing allowed targeting of a precise location 
and the process of brushing cells removes only the mucosal layer, therefore all epithelial 
cells were reproducibly isolated from the same location between patient participants. 
Epithelial cells were grown in standardised submerged culture conditions.  Upon initial 
harvesting epithelial cells demonstrated motile cilia visible with live phase contrast 
microscopy.  Motile cilia were present for typically four days of standard submerged tissue 
culture upon which there mobility were lost.  In an effort to maintain motile cilia numerous 
attempts were made to culture the primary epithelial cells at a more physiological air liquid 
interface (Muller et al., 2013, Ong et al., 2016).  Unfortunately despite these attempts using 
a variety of protocols I was not able to successfully culture primary nasal epithelial cells 
reliably to form a differentiated epithelium with motile cilia.  From the literature it typically 
takes up to thirty days to form a differentiated epithelium, though within that time I found 
that cells would become non-viable detach, float in the media and promote infection of the 
cultures.  Bearing this in mind, I was concerned that further study using this system would 
more likely be characterising the inflammation from dead and dying cells undergoing 
physiological inflammatory processes such as necrosis rather than any inflammatory 
processes from the inflamed CRSsNP tissues and cells of origin.   
The primary epithelial cells grown in culture were compared between those from healthy 
control participants and those from CRSsNP.  Comparison with electron microscopy showed 
the greatest difference, with healthy control epithelial cells showing cilial like structures on 
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their apical surface in both scanning and transmission electron microscopy in addition to the 
formation of a pseudostratified epithelium.  It is perhaps not surprising that primary 
epithelial cells from sinusitis participants did not demonstrate features consistent with a 
healthy epithelium when the histological analysis of the parent tissue biopsies also do not 
show a healthy ciliated pseudostratified epithelium. 
The RPMI 2650 commercially available cell line was investigated to see if in selected 
circumstances it could be used as a substitute for primary epithelial cells when large 
numbers of cells were needed, to rapidly expand a cell line or if participants were in short 
supply.  Unlike in many other human conditions, there is a lack of well-validated reliable 
cellular models to study CRS.  The only readily available commercial sinonasal cell line RPMI 
2650 is often used in sinonasal studies (Bruno et al., 2014, Pace et al., 2014, Kim et al., 2014, 
Prevete et al., 2011) yet there is little published data about its relationship to sinonasal cells 
and its validity as a cellular model.  There are no commercially available sinonasal fibroblast 
cell lines in either the European Collection of Authenticated Cell Cultures (ECACC) or the 
American Type Culture Collection (ATCC).  There are of course some shortcomings from the 
experimental approach used to compare patient derived primary nasal epithelial cells 
(PNECs) with the sinonasal cell line RPMI 2650.  Firstly both cell types have been grown in 
submerged culture rather than at a more physiological air-liquid interface to force 
differentiation.  This approach was chosen as earlier air-liquid interface culture experiments 
were not successful to create a differentiated ciliated epithelium with RPMI 2650 cells in 
agreement with previous work investigating the cell line in nasal drug delivery studies 
(Wengst and Reichl, 2010, Merkle et al., 1998).  Secondly, a major function of cells of the 
sinonasal cavity is in mucociliary clearance, which due to the nature of submerged culture 
could not be assessed here. 
From these discrete investigations the sinonasal cell line RPMI 2650 has been shown to be 
significantly different from patient derived PNECs in terms of its cellular morphology, surface 
marker expression and biological response to CRS disease relevant inflammatory ligands 
such as TNF-α (Karosi et al., 2012, Nonaka et al., 2010a, Mfuna-Endam et al., 2011, Cormier 
et al., 2009).  Whilst this is initially disappointing it is perhaps not surprising on further 
investigation of the cell-line.  It was derived from an anaplastic squamous cell carcinoma of 
the nasal septum in a 52 year old male patient (Moore and Sandberg, 1964).  Tumour cells 
were isolated from the patient’s metastatic pleural effusion and grown as adherent nasal 
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epithelial cells.  The cell line demonstrates a similar diploid karyotype to healthy nasal 
epithelial cells (Moorhead, 1965).  It has also been shown to have similarity in terms of the 
expressed surface cytokeratins (Moll et al., 1983) and produces a typical functional mucoid 
material visible on the cells apical surface (Moore and Sandberg, 1964).  To date the cell line 
has only been validated as a model to study the regulation of TGF-β biology in house dust 
mite related allergic rhinitis (Salib et al., 2005).  The metastatic, neoplastic source of these 
cells perhaps explains the mixed epithelial and mesenchymal phenotype and growth pattern 
in cell culture.  The combination of the marked morphological differences, growth pattern 
and response to inflammatory stimulus demonstrated by RPMI 2650 cells are significantly 
different to primary nasal epithelial cells.  In conclusion no further work was pursued with 
this cell line and all remaining work was done with patient derived primary human cells.  
Fibroblast cells were generated by an outgrowth technique in selective cell culture media 
from characterised tissue biopsy samples.  All samples collected from CRSsNP participants 
were of the uncinate process, an anatomically consistent landmark in the ostiomeatal 
complex of the middle meatus allowing reproducibility between patient participants.  
Healthy control participants were recruited undergoing operations that used the nose as an 
access route for other structures, such as non-functioning pituitary gland lesions or for the 
repair of a leak of cerebrospinal fluid from the skull base.  All healthy control participants 
were confirmed to have no sinusitis symptoms, endoscopic or radiological findings therefore 
it is not ethically appropriate to operate surgically on their healthy sinuses.  For this reason, 
healthy control participants’ tissue biopsies were all taken from the sphenoid sinus or skull 
base as part of their operative procedure.  This allowed consistency in the tissue biopsy 
sample and hence fibroblast cells from healthy controls.  However, the healthy control tissue 
biopsies are from an anatomically different sinus location to the CRSsNP participants. This is 
the current standard in the literature for healthy control tissue samples (Miljkovic et al., 
2014, Jardeleza et al., 2013, Tomassen et al., 2016, Wang et al., 2015). 
By isolating and characterising the cultured epithelial and fibroblast structural cells I have 
removed the recruited immune cells typical of the resulting chronic inflammatory processes 
as shown in Figure 13.  Exactly why the immune cell chemotaxis takes place is not clear and 
by removing them from the main structural cells it may be that there are differences 
between the epithelial and fibroblast cells from healthy control and CRSsNP participants that 
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initiate or maintain the state of persistent inflammation similar to that seen in other chronic 
inflammatory conditions (Naylor et al., 2013). 
The differences in the microscopic appearance between healthy control and chronic 
rhinosinusitis patient participants are quite dramatic.  In health the mucosal layer is best 
demonstrated in the scanning and transmission electron microscopic appearances with the 
abundant cilia upon a pseudostratified epithelial layer.  In CRSsNP the epithelial loss is 
marked and the epithelium is replaced by fibrotic matrix as seen in the electron microscopic 
appearances, tinctorial and immunohistochemically stained images (Figure 13 - Figure 16).  
This is in keeping with the published literature regarding the pathophysiology of CRSsNP 
(Van Crombruggen et al., 2011) (Van Bruaene et al., 2012, Kou et al., 2012).  The 
transmission electron microscopy images of tissue biopsies from CRSsNP interestingly show 
a marked difference in terms of the mitochondria visible.  Healthy control participant’s 
images show abundant, healthy mitochondria which supply the energy to the cilial 
axonemes for mucociliary clearance function of the mucosa.  The presence of abnormal, 
swollen unhealthy looking mitochondria, or even loss of mitochondria in CRSsNP participant 
biopsies may well be a source of sterile inflammation from necrotic and related cell death 
pathways as the organelles release their alarmins (Conrad et al., 2016).  The increased 
fibrosis seen in CRSsNP may also be a key factor in the pathophysiology in the disease 
process.  As a result study of the fibroblast in sinonasal disease may offer important insights 
into the CRSsNP disease process.  Additionally analysis of fibroblasts in upper airway 
diseases may offer insights into conditions with related fibrotic and mucosal inflammatory 
processes.  If the core mechanisms of fibrosis and inflammation were understood and 
applicable in anatomically different tissue sites it would allow aspects of fibrosis research to 
be carried out where access to disease tissue is simplest.  With the exception of the skin, the 
sinonasal mucosa is amongst the most accessible epithelial surfaces in the body.  Access to 
material to harvest for cell, tissue and microbiological research can be provided by a variety 
of brushings, small biopsies, mucosal scrapes or swabs from the clinic.  The nose thus offers 
a convenient portal for the study of generic inflammatory mechanisms and the introduction 
of novel therapies. Sinonasal disease surveillance is likewise very straightforward, as office 
based endoscopic nasal assessment readily supplements well-validated disease symptom 
scores.  Sinonasal medications are also often topically applied via a nasal aerosol, with 
minimal systemic exposure.   
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Within the respiratory system Idiopathic pulmonary fibrosis (IPF) represents the most 
common progressive interstitial lung disease, characterised by proliferation of fibroblasts 
and deposition of extracellular matrix.  Once established, the disease typically progresses to 
respiratory failure.  The postulated pathogenesis is of repetitive respiratory epithelial injury, 
followed by airway remodelling and an increase in mesenchymal cells including fibroblasts 
and activated myofibroblasts, either by proliferation of pre-existing resident cells or via 
epithelial to mesenchymal transition (EMT) (Loomis-King et al., 2013).  Accumulation of 
fibroblasts is associated with an increase in chronic inflammation.  Similar epithelial cell loss, 
fibroblast accumulation and chronic inflammation are seen in upper airway inflammatory 
diseases.  There are no in vivo IPF models that mirror human disease progression, and 
animal models of upper airway inflammation are similarly limited.  Human studies targeting 
the fibro-proliferation in IPF have shown initial promise, though no superiority to placebo in 
randomised controlled trials of prednisolone, azathioprine, Interferon-γ, anti-TNF-α and 
endothelin receptor antagonists has been shown.  Focus is now shifting towards specific 
fibroblast targeted therapies.   Lower airway tissue samples can be isolated using variety of 
methods such as bronchoscopic guided biopsy or cellular brushings, though in patients with 
declining respiratory function these are not without risk.  However, since the upper airways 
are lined by similar respiratory epithelium, it would be possible to use the more accessible 
sinonasal epithelium as a window into the mechanisms of disease further down the airway.   
The literature detailing the potential mechanisms of lower airway inflammatory disease is 
much more extensive than the published work on the upper airway and sinusitis.  As a result 
the cellular investigations described here are guided by advances in the lower airway disease 
literature.  A similar approach in an unrelated field within otolaryngology, Human Papilloma 
Virus (HPV) mediated head and neck cancer research, following progress in the 
gynaecological cancer literature has yielded significant translational benefits for patients 
with oropharyngeal cancer (D'Souza et al., 2007, Guo et al., 2016).  Within our airways 
research group colleagues have identified that the epithelial alarmin IL-1α is sufficient and 
essential to generate inflammatory responses in human lung fibroblasts (Suwara et al., 
2014).  Further, the inflammation can be pharmacologically blocked by commercially 
available monoclonal blocking antibodies and receptor antagonists that have been shown to 
be safe in clinical trials (Singh et al., 2016).  Due to the ready availability for potential topical 
delivery of IL-1α medications and the extensive epithelial damage seen in CRSsNP the 
epithelial IL-1α alarmin mechanism was investigated with the primary sinonasal cells.  
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Epithelial cells were stimulated with a range of disease specific stimuli together with 
thapsigargin (Figure 34), a known potent inducer of epithelial stress as a positive control 
(Suwara et al., 2014).  The viability of primary epithelial cells was maintained across a range 
of concentrations of respiratory tract bacteria and cigarette smoke extract.  Significant cell 
death was only seen with supra physiological concentrations of 100% cigarette smoke 
extract, mM concentrations of the oxidative stress inducing hydrogen peroxide and high 
doses of the endoplasmic reticulum stressor thapsigargin.  When the culture supernatants of 
these matched cultures were measured for release of the epithelial alarmin IL-1α only very 
small amounts were measurable (Figure 35).  The only measurably significant IL-1α release 
was demonstrated with supra physiological hydrogen peroxide or thapsigargin.  The 
epithelial cells however, are not the only possible mucosal source of alarmins such as IL-1α.  
Since lower airway fibroblasts have previously been shown to be particularly inflammatory in 
response to IL-1α, the response of sinonasal fibroblasts to alarmins as a driver of 
inflammation was investigated.  Primary cultures of nasal fibroblasts were shown to be 
responsive to a range of alarmins, mounting appropriate pro-inflammatory cytokine 
responses.  Across the panel of alarmins investigated, IL-1α produced the most potent and 
significant response in primary nasal fibroblasts.  When directly compared to primary lung 
fibroblasts in the same experimental conditions nasal fibroblasts were approximately twice 
as responsive to co-culture with IL-1α. However, direct comparisons between healthy 
control and CRSsNP participant primary nasal fibroblasts’ response to alarmins did not show 
any statistically significant differences, suggesting there are potentially more factors 
involved, most likely the local inflammatory environment of the sinonasal mucosa.    Since 
nasal fibroblasts demonstrated such a potent response to the alarmin IL-1α alternate 
sources of IL-1α were investigated within the inflammatory milieu of the nasal mucosa.   
Resident tissue macrophages are a prominent source of IL-1α and on reviewing the histology 
of CRSsNP and healthy control tissue in Figure 13 there is an increase in the number of 
macrophages in CRSsNP tissue biopsies. Tissue resident macrophages are also able to 
recognize the danger signals released from necrotic cells via pattern recognition receptors 
and secrete IL-1 resulting in acute neutrophilic inflammation (Kono et al., 2014). Neutrophilic 
infiltration is also seen as feature in the presented CRSsNP histology.  It is therefore plausible 
that the epithelial cell damage, a hallmark of CRSsNP (Kou et al., 2012) is sensed either 
directly by the underling stromal fibroblasts or in combination by the resident macrophages, 
which in turn amplify the immune response by secretion of pre-formed IL-1 with neutrophil 
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chemotaxis.  Within the histology of Figure 13 there is also an increase in the number of CD3 
positive T-cells which is also not surprising; the cell death visible in the epithelial layer will 
also stimulate the acquired immune response by activating T cells.   
The possible mechanism of macrophage mediated IL-1α was investigated by co-culture 
experiments together with independent pharmaceutical blockage of IL-1α and IL-1β using 
neutralising antibodies and blockage of the IL-1 receptor with IL-1α receptor antagonist.  
Primary fibroblasts cultured with conditioned media from resting M0 macrophages, 
classically activated M1 macrophages or alternatively activated M2 macrophages were 
measured for the most prominent inflammatory cytokines, IL-6 and IL-8, shown to be 
released in earlier stimulus experiments (Figure 41).  Neither conditioned media from 
patient derived M0 or M2 macrophages produced significant IL-6 or IL-8 responses in 
primary nasal fibroblasts.  In contrast, however conditioned media from classically activated 
M1 macrophages produced a dramatic release of nanogram concentrations of IL-6 and IL-8 
which could be significantly blocked with a combination of blocking the IL-1α and IL-1β 
components of the IL-1 receptor pathway.  When the effects of conditioned media from 
activated M1 macrophages were blocked by either IL-1α or IL-1β alone it resulted in less IL-6 
and IL-8 release, though the reduction was not as marked as in combination with blockage of 
IL-1α demonstrating greater inhibition than IL-1β.  When used in combination the IL-1α and 
IL-1β neutralising antibodies had the greatest effect.  This result is not surprising as either IL-
1α or IL-1β ligands can stimulate the IL-1 receptor.  The combined effect of IL-1α and IL-1β 
neutralising antibodies was as expected and similar to the effect size when the IL-1 receptor 
antagonist was used as both strategies should block stimulus of the IL-1 signalling pathway. 
The high IL-8 release from nasal fibroblasts cultured with conditioned media from classically 
activated M1 macrophages was in the order of 150-200ng/ml.  When reviewing the CRSsNP 
immunohistochemical immune cell staining the high levels of nasal fibroblast derived IL-8 
would correlate well with the neutrophilic infiltrate seen as IL-8 is a known potent C-X-C 
motif neutrophil chemokine (de Oliveira et al., 2016).  IL-8 primarily induces chemotaxis in 
neutrophils (Kay et al., 2008), was historically called neutrophil chemotactic factor 
(Yoshimura et al., 1987) and is also chemotactic for other granulocytes (Proudfoot, 2002).  
When the immunohistochemical staining for immune cells in chronic sinusitis tissues are 
compared to the fluorescent immunohistochemical staining of tissue sections for epithelial 
and fibroblast markers there is co-localisation of recruited immune cells and nasal fibroblasts 
within the lamina propria. 
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Taken together the histological images presented in this chapter of CRSsNP with the isolated 
primary sinonasal cells and their co-culture experiment responses may help to explain some 
of the characteristic appearances of epithelial cell loss, immune cell recruitment and fibrotic 
basement membrane thickening seen when compared to healthy sinonasal mucosa. 
3.6 Conclusion 
A well phenotyped cohort of healthy control and chronic rhinosinusitis patient participants 
has been recruited.  From this cohort the participants have been characterised based on 
their clinical, endoscopic, radiological, microbiological and histological appearances 
consistent with the published literature.  An initial analysis of possible inflammatory 
mechanisms has been considered and a HTA approved biobank of recruited tissue biopsy, 
microbiological and primary cellular samples established for further study as described in the 
following chapters 4 and 5. 
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4 Results – Sinonasal environment analysis 
 
4.1 Specific aims & objectives 
The specific aims and objectives for this phase of research were to measure the sinonasal 
micro environment of participants and their subsequent study samples with non-polypoid 
chronic rhinosinusitis (CRSsNP) and a cohort of healthy control volunteers.  I aimed to 
measure the environmental milieu of the sinonasal mucosal lining fluid - i.e. the mucus- in 
continuity with the mucosal surface to characterise its constituent inflammatory mediators 
in health and CRSsNP.  The same panel of inflammatory mediators were investigated in 
whole lysates of matched tissue biopsies, isolated primary epithelial and fibroblast samples 
and venous blood serum samples to determine if the inflammatory micro environment was 
preserved between different types of study samples. 
 
4.2 Scientific rationale for experimental approach 
To ensure the laboratory study of my CRSsNP and control samples are as representative of 
the situation in vivo I assayed the mucosal microenvironment in health and CRSsNP.  In 
chapter 3, I have demonstrated well phenotyped cohorts of CRSsNP participants and 
controls and their associated study samples.  So far I have presented information on the 
morphological appearance of histological and cellular samples together with clinical 
symptom scores, surface protein expression and microbiological data.  However, I do not 
have any information on the inflammatory micro environment of the mucosal surfaces in 
CRSsNP and health.  It is important to identify the mediators present in the inflammatory 
environment in the sinonasal cavities (a) so that this information can be used to help 
replicate these physiological conditions in any in vitro cellular based experiments and (b) can 
be used to help develop CRS biomarkers. 
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4.3 Methods 
4.3.1 Mucosal lining fluid samples 
Once enrolled in the study, patients proceeded to surgery as normal.  Following induction of 
general anaesthesia prior to their operation a mucosal lining fluid analysis sample was taken.  
A 7x30mm piece of leukosorb filter paper (BSP0669 Pall life sciences, US) was applied to the 
anterior portion of the inferior nasal turbinate for two minutes (Figure 42) to absorb nasal 
secretions as has been utilised in studies of allergic rhinitis (Nicholson et al., 2011).  It was 
transported back to the lab and stored at -80˚C.   
Once ready for analysis the mucosal lining fluid was eluted out of the filter paper.  The filter 
paper was placed into filter cups within Eppendorf tubes (Costar spin-X, cellulose acetate) 
and 500µl of assay buffer added (PBS, 1% BSA, 0.05% Tween-20, Sigma UK).  Spin filtration 
was performed by centrifugation at 16 000g for 5 minutes.  The eluted fluid was collected 
and either used immediately for analysis by ELISA or stored as aliquots at -80˚C. 
 
 
 
Figure 42.  Mucosal lining fluid analysis technique. (a) The leukosorb filter paper strips are 
placed along the inferior turbinate, just inside the nose.  (b) Photograph of a healthy 
volunteer for mucosal lining fluid analysis, once inserted in the nose a spirometry nasal clip is 
placed to apply even pressure for absorption for two minutes. (a) Image adapted from 
(Chawes et al., 2010). 
 
(a) (b) 
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4.3.2 Serum sample processing 
A blood sample was taken from each participant to determine if chronic sinusitis is 
associated with any systemic signal of inflammation in the peripheral blood.  A 5ml sample 
was collected, stored in a serum separating vacutainer tube and transported back to the 
laboratory.  The serum was separated out by centrifugation at 3500 rpm for 10 minutes in a 
Thermo IEC Centra CL2 centrifuge, with 500µl aliquots stored at -80˚C. 
 
4.3.3 Protein isolation 
Protein was isolated from tissue biopsies by homogenisation with a lysis buffer and protease 
inhibitor.  Two tablets of protease inhibitor (Roche Complete Mini 11836153001, 
Switzerland) were dissolved in 10ml of RIPA lysis buffer (Sigma R0278, UK).  500µl aliquots of 
RIPA buffer/protease inhibitor were prepared and 100mg of tissue was added.  Samples 
were homogenised with a bead homogeniser (Qiagen TissueLyser II, Netherlands) for two 
cycles of 2 minutes at 30Hz.  Homogenised samples were then centrifuged at 13 000 RPM for 
10 minutes at 4˚C to pellet any debris.  Samples were then transferred to a new Eppendorf 
tube to determine the protein extraction yield. 
4.3.4  Protein extraction quantification 
Determination of the yield of protein extracted was performed by the copper ion based 
colorimetric BCA (bicinchoninic acid assay) technique (Pierce 23225, USA). The technique 
was run as per manufacturer’s instructions using the 96 well microplate method.  25µl of 
standards and samples were pipetted onto a 96 well plate and the absorbance was 
measured at 562nm on a Multiskan FC spectrophotometer (Thermoscientific, USA). 
4.3.5 Enzyme linked Immunosorbent assay (ELISA) 
Sandwich ELISA kits were used in a pilot study to quantify the amount of mediators present 
in mucosal lining fluid swabs. A 96 well format ELISA kit was used to measure the amount of 
cytokines including IL-8 and IL-1α present as per manufacturer’s instructions (DY208, R&D 
systems USA).  The amount of cytokine present was read by the optical densities at 450nm 
compared to the standard curve on a Multiskan FC spectrophotometer (Thermoscientific, 
USA). 
  
 103 
4.3.6 MSD Electrochemiluminescence multiplex analysis 
Multiplex MSD electrochemiluminesce is a similar technique to ELISA, using a 96 well 
microplate format to quantify the total protein concentration of a given sample (Figure 43).  
The main advantage it offers over conventional ELISA is the ability to analyse individual 
samples for multiple mediators from small sample volumes that would not otherwise be 
possible to achieve from individual ELISAs.  MSD assays are also sandwich immunoassays, 
though they utilise electrochemiluminescence to generate a light signal rather than a colour 
change.  Sample analytes bind to capture antibodies that are immobilised on a working 
electrode; detection antibodies complete the sandwich technique.  Appropriate buffers are 
added to provide the chemical environment for electrochemiluminescence, a voltage is then 
applied to the working electrode which causes captured analytes to emit light which is then 
measured in the MSD QuickPlex SQ 120 plate reader (Mesoscale discovery, US). 
 
 
 
 
 
 
Figure 43.  Principle of MSD electrochemiluminescence.  Capture of a mediator within a 
sandwich immunoassay which generates light on the application of an electric current.  
Image adapted from (Discovery, 2016).  
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4.3.6.1 Bioinformatics analysis of inflammatory mediators 
Results from the multiplex analysis of sample analytes were interrogated using 
bioinformatics techniques to identify how the various mediators may interact in CRSsNP.  
Differentially expressed mediators were entered into the open access bioinformatics tools 
NetworkAnalyst (http://www.networkanalyst.ca) as per Xia et al in Nature Protocols (2015), 
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) (http://www.webgestalt.org/) as per 
Wang et al (2013), GOstats Bioconductor Gene ontology and gplots Heatmap2 open source R 
package (https://www.bioconductor.org/packages/devel/bioc/html/GOstats.html/) as per 
Falcon and Gentleman (2007) and (Gregory R. Warnes et al., 2016).  
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4.4 Results 
4.4.1 Sinonasal micro environment analysis 
A pilot group for mucosal lining fluid analysis was used to see if I could utilise the technique 
to assay the sinonasal micro environment.  Five volunteers participated in this test group 
with a range of nasal symptoms.  Their sinonasal outcome test 22 (SNOT-22) scores varied 
from 3 to 22.  From each participant the fluid eluted from the mucosal lining fluid analysis 
was analysed to determine firstly if any alarmins or cytokines could be detected by ELISA and 
if so, their respective concentrations. 
Analysis of the eluted mucosal lining fluid demonstrated measurable amounts of the alarmin 
IL-1α and the cytokine IL-8.  IL-1α was measured in the range 130 – 320pg/ml and IL-8, 40-
140ng/ml, demonstrating mucosal lining fluid concentrations well within the working 
tolerances of the ELISA kits (Figure 44).  Whilst the sample number is much too small to draw 
statistically significant inferences, the  possibility of  a positive correlation between SNOT-22 
score and IL-1α mucosal lining fluid concentrations appears to warrant further exploration. 
 
 
Figure 44. Histograms to show the pilot amounts of IL-8 and IL-1α detected from eluted 
mucosal lining fluid of anonymised volunteers by ELISA.  The volunteers are identified by 
their Sino Nasal Outcome Test-22 (SNOT-22) score along the x axis (n=5). 
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Following pilot proof of principle, 40 participants consisting of 18 healthy controls and 22 
CRSsNP patients were selected for further analysis.  The technique established in section 
4.3.1 was used to generate mucosal lining fluid samples for multiplex MSD 
electrochemiluminesce using the V-PLEX Human Biomarker 40-Plex Kit (Mesoscale discovery, 
US).  The measurements for the 40 different human biomarker mediators were compared 
between the CRSsNP and control groups and are displayed in Figure 45 and Table 6.  The 
expression of 13 of the 40 human biomarker panel mediators was significantly different in 
CRSsNP and healthy control samples using a Mann Whitney U test (p<0.05 – p<0.005).  The 
raw data was Log 10 transformed to make the data spread more uniform and the same 
pattern of difference was obtained with an un-paired t-test.  The 13 mediators comprised a 
group of 5 chemokines, 3 cytokines, 3 angiogenesis mediators and 2 vascular injury 
mediators (Table 5). 
 Mediator 
5 chemokines Macrophage inflammatory protein 1-alpha (MIP-1alpha/CCL3) 
Macrophage inflammatory protein 1-beta (MIP-1beta/CCL4) 
Monocyte chemoattractant protein 4 (MCP-4/CCL13) 
Thymus and activation regulated chemokine (TARC/CCL17) 
Eotaxin 3 (CCL26) 
3 cytokines Interleukin 10 (IL-10) 
Interleukin 6 (IL-6) 
Interleukin 17 (IL-17) 
3 angiogenesis mediators  Basic fibroblast growth factor (bFGF) 
Placental growth factor (PlGF) 
Soluble Fms-like tyrosine kinase 1 (sFlt-1) 
/ vascular endothelial growth factor receptor 1 (VEGFR1) 
2 vascular injury 
mediators 
Serum amyloid A (SAA) 
Vascular cell adhesion molecule 1 (VCAM-1/CD106) 
 
Table 5.  List of significantly different CRSsNP mucosal lining fluid mediators. 
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Figure 45.  Histograms to show the relative fold change of mucosal lining fluid markers in 
CRSsNP participants compared to controls.  * = p<0.05, ** =p<0.005, n=40 participants.  
 
Table 6.  Table to summarize mucosal lining fluid marker data.  ns = non-significant p value. 
Marker Median (pg/ml) Range (pg/ml) Median (pg/ml) Range (pg/ml) fold change p-value p-value
Eotaxin 3 11.68 0-708.57 93.42 0-2799.62 8.00 0.0207 *
MIP-1beta 46.58 9.19-244.86 200.4 7.93-1740 4.30 0.0018 **
IL-10 0.09104 0-1.22 0.3635 0-2.66 3.99 0.0344 *
MIP-1alpha 22.41 7.34-133.77 88.77 8.89-809.32 3.96 0.0037 **
IL-6 3.353 0.79-46.22 10.82 0.30-815.95 3.23 0.0416 *
IL-17 1.445 0-17.73 3.637 0.07-21.72 2.52 0.0475 *
SAA 1257 216.77-13953.01 3152 321.80-134678.30 2.51 0.0174 *
MCP4 11.07 5.41-78.96 23.96 3.02-87.33 2.16 0.0148 *
TARC 18.1 3.70-159.38 37.9 2.03-133.31 2.09 0.0388 *
PIGF 25.55 13.30-95.21 49.86 11.17-206.01 1.95 0.0188 *
sFLT1 256.2 96.83-1067.99 429.8 28.90-3057.15 1.68 0.0218 *
bFGF 15.88 1.02-79.85 25.33 2.21-69.24 1.60 0.0218 *
VCAM-1 1506 88.03-8366.40 2071 98.16-27388 1.38 0.0416 *
TNFalpha 0.207 0-2.48 0.626 0-5.91 3.02 0.1422 ns
IL-8 4158 79.36-186497.7 12028 309.26-183320 2.89 0.3769 ns
IL-12p40 1.399 0.27-9.51 3.62 0.37-18.77 2.59 0.0741 ns
IFNgamma 0.7294 0-2992.93 1.723 0-145.68 2.36 0.1253 ns
IL-7 13.8 3.91-48.95 28.59 4.79-60.31 2.07 0.0787 ns
IL-1beta 17.21 0.86-637.23 34.45 0.97-1047.46 2.00 0.3347 ns
IL-4 0.05214 0-0.30 0.102 0-1.17 1.96 0.1778 ns
ICAM-1 2689 385.24-9382.23 5038 264.52-16112.08 1.87 0.0577 ns
VEGF-D 66.29 0-489.13 117.3 23.34-366.22 1.77 0.3769 ns
MDC 56.77 12.11-360.09 100.1 14.26-323.23 1.76 0.2713 ns
MCP1 164.9 25.74-461.99 288.1 13.31-784.12 1.75 0.1311 ns
CRP 7249 540.09-60334.98 12059 723.38-398357.1 1.66 0.1616 ns
TNFbeta 0.136 0-0.67 0.2249 0.08-1.44 1.65 0.062 ns
Tie2 185.9 0-556.27 301.2 20.70-967.78 1.62 0.1383 ns
VEGF 865.5 228.78-5047.48 1362 202.17-4593.71 1.57 0.2065 ns
IL-5 1.36 0.37-3.26 2.12 0.15-5.94 1.56 0.0615 ns
IL-15 1.363 0.37-3.25 2.117 0.15-5.94 1.55 0.0615 ns
VEGF-C 176.7 87.22-1629.34 258.1 34.51-3333.66 1.46 0.1535 ns
GMCSF 0.4908 0.09-2.52 0.7013 0.08-9.39 1.43 0.2956 ns
Eotaxin 47.45 8.46-244.39 66.1 4.43-268.09 1.39 0.2065 ns
IP-10 471.1 19.70-6424 628.2 60.96-8749.44 1.33 0.1985 ns
IL-16 527.7 4.35-2058.67 661 9.22-6919.09 1.25 0.2268 ns
IL-12p70 0.1194 0-0.65 0.1494 0-1.88 1.25 0.5836 ns
IL-1alpha 89 13.95-424.83 100.4 12.89-393.17 1.13 0.6311 ns
IL-13 0.7633 0-1.81 0.7959 0-4.83 1.04 0.3148 ns
IL-2 0 0-1.23 0 0-3.67 0.00 0.6818 ns
Control CRS
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Figure 46.  Column scatter plots of discriminant chemokine mediators between CRSsNP and 
healthy control participants. * = p<0.05, ** =p<0.005, n=40. 
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Figure 47 Column scatter plots of the discriminant cytokine and angiogenesis mediators 
between CRSsNP and healthy control participants. * = p<0.05, ** =p<0.005, n=40. 
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Figure 48.  Column scatter plots of the discriminant vascular injury mediators between 
CRSsNP and healthy control participants. * = p<0.05, ** =p<0.005, n=40. 
 
 
4.4.1.1 Relationship between mediators and symptom scores 
The 13 discriminant mucosal lining fluid mediators (Table 5) were compared to the 
rhinological subscale of the sinonasal outcome test 22 (RSNOT-22) patient reported outcome 
measure scores.  All 13 were associated with the SNOT-22 rhinological sub-scale symptom 
scores (p<0.05 – p<0.01) by Spearman’s rank-order correlation (Appendix and Figure 49- 
Figure 51).  A Spearman's rank-order correlation was also run to assess the relationship 
between RSNOT-22 and mucosal lining fluid mediators in CRSsNP participant samples alone. 
Preliminary analysis showed the relationship to be monotonic, as assessed by visual 
inspection of a scatterplot.  Within this CRSsNP sub group analysis there was a positive 
correlation between RSNOT-22 and MIP1a, MIP1b, sFLT1 and VCAM (rs = .424,.455,.453,.498 
respectively, all p < 0.05). 
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Figure 49.  XY plots to show relationship between SNOT-22 rhinological subscale symptom 
scores and significantly differentially expressed mucosal lining fluid chemokine markers, 
n=40. 
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Figure 50.  XY plots to show relationship between SNOT-22 rhinological subscale symptom 
scores and significantly differentially expressed mucosal lining fluid cytokine and 
angiogenesis markers, n=40. 
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Figure 51.  XY plots to show relationship between SNOT-22 rhinological subscale symptom 
scores and significantly differentially expressed mucosal lining fluid vascular injury markers, 
n=40. 
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4.4.2 Factor analysis 
A factor analysis was used to try to make sense of the multiple correlations among the 
markers which discriminate controls and patients. Measurement of the nasal 
microenvironment in such a way has the potential to revolutionise CRS phenotyping which is 
currently quite crude – allergy or no allergy; polyps or no polyps.  Exploratory factor analysis 
was run on the 13 discriminant biomarker levels in my 40 CRSsNP and control participants.  
The suitability of factor analysis was measured as a part of the analysis.  Firstly, inspection of 
the correlation matrix shows that all protein markers had multiple correlation co-efficients 
greater than 0.4 (Table 8).  Secondly, the cumulative Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy was satisfactory at 0.700, classified as ‘middling’ by Kaiser (Kaiser, 1974).  
Finally, Bartlett’s test of sphericity was statistically significant (p<0.0005), again suggesting 
that the data was likely to be suitable for factor analysis. 
On performing a factor analysis five factors explained more than 89.5% of the total variance 
of the mediators: 44.1%, 19.8%, 11.9%, 7.6% and 6.3% respectively (Figure 52).  Analysis of 
the scree plot shows an inflection point at four factors where the graph flattens (Figure 52) 
and addition of further factors adds very little to the total variance explained (Cattell, 1966).  
Inspection of the rotated component matrix confirmed the selection of a four factor solution 
as it met the interpretability criterion. 
Use of a four factor solution explained 83.3% of the total variance.  Varimax orthogonal 
rotation was used to aid interpretation (Table 7).  Analysis of the rotated solution confirmed 
a simple structure (Thurstone, 1948)  with strong loadings of pro-inflammatory items on 
factor 1, vascular inflammatory items on factor 2, chemokine and growth factor items on 
factor 3 and regulatory items on factor 4. The model thus has convincing face validity, 
though being critical of these groupings factor 3 does not demonstrate as clean loading of 
items into the factor.  Placental growth factor (PlGF) and basic fibroblast growth factor 
(bFGF) do not show as clean loading between the factors compared to the remaining 11 
mediators in the rotated component matrix (Table 8) and have therefore been italicised in 
Table 9. 
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Figure 52.  Scree plot demonstrating Eigen values for the 13 CRSsNP discriminatory mucosal 
lining fluid mediator factor analysis. 
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Rotated Component Matrixa 
 Factor 
1 2 3 4 
IL6 .941 .003 .058 .219 
MIP1a .894 .052 .182 .317 
MIP1b .884 .099 .349 .229 
SAA -.045 .970 .051 -.008 
sFlt1 .075 .902 .170 .144 
VCAM1 .139 .894 .262 .090 
TARC .296 .233 .863 .037 
Eotaxin3 .067 -.032 .807 -.117 
MCP4 .330 .171 .702 .455 
bFGF -.079 .359 .646 .330 
PIGF .340 .324 .518 .091 
IL17 .279 .085 .141 .882 
IL10 .353 .086 -.009 .843 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. 
a. Rotation converged in 6 iterations. 
Table 8.  Discriminant CRSsNP mucosal lining fluid factor analysis rotated loadings matrix. 
Factor Name Mucosal lining fluid marker 
Factor 1 Pro-inflammatory Macrophage inflammatory protein 1α (MIP-1α) 
Macrophage inflammatory protein 1β (MIP-1β) 
Interleukin 6 (IL-6) 
Factor 2 Vascular inflammatory Serum amyloid A (SAA) 
Fms-like tyrosine kinase 1 (sFlt1) 
Vascular cell adhesion molecule 1 (VCAM-1) 
Factor 3 Chemokine & growth 
factor 
Eotaxin 3 
Thymus and activation regulated chemokine (TARC) 
Monocyte chemo attractant protein 4 (MCP-4)  
Placental growth factor (PlGF) 
Basic fibroblast growth factor (bFGF) 
Factor 4 Regulatory Interleukin 10 (IL-10) 
Interleukin 17 (IL-17) 
Table 9.  The four key components characterising CRSsNP inflammation and their 13 key 
constituent mediators. 
 118 
4.4.3 Bioinformatics analysis of inflammatory gene pathways 
WEB-based Gene SeT AnaLysis Toolkit (WebGestalt) was used to identify other disease 
associations of the 13 key mucosal lining fluid mediators (Table 6) and multiple hypothesis 
testing correction has been applied, the results are shown in (Table 10).  The top 15 disease 
associations included respiratory tract infections, inflammation, common cold, nasal polyps 
and sinusitis further confirming the specificity of the mucosal lining fluid analysis results.  
WebGestalt also provides details of drug associations (Table 11). Dexamethasone, 
dinoprostone - a prostaglandin E2, anakinra - an IL-1 receptor antagonist, and immune 
globulin were found to be significantly associated with the CRSsNP differentially expressed 
mucosal lining fluid mediators. 
The 13 key CRSsNP mediators were inputted into Network Analyst. The protein-protein 
interaction network generated is shown in Figure 53.  Using Heatmap2 in gplots a heat map 
displaying log(protein concentration) of the 13 key CRSsNP mediators was created (Figure 
54).  GOstats was used to further analyse the differentially expressed mediators. A flow 
diagram highlighting key gene ontology biological processes (GO BP) categories significantly 
overrepresented in red was created (Figure 55 & Figure 56). 
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WebGestalt top 15 disease associations Corrected p value 
Respiratory Tract Infections p=1.17x10-11 
Inflammation p=1.17x10-11 
Common Cold p=1.17x10-11 
Bronchiolitis p=5.59x10-10 
Bronchitis p=7.40x10-10 
Necrosis p=5.89x10-9 
Immune System Diseases p=1.01x0-8 
Infection p=9.33x10-8 
Respiratory Tract Diseases p=3.74x10-7 
Lymphoproliferative Disorders p=3.74x10-7 
Nasal Polyps p=3.74x10-7 
Chorioamnionitis p=4.69x10-7 
Sinusitis p= 7.49x10-7 
Encephalitis p= 7.88x10-7 
Disease Progression p= 1.09x10-6 
Table 10.  The top 15 disease associations calculated by WEB-based Gene SeT AnaLysis 
Toolkit (WebGestalt) of the 13 key CRSsNP mediators.  p values corrected for multiple 
hypothesis testing. 
 
WebGestalt drug associations Corrected p value 
Dexamethasone p=0.0012 
Dinoprostone p=0.0008 
Anakinra p=0.0004 
Immune globulin p=0.0003 
Table 11.  Four identified drug associations calculated by WEB-based Gene SeT AnaLysis 
Toolkit (WebGestalt) of the 13 key CRSsNP mediators.  p values corrected for multiple 
hypothesis testing. 
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Figure 53.  NetworkAnalyst protein-protein interaction network of the 13 key CRSsNP 
mediators shown in red, with their associated receptors and interactions in blue.
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Figure 56.  Flow diagram highlighting key gene ontology (GO) molecular and cellular 
categories significantly overrepresented in red. 
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4.4.4 qRT-PCR tissue biopsy replications of differentially expressed mucosal 
lining fluid mediators 
Quantitative real time PCR was used to investigate tissue biopsy mRNA for the 13 key 
CRSsNP mediators.  The five chemokine mediators (Factor 3, Table 9) were also replicated at 
the mRNA level in their tissue biopsies (p<0.001-p<0.05, Figure 58).  Two of the three 
cytokine mediators seen in mucosal lining fluid could also be replicated at the mRNA level in 
tissue biopsies (Figure 59); interleukin 10 and interleukin 17 (p<0.001).  However, differential 
expression of interleukin 6 mRNA in tissue biopsies was not replicated despite multiple 
attempts.  Only one of the three angiogenesis biomarkers, basic fibroblast growth factor 
showed a statistically significant (p<0.05) upregulation in mRNA from CRSsNP tissue biopsies 
compared to controls (Figure 58).  Whilst both vascular injury mediators, Serum amyloid A 
(SAA) and Vascular cell adhesion molecule 1 (VCAM-1/CD106) showed increased mRNA 
levels in CRSsNP participants consistent with the mucosal lining fluid protein samples, 
neither reached statistical significance (Figure 57). 
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Figure 57.  qRT-PCR tissue biopsy sample replications of key CRSsNP Factor 1 pro-
inflammatory mediators (left column) and Factor 2 vascular inflammatory mediators (right 
column), n=6 with triplicate repeat.   *** = p<0.001, ** = p<0.01, * = p<0.05. 
 
 126 
 
 
  
Figure 58.  qRT-PCR tissue biopsy sample replications of key CRSsNP Factor 3 chemokine & 
growth factor mediators, n=6 with triplicate repeat.  .  *** = p<0.001, ** = p<0.01, * = 
p<0.05. 
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Figure 59.  qRT-PCR tissue biopsy sample replications of key CRSsNP Factor 4 regulatory 
mediators, n=6 with triplicate repeat.   
4.4.5 qRT-PCR cellular analysis of differentially expressed mucosal lining fluid 
markers 
Quantitative real time RT-PCR was also used to investigate if the 13 key CRSsNP mediators 
were preserved in primary cultures of CRSsNP and control epithelial and fibroblast cells.   
Only one of the mediators, macrophage inflammatory protein 1-alpha (MIP-1alpha/CCL3) 
demonstrated statistically significant (p<0.01) expression between primary cell cultures from 
CRSsNP participants and healthy controls.  Fibroblasts from CRSsNP participants 
demonstrated an approximately three fold upregulation in their MIP-1alpha mRNA when 
compared to healthy control fibroblasts (Figure 60). MIP-1beta and MCP-4 appear to show a 
similar trend to MIP-1alpha, though do not reach statistical significance.  The relative gene 
expression levels detectable in the cells, however were markedly less than those seen in 
tissue biopsy samples as highlighted by the split in the y axis. In general the levels of the 13 
key CRSsNP mediator genes were notably lower in primary cultures of both epithelial and 
fibroblast cells than in tissue biopsy samples.  The sole exception was basic fibroblast growth 
factor (bFGF) which showed the highest expression in primary cultures of fibroblast cells 
(Figure 61), with an approximate 10 fold increase in fibroblast mRNA levels compared to 
tissue samples.  This is perhaps not surprising as it is a fibroblast derived product.  Vascular 
cell adhesion molecule 1 (VCAM-1/CD106) and interleukin 6 (IL-6) both also showed higher 
relative gene expression in primary cultures of nasal fibroblasts than in their respective 
tissue biopsy samples (Figure 61 and Figure 62). 
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Figure 60.  qRT-PCR PNEC, PNF and tissue biopsy sample replications of differentially 
expressed mucosal lining fluid chemokine mediators, n=6 with triplicate repeat.   
*** = p<0.001, ** = p<0.01, * = p<0.05. 
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Figure 61.  qRT-PCR PNEC, PNF and tissue biopsy sample replications of differentially 
expressed mucosal lining fluid cytokine and angiogenesis mediators, n=6 with triplicate 
repeat.  *** = p<0.001, ** = p<0.01, * = p<0.05. 
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Figure 62.  qRT-PCR PNEC, PNF and tissue biopsy sample replications of differentially 
expressed mucosal lining fluid vascular injury mediators, n=6 with triplicate repeat.  ***  
p<0.001, **  p<0.01, *  p<0.05. 
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4.4.6 Tissue biopsy samples multiplex protein analysis 
Total protein was isolated from tissue biopsies of CRSsNP and healthy control participants 
and compared with the MSD multiplex analysis findings from mucosal lining fluid swabs 
(Section 4.3.1).  Protein was isolated, quantified and standardised at 2mg/ml (see 4.3.3 and 
4.3.4)  prior to analysing with an identical multiplex MSD electrochemiluminesce using the V-
PLEX Human Biomarker 40-Plex Kit (Mesoscale discovery, US). 
Analysis of isolated protein from the tissue biopsy samples showed 15 (p<0.05 – p<0.001) 
differentially expressed mediators between CRSsNP and healthy control samples (Figure 
63Table 13).  The proteins identified from the tissue biopsy samples consisted of a group of 7 
chemokines, 6 cytokines, and 2 vascular injury mediators (Table 12).  
 
 Mediator 
7 chemokines Monocyte chemoattractant protein 1 (MCP-1/CCL2)  
Macrophage inflammatory protein 1-beta (MIP-1beta/CCL4) 
Eotaxin (CCL11) 
Monocyte chemoattractant protein 4 (MCP-4/CCL13) 
Thymus and activation regulated chemokine (TARC/CCL17) 
Macrophage-derived chemokine (MDC/CCL22) 
Eotaxin 3 (CCL26) 
6 cytokines Interleukin 4 (IL-4) 
Interleukin 5 (IL-5) 
Interleukin 8 (IL-8) 
tissue necrosis factor alpha (TNF-alpha) 
tissue necrosis factor beta (TNF-beta) 
granulocyte monocyte colony stimulating factor (GM-CSF) 
2 vascular injury 
mediators 
Serum amyloid A (SAA) 
C reactive protein 
 
Table 12.  List of significantly different CRSsNP tissue biopsy mediators. 
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Figure 63.  Histograms to show the relative fold change of tissue biopsy lysates in CRSsNP 
participants compared to controls.  *** p<0.001, **  p<0.01, *  p<0.05., n=19 participants 
 
Table 13.  Table to summarize tissue biopsy lysate data.  ns = non-significant p value. 
Marker Median (pg/ml) Range (pg/ml) Median (pg/ml) Range (pg/ml) fold change p-value p-value
IL-5 0.22 0.05-0.86 11.31 0.53-24.35 51.41 0.0029 **
MCP4 29.49 14.9-55.35 1118 28.20-3444 37.91 0.0005 ***
Eotaxin 3 963.2 322.4-2186.8 25771 793.9-85203 26.76 0.0026 **
TARC 11.47 6.74-29.47 101.8 11.47-146.5 8.88 0.0012 **
Eotaxin 20.94 9.97-60.49 112 23.50-824.9 5.35 0.0012 **
TNFbeta 0.126 0.072-0.196 0.619 0.08-2.57 4.91 0.0245 *
MIP-1beta 102.2 35.23-282.62 342 98.88-5219.17 3.35 0.0098 **
TNFalpha 0.424 0.296-0.839 1.281 0.267-9.153 3.02 0.0283 *
IL-4 0.1066 0.07-0.22 0.3144 0.06-0.591 2.95 0.0221 *
SAA 29673 12518-61053 84103 26663-1187515 2.83 0.0130 *
MCP1 189 90.64-392.62 498 33.28-4901.6 2.63 0.0283 *
IL-8 174.9 758.49-2034 438 93.36 2.50 0.0358 *
MDC 162.7 142.3-402.9 363.9 211.26-2419 2.24 0.0026 **
GMCSF 0.2113 0.054-.218 0.4391 0.09-1.398 2.08 0.0220 *
CRP 49836 33844-60927 75419 9499-174336 1.51 0.0283 *
VCAM-1 740.8 476-3149 2736 543.1-13649 3.69 0.0831 ns
IL-2 0.3542 0.126-2.28 0.9326 0.20-2.27 2.63 0.1490 ns
MIP-1alpha 58.19 33.33-157.41 134 41.03-9291.34 2.30 0.0831 ns
IL-6 11.55 0.29-51.6 24.66 0.12-796.7 2.14 0.3402 ns
IL-1alpha 0.3883 0.09-0.48 0.829 0.27-5.45 2.13 0.2667 ns
IP-10 202.8 134.6-2526 420.1 72-107981 2.07 0.4789 ns
IL-12p40 4.06 1.22-5.59 6.787 2.64-25.20 1.67 0.0556 ns
IL-7 1.016 0.52-4.88 1.902 0.42-5.04 1.87 0.7732 ns
IL-16 1969 958.3-3504.4 3569 639.7-6220.4 1.81 0.1198 ns
ICAM-1 35507 21857-47052 56903 3915-288877 1.60 0.2268 ns
IL-15 3.078 2.17-5.21 4.289 0.89-14.30 1.39 0.5918 ns
IL-13 2.295 1.748-3.873 3.062 1.77-8.71 1.33 0.2268 ns
VEGF-C 146.3 103.6-222.9 182.8 67.8-600.4 1.25 0.4824 ns
PIGF 104.2 93.73-171.40 121.6 21.76-357.43 1.17 0.4824 ns
sFLT1 4220 3614-8368 4805 318.2-8392 1.14 0.7108 ns
IL-1beta 0.967 0.31-1.33 1.101 0.10-52.42 1.14 0.5962 ns
IL-10 0.1138 0.089-0.127 0.1263 0.067-0.597 1.11 0.9636 ns
Tie2 12272 0-556.27 12218 20.70-967.78 1.00 0.9999 ns
IL-17 0.7785 0.09-9.27 0.7097 0.528-62.94 0.91 0.3355 ns
bFGF 43892 21337-77393 38646 318.95-57866 0.88 0.3845 ns
IFNgamma 1.034 0.39-1.68 0.878 0.31-20.83 0.85 0.9999 ns
IL-12p70 0.0346 0.02-0.04 0.0268 0.02-0.09 0.77 0.8000 ns
VEGF 270.6 135.9-533.9 194.9 202.17-4593.71 0.72 0.1956 ns
VEGF-D 130.5 54.81-216.1 78.05 34.1-162.84 0.60 0.2991 ns
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4.4.7 Isolated epithelial and fibroblast cells multiplex protein analysis 
Protein was also isolated from cultures of primary nasal epithelial cells and primary nasal 
fibroblasts using the same methods detailed in sections 4.3.3 and 4.3.4.  Samples of protein 
were standardised at 2mg/ml and healthy control samples were compared to CRSsNP using 
the V-PLEX Human Biomarker 40-Plex Kit (Mesoscale discovery, US).  When compared to 
healthy control samples epithelial cells from CRSsNP participants showed one statistically 
significant mediator (p=0.0274), interleukin 5  (IL-5) to be upregulated by a factor of 1.34x 
compared to healthy control cells. 
When primary nasal fibroblasts were analysed using the same technique, one mediator – 
interleukin 1β (IL-1β) - was also shown to be statistically significantly upregulated by a factor 
of 3.3x (p= 0.0469) in CRSsNP participants compared to healthy control fibroblasts.   
The comparison of mediators differentially expressed in tissue biopsies, mucosal lining fluid 
and cellular samples is tabulated (Table 14), presented in a Venn diagram (Figure 64) and in 
histograms detailing the relative concentrations of a representative selection of matched 
participant samples (Figure 65).  Figure 65 shows the most marked differences are seen 
between CRSsNP participants and controls in tissue biopsy samples. 
4.4.8 Serum samples multiplex protein analysis 
Serum samples from CRSsNP and healthy control participants were compared using the 
same V-PLEX Human Biomarker 40-Plex Kit (Mesoscale discovery, US) to determine if any 
systemic signals from CRSsNP can be detected in participants’ blood.  No significant 
differences were identified. 
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Mucosal lining fluid 
 
  Tissue   
Marker 
fold change p-value 
 
Marker 
fold 
change 
p-value 
Eotaxin 3 8.00 0.0207 
 
IL-5 51.41 0.0029 
MIP-1beta 4.30 0.0018 
 
MCP4 37.91 0.0005 
IL-10 3.99 0.0344 
 
Eotaxin 3 26.76 0.0026 
MIP-1alpha 3.96 0.0037 
 
TARC 8.88 0.0012 
IL-6 3.23 0.0416 
 
Eotaxin 5.35 0.0012 
IL-17 2.52 0.0475 
 
TNF beta 4.91 0.0245 
SAA 2.51 0.0174 
 
MIP-1beta 3.35 0.0098 
MCP4 2.16 0.0148 
 
TNF alpha 3.02 0.0283 
TARC 2.09 0.0388 
 
IL-4 2.95 0.0221 
PIGF 1.95 0.0188 
 
SAA 2.83 0.0130 
sFLT1 1.68 0.0218 
 
MCP1 2.63 0.0283 
bFGF 1.60 0.0218 
 
IL-8 2.50 0.0358 
VCAM-1 1.38 0.0416 
 
MDC 2.24 0.0026 
    
GMCSF 2.08 0.0220 
    
CRP 1.51 0.0283 
Table 14.  Comparison of the discriminant CRSsNP mediators in mucosal lining fluid swabs 
and tissue biopsy lysates. 
 
 
Figure 64.  Venn diagram demonstrating the statistically significant protein mediators 
compared between the different CRSsNP and healthy control samples. 
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   Figure 65.  Representative histograms to compare the amounts of mediators 
present in matched participants tissue, mucosal swab, serum and cellular samples.  
Control samples are shown on the left column and CRSsNP the right column. 
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4.5 Discussion 
4.5.1 Potential value of CRS biomarker profiling 
The current gold standard criteria for the diagnosis and management of chronic 
rhinosinusitis are presented in the EPOS 2012 international consensus document (Fokkens et 
al., 2012).  The principal factors that determine diagnosis and management algorithms are 
the presence of sinonasal symptoms supported by endoscopic and radiological appearances.  
Within current clinical practice no biomarkers have been defined to support the diagnosis or 
guide medical or surgical treatment selection in CRS patients.  In contrast, there are well 
recognised biomarkers of systemic inflammatory conditions with CRS components - e.g. 
serum cANCA in granulomatosis with polyangiitis (GPA) (Thai et al., 2014) (Kallenberg et al., 
2006) serum angiotensin converting enzyme (ACE) in sarcoidosis (Costabel and Teschler, 
1997) and rheumatoid factor in rheumatoid arthritis (Onuora, 2012). Such biomarkers are 
valuable adjuncts in confirmation of diagnosis and monitoring response to treatment.  The 
ability to assay the sinonasal environment with a biomarker or panel of markers may offer 
an objective ‘inflammatory score’ measure in addition to the subjective self and observer 
rated symptom, endoscopic and radiological scores.  In particular, there is currently lack of 
clarity and guidance as to the optimum point at which to progress from medical 
management to surgical intervention (Bassiouni et al., 2013) (Benninger et al., 2015).  CRS 
biomarkers have the potential therefore both to rationalise and personalise management 
(Deroee et al., 2009, Divekar et al., 2015, Riechelmann et al., 2005). Measurement of the 
local micro environment in health and CRSsNP also usefully informs replication of the CRS 
inflammatory milieu in future in vitro studies.  
4.5.2 Sampling Methods  
A variety of sampling techniques are available to collect nasal specimens.   
1. The commonest is the conventional microbial culture swab on a stick, which can also be used 
for molecular analysis (Chalermwatanachai et al., 2015). The main drawback is its small 
surface area for absorption of nasal cavity mucus.  Further, the convex shape of the tip 
restricts the portion of the absorbent swab tip which achieves tissue contact and sampling.   
2. Nasal lavage to collect samples of mucus and nasal fluid has the drawback of a substantial 
dilutional effect from the 5-10 ml of irrigation fluid, precluding detection of certain low 
concentration mediators. (Bisgaard et al., 1988).  Some lavage fluid may escape posteriorly 
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into the nasopharynx, which limits reproducibility.  Nasal lavage is also variably tolerated by 
the subject.   
3. A suction trap to aspirate nasal secretions can be used, though often yields pooled secretions 
rather than those in continuity with the sinonasal mucosa.  
4. Nasal sampling can also be performed with brushings or a rhinoprobe curette, both of which 
provide cellular specimens for analysis and are relatively atraumatic although they will collect 
more than the mucosal layer.  Lin and colleagues found that the rhinoprobe curette was 
especially helpful if measures of mucosal leukocytes were required in addition to epithelial 
cells (Lin et al., 2001).  
5. Larger mucosal and tissue samples can be collected with an endoscopic guided biopsy 
performed under local or general anaesthesia. This however provides only a small amount of 
covering nasal secretions or mucus along with the tissue biopsy.   
 
The use of a mucosal lining fluid swab as presented in this chapter has a number of distinct 
advantages for sampling the mucosa.  Firstly it is atraumatic and well tolerated as confirmed 
from the pilot group of healthy laboratory colleagues, the larger patient participant cohort 
and from personal experience.  It has a large flat standardised area of 210 mm2 (7x30mm) 
that can be placed in continuity along the inferior turbinate with the aid of a simple 
headlight to maximise mucosal contact along its length.  The strip is made of Leukosorb, a 
hydrophilic, synthetic absorptive matrix and measures the mucosal lining fluid directly 
without further dilution, enabling low concentration mediators to be detected that would 
not be possible with other mucus sampling techniques.  The mucosal lining fluid swab 
technique is also relatively quick, being completed in just over two minutes confirming its 
suitability for use in routine clinical outpatient assessments.  The ability to complete a 
mucosal lining fluid analysis swab with each patient would enable personalised, longitudinal 
monitoring of the natural history of the CRS mucosal micro environment and its response to 
different treatments. 
4.5.3 Mucosal lining fluid characterisation 
The mucosal lining fluid assay demonstrated that within this sample the expression of 13 
mediators differed between CRSsNP patients and healthy control participants (Figure 45).   
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4.5.3.1 Chemokines 
The largest group of mediators identified comprised five chemokines; macrophage 
inflammatory protein 1-alpha (MIP-1alpha/CCL3), macrophage inflammatory protein 1-beta 
(MIP-1beta/CCL4), Monocyte chemoattractant protein 4 (MCP-4/CCL13), thymus and 
activation regulated chemokine (TARC/CCL17) and eotaxin 3 (CCL26).   
The identification of chemokine upregulation in the micro environment of the sinonasal 
cavities is consistent with the histological data presented in chapter 3.  These results showed 
increased macrophages, monocytes, T-cells, eosinophils and neutrophils in CRSsNP 
participants compared to healthy controls appropriate for the group of C-C motif 
chemokines identified.  MIP-1alpha/CCL3 and MIP-1beta/CCL4 are C-C motif chemokines 
which recruit and activate polymorphonuclear leukocytes via CCR chemokine receptors.  
They were first identified from lipopolysaccharide (LPS) stimulated murine macrophages in 
1988 (Wolpe et al., 1988), with their human equivalents reported over the next few years 
(Zipfel et al., 1989) followed by a new systematic nomenclature for the emerging chemokine 
superfamily (Zlotnik and Yoshie, 2000) based on the position of the first two cysteine 
residues.  MIP-1alpha and MIP-1 beta share more than 50% homology and both chemokines 
are inducible in most mature haematopoietic cells.  Functionally both MIP-1alpha and MIP-
1beta are chemoattractant for monocytes, T-cells, neutrophils and natural killer cells 
(Menten et al., 2002), however MIP-1alpha is preferentially chemoattractant for CD8 
cytotoxic T-cells and MIP-1beta attractant for CD4 T helper cells (Taub et al., 1993).   
Monocyte chemoattractant protein 4 (MCP-4/CCL13) is another member of the C-C motif 
chemokine family that signals via the CCR 2 and CCR 3 chemokine receptors.  MCP-4 is highly 
chemoattractant for monocytes, lymphocytes, eosinophils and basophils in chronic 
inflammatory diseases (Romagnani, 2002) and it would therefore seem appropriate that it 
has been shown to be upregulated in mucosal lining fluid samples from CRSsNP participants 
together with the corresponding histological appearances shown in chapter 3.   
Thymus and activation regulated chemokine (TARC/CCL17) is also a member of the C-C motif 
chemokine family and signals by the CCR4 chemokine receptor to induce chemotaxis in T-
cells (Imai et al., 1997).  Immunohistochemical staining of CRSsNP tissues in the previous 
chapter has demonstrated an increase in T-cell recruitment compared to healthy control 
tissues which would corroborate the upregulation of TARC identified in CRSsNP mucosal 
lining fluid swabs.   
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The final upregulated mucosal lining fluid chemokine to be identified was Eotaxin 3 (CCL26), 
also belonging to the C-C motif chemokine family.  Eotaxin 3 is chemotactic for eosinophils 
and basophils via the CCR 3 chemokine receptor and typically results in a Th2-polarised 
environment including interleukins IL-4 and IL-13.  A Th-2 polarised cytokine environment 
has been suggested to be more typical of chronic rhinosinusitis with nasal polyps (CRSwNP) 
(Van Crombruggen et al., 2011), although there still remains overlap between the distinct 
phenotypes reflecting the degree of heterogeneity in chronic rhinosinusitis (Sanchez-Segura 
et al., 1998, Tomassen et al., 2016) (Lee and Lane, 2011) (Derycke et al., 2014).  The 
identification of Eotaxin 3 is also supported by an increase in CRSsNP eosinophils 
histologically in the previous chapter. 
The identification of a group of increased chemokines in CRSsNP samples is interesting when 
viewed in combination with the histological data of CRSsNP in chapter 3.  Histological images 
show damage to epithelial membranes and cilial loss suggestive of cell death pathways such 
as necrosis, apoptosis and also senescence –there is also airway remodelling present with 
increased fibrosis.  The combination of these processes may suggest a role for the 
senescence associated secretory phenotype in CRSsNP, where senescent cells trigger 
production of chemokines, cytokines and proteases which can create a vicious cycle of 
worsening tissue damage (Munoz-Espin and Serrano, 2014).  The senescence associated 
secretory phenotype has thus far not been investigated in CRS – and certainly merits further 
study - though is better characterised in respiratory diseases such as COPD (Kumar et al., 
2014) and organ transplantation (Tchkonia et al., 2013) 
4.5.3.2 Cytokines 
Three cytokines upregulated in CRSsNP participants compared to healthy controls were 
found to be interleukin 6 (IL-6), interleukin 10 (IL-10) and interleukin 17 (IL-17).  
 IL-6 is a pleiotropic cytokine produced by almost all stromal and immune cells  with a 
number of differing functions; it can promote granulopoiesis and neutrophil accumulation,  
clonal T-cell expansion, B-cell differentiation and control the acute phase response (Hirano, 
2014) (Hunter and Jones, 2015), in line with the upregulation demonstrated here in my 
CRSsNP participants.  IL-6 is regarded as a major cytokine in inflammation and host defence.  
It is regulated by basal physiological homeostatic mechanisms and can be significantly 
elevated in infective, inflammatory or neoplastic conditions.  In acute infections IL-6 has 
protective inflammatory, anti-infective actions, however, the same anti-infective 
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inflammatory properties can persist and be key to the generation of chronic inflammation. 
Due to its pleiotropic nature the local environmental context in which IL-6 is investigated is 
key to its functional significance.  With diseases such as CRSsNP,  the sinonasal cavity is a 
peripheral site of inflammation therefore elevated IL-6 functions are most likely important in 
the recruitment of leukocytes, inflammatory activation of stromal cells and promotion of T-
cell function (Jones, 2005).  
Interleukin 17 is a pro-inflammatory cytokine produced from a subset of T helper (Th) cells - 
hence ‘Th17’ cells.  IL-17 contributes to the pathogenesis of a number of chronic 
inflammatory conditions including psoriasis (Krueger, 2012), rheumatoid arthritis and 
ankylosing spondylitis (Komatsu et al., 2014).  IL-17 was first cloned in 1993 and can to 
increase the pro-inflammatory IL-6 and IL-8 production in skin fibroblasts and synovial cells.  
IL-8 is a potent neutrophil chemokine which signals via the CXC chemokine receptor CXCR2, 
and so IL-17 is chemotactic for neutrophils and also monocytes.  It would therefore seem 
appropriate that increased levels of IL-17 have been identified in mucosal lining fluid 
samples of CRSsNP participants.  The elevated cytokine levels detected are also supported by 
the histology of CRSsNP participants presented with increased neutrophil and monocyte 
populations seen on immunohistochemistry.  The common signalling between IL-17 and IL-6 
is also reflected in the mucosal lining fluid samples of CRSsNP participants with upregulation 
of both cytokines (Figure 45 & Table 6).  IL-17 is synergistic with tumour necrosis factor alpha 
(TNF-α) (Chabaud et al., 1999), a Th1 cytokine previously thought to be important in CRSsNP 
pathophysiology (Tomassen et al., 2016, Van Crombruggen et al., 2011).  However in the 
mucosal lining fluid samples of my CRSsNP participants I was unable to measure a 
statistically significant increase in TNF-α levels compared to controls, although there was a 
trend suggesting a potential increase in CRSsNP TNF-α levels (Figure 45 and Table 6), though 
these did not reach significance perhaps due to the sample size.   
IL 10, unlike IL-6 and IL-17 which are both predominantly pro-inflammatory is an anti-
inflammatory cytokine. Why might it be upregulated in a pro-inflammatory condition?  IL-10 
is predominantly produced by monocytes, macrophages, neutrophils, T lymphocytes and 
regulatory T-cells (Moore et al., 2001) following programmed death 1 protein (PD1) 
signalling (Said et al., 2010).  However, the detection of increased IL-10 is probably a 
measure of the immune systems attempt to apply a brake on the pro-inflammatory actions 
of the immune cells and their associated cytokines to control the levels of inflammation, 
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prevent host damage from an unchecked immune response and the development of 
autoimmune disease (Hawrylowicz and O'Garra, 2005).  The increased immune cells 
demonstrated in CRSsNP by immunohistochemistry are all capable of producing IL-10. The 
increased amounts detected in the mucosal lining fluid thus most likely reflect the normal 
negative feedback mechanisms of the local sinonasal environment attempting to curtail 
inflammation.  Without IL-10 production, the levels of inflammation in the sinonasal cavities 
could be far greater.  Therefore augmenting IL-10 action emerges as a potential therapeutic 
target in CRS.  Unfortunately, clinical trials in other inflammatory conditions to date have not 
translated into efficacy for IL-10 therapy in Crohn’s disease (Buruiana et al., 2010), 
rheumatoid arthritis (van Roon et al., 2003) or psoriasis (Kimball et al., 2002).  
4.5.3.3 Angiogenesis Mediators 
Basic fibroblast growth factor (bFGF), Placental growth factor (PlGF) and soluble Fms-like 
tyrosine kinase 1 (sFlt-1), also known as vascular endothelial growth factor receptor 1 
(VEGFR1) were elevated in my CRS cohort.  Basic fibroblast growth factor has numerous 
effects on tissue repair and regeneration.  It is found in the basement membrane of healthy 
tissue and extracellular matrix in blood vessels and can be released from damaged cells 
directly or by exocytosis (Ornitz and Itoh, 2001).  In the previous chapter the histology of 
CRSsNP and healthy control participants have been evaluated and shown epithelial cell loss, 
infiltration of immune cells in the fibroblast rich lamina propria and basement membrane 
thickening.  Within the CRSsNP tissues presented there is marked cellular damage and loss of 
epithelia with exposed basement membranes as a source for increased bFGF release from 
damaged cells.  The increased bFGF measured in mucosal lining fluid may be increased as 
the by-product of attempted mucosal repair.   
Placental growth factor (PlGF) was also measured at increased levels in CRSsNP participants.  
PIGF is a member of the vascular endothelial growth factors (VEGF), important mediators in 
angiogenesis and tissue repair, cloned from a cDNA library obtained from a human placenta 
(Maglione et al., 1991). In fact, it can stimulate angiogenesis by activation with VEGF 
receptor 1 which is expressed on many tissues.  PlGF has been demonstrated to have a 
central role in pathological angiogenesis in bronchial (Mohammed et al., 2007), skin 
(Odorisio et al., 2006), cardiac (Luttun et al., 2002) and retinal cells (Hollborn et al., 2006) as 
a direct result of hypoxia and inflammatory cytokines such as interleukin 1 and the proposed 
CRSsNP cytokine TNF-α together with the pro-fibrotic growth factor transforming growth 
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factor β-1 (TGF-β).  Within the sinonasal cavity hypoxia (Ball et al., 2016) has been 
demonstrated along with increased TNF-α (Tomassen et al., 2016, Van Crombruggen et al., 
2011) and TGF-β upregulation (Van Bruaene et al., 2009, Van Bruaene et al., 2012) which 
may be due to altered PlGF levels.  As a result the detection of increased PlGF in CRSsNP 
mucosal lining fluid most likely reflects the attempted tissue reparatory process occurring in 
the damaged sinonasal mucosa.   In addition to upregulation of bFGF and PlGF soluble Fms-
like tyrosine kinase 1 (sFlt-1), also known as vascular endothelial growth factor receptor 1 
(VEGFR1) was measured with a statistically significant increase in CRSsNP mucosal lining 
fluid.  Soluble Fms-like tyrosine kinase 1 is the receptor for circulating proangiogenic VEGF 
growth factors and binds free VEGF or PlGF, thus reducing their effect.  As with the 
relationship of IL-10 to IL-6 and IL-17, sFlt-1 is a natural brake on unchecked angiogenesis 
and dysregulated tissue repair.  The pro-angiogenic placental growth factor was found to 
have a fold change increase of 1.95 (p=0.0188), whereas the antiangiogenic sFlt-1 had a 
slightly lower fold change of 1.67 (p=0.0218), which although represents a crude assumption 
independent of stoichiometry of the ligand and receptor interactions, may suggest a net 
increase in the pro-angiogenic effect of PlGF. 
4.5.3.4 Vascular Injury Mediators 
The final mucosal mediators to be upregulated in CRSsNP mucosal lining fluid were the two 
vascular injury mediators; Serum amyloid A (SAA) and Vascular cell adhesion molecule 1 
(VCAM-1/CD106).  Serum amyloid A proteins are acute phase proteins produced in response 
to pro-inflammatory cytokines and have been implicated in a number of pathologies 
including atherosclerosis (King et al., 2011), Alzheimer’s disease (Chung et al., 2000) and 
rheumatoid arthritis (O'Hara et al., 2000).  Serum amyloid A proteins are produced in 
response to IL-1, IL-6 and TNF-α pro-inflammatory cytokines which have been previously 
measured at increased levels in CRS (Castano et al., 2009, Mfuna Endam et al., 2010), 
consistent with the present findings.  Vascular cell adhesion molecule 1 is a cell adhesion 
molecule that promotes the adhesion of monocytes, lymphocytes and eosinophils to 
vascular endothelium hence aiding their migration to sites of inflammation (Vestweber, 
2015).  The expression of vascular adhesion molecules on endothelial surfaces is induced by 
pro-inflammatory cytokines (van Buul et al., 2007) so the chemotaxis of circulating immune 
cells to the sinonasal mucosa is a co-ordinated response dependent on a combination of 
chemokines, pro-inflammatory cytokines and adhesion molecules.  These individual factors 
represent the mediators that have been identified within the mucosal lining fluid of CRSsNP 
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participants and the combination of their actions is demonstrated in the immune cell 
histological images in chapter 3. 
4.5.4 Mucosal lining fluid mediator summary 
This work represents a larger panel of biomarkers than has been previously published in this 
disease.  Riechelmann and colleagues (2005) investigated fifteen cytokines, three cellular 
activation markers and total IgE in nasal secretions collected with nasal packing sponges in a 
cohort of 12 patients with CRSsNP.  The nasal secretions were extracted by centrifugation 
and then diluted by a factor of 10 prior to performing a multiplex ELISA (IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17, TNF-α, IFN-γ, granulocyte-macrophage colony-
stimulating factor (GM-CSF), granulocyte colony-stimulating factor (GCS), monocyte 
chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1β (MIP-1β)).  
From their panel of cytokines the pro-inflammatory cytokine IL-17 was below the level of 
detection and GM-CSF did not vary between patient groups.  No statistical analysis of the 
individual mediators present in the healthy control and CRSsNP patient groups was 
performed, although they reported the remainder of nasal secretion biomarker 
concentrations 1-2 log fold higher in CRS participants compared to controls.  The results 
presented in this chapter show similar results to Riechelmann et al. with increased 
inflammatory cytokines in the nasal mucus, however they are not in complete agreement.  
There may be a few reasons for this, firstly Riechelmann et al have a relatively small size of 
n=6 healthy controls – although there is no mention of what their criteria for healthy 
controls are – and n=12 CRSsNP patients.  The authors acknowledge the number of study 
participants is too low and that the findings are exploratory.  Their sampling methods are 
slightly different using a larger nasal packing sponge which may be significant.  Nasal packing 
can be traumatic to the mucosa of the nasal cavities and cause small mucosal tears releasing 
blood onto the packing device in addition to the nasal mucus.  The possibility of mucosal 
damage would be increased in an inflamed CRS environment with swollen, more friable 
mucosa and an increased blood supply related to the inflammatory process.  Contamination 
of blood on the nasal packing sponges will mean the ELISA will not simply be measuring the 
mucus.  In contrast to this within my study the mucus was collected atraumatically by a flat 
piece of 7x30mm filter paper applied to the mucosa of the inferior turbinate with no 
bleeding incurred. 
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Kuehnemund and colleagues (2004) measured the levels of inflammatory mediators in the 
nasal mucosa of untreated chronic rhinosinusitis patients over a period of 4 weeks.  From 
nasal secretions using foam rubber sampling devices analogous to nasal packing they 
measured peptido-leukotriene (PLT) and prostaglandin E2 (PGE2) using ELISA.  Additionally 
they measured a panel of cytokines and chemokines mRNA from an initial approximately 
5mg tissue biopsy of the lateral portion of the middle turbinate of the nasal cavity and a 
second one after four weeks.  Messenger RNA for interleukin-1α (IL-1α), interleukins 3, 5, 6, 
and 8, interferon gamma; tumour necrosis factor α, monocyte chemotactic proteins 1, 3, and 
4 and granulocyte-macrophage colony-stimulating factor was quantified from the biopsies 
by quantitative real time RT-PCR.  The authors were only able to measure IL-1, IL-6, IL-8, 
MCP-1, and TNF-α in the nasal mucosa and there was no significant difference between the 
initial biopsy and the one four weeks later at the end of the study.  In nasal secretions very 
small amounts of Peptido-leukotriene (1.4x 10-6 mg per milligram of protein) PGE2 (2.99x10-6 
mg per milligram of protein) were measured and there was no significant difference 
observed over the four week study period.  Kuehnemund et al reported the first study to 
measure the natural course of CRS, although over a relatively short four week period.  Their 
study shows no significant change in inflammatory mediators in the nasal cavity, however no 
comparator control group was included and patients were not phenotyped on the presence 
of nasal polyps.  It is interesting that despite using a sensitive test such as qRT-PCR they were 
unable to measure a number of chemokines and cytokines in patients with established 
inflammation in their nasal cavities. 
Divekar et al. (2015) published work measuring a panel of mediators in nasal mucus and 
serum in a cohort of 9 CRS with nasal polyp (CRSwNP) patients from baseline levels 
throughout the course of an acute symptomatic exacerbation compared to 10 healthy 
controls.  They collected nasal secretions using a suction mucus trap, diluted them in NaCl 
and added protease inhibitors.  The nasal secretions were then measured for a range of 
mediators IFN-γ, IL-5, IL-13, IL-17F, IL-17A, IL-17E, IL-33, IL-6, TNF-α, TNF-β and eosinophil 
major basic protein (MBP) using a multiplex ELISA technique.  At baseline inclusion in the 
study CRSwNP patients had statistically significant increased levels of IL-6 in nasal secretions 
in agreement with the findings presented in this chapter.  During an acute exacerbation their 
CRSwNP participants demonstrated a significant increase in IL-5, IL-6 and MBP compared to 
controls, with the remainder of cytokines not showing statistically significant differences. 
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Groger and colleagues (2013) published a study measuring nasal discharge collected from 
cotton wool pieces placed in the middle meatus of the sinonasal cavity for 20 minutes to 
allow secretion uptake.  The cotton wool samples were then centrifuged to extract the nasal 
discharge.  Unfortunately the published methodological details for the nasal secretion 
analysis was not complete and therefore do not allow a thorough comparison, though they 
report that eosinophilic cationic protein (ECP) showed statistically significant difference in 
nasal discharge in CRSwNP and tryptase in allergic rhinitis compared to healthy controls. The 
use of cotton wool pledglets in the middle meatus appears a useful atraumatic technique to 
measure nasal secretions, though care would have to be taken to ensure a standard volume 
of cotton wool is used to reproducibly compare the amounts of secretions yielded.  
The 13 key CRSsNP mediators were investigated for correlations with sinonasal symptom 
score.  The total SNOT score has been shown to measure a number of different constructs in 
addition to the rhinological symptoms (Browne et al., 2007).  Total SNOT-22 scores are a 
helpful measure in the clinic, providing a holistic overview of both rhinological symptoms 
and quality of life.   Using exploratory factor analysis Browne at al. identified that SNOT is 
not unidimensional and in fact contains four separate constructs within SNOT; rhinologic 
symptoms, ear/facial symptoms, psychological issues and sleep function.  When measuring 
how sinonasal inflammation influences CRS, correlation of mucosal lining fluid mediators 
with rhinological symptoms is probably more appropriate.   As a result, the mucosal lining 
fluid mediators were subsequently compared to the rhinological subscale of the SNOT-22 
score i.e. the seven rhinological questions out of the 22 item scoring; need to blow nose, 
sneezing, runny nose, post nasal discharge, thick nasal discharge, facial pain/pressure and 
blockage/congestion of nose giving a rhinological SNOT-22 (RSNOT-22) score out of a 
maximum total of 35.  A RSNOT-22 scoring method can help to address specific nasal 
symptoms rather than in combination with health related quality of life aspects such as 
psychological issues and sleep function which can sometimes confuse the message.  All 13 
key mediators showed significant non-parametric correlations with RSNOT-22.  It is tempting 
to deduce that the greater the local mediator concentrations are in the nasal cavities, the 
greater the nasal symptom burden.  However, such direct causal attribution is problematic, 
and often represents a complex mix of biological disease activity and personality together 
with individual perception of illness and disease reporting behaviour (Pennebaker, 1976).   
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Although this is the largest sample of mediators investigated in CRSsNP to date, it is still 
exploratory with a relatively small n=40 group and a greater sample size would provide more 
detailed information.  Retrospective power calculations are not without problem and in 
general are probably best avoided as they can simply be transformations of the p value 
(Length, 2000).  However, in this case it is interesting to look at the mucosal lining fluid 
mediators which fall just below significance, for example Intercellular Adhesion Molecule 1 
(ICAM-1) which is used to aid leukocyte migration via endothelial cells into tissues and also 
by rhinovirus as a receptor – hence would seem biologically relevant to CRSsNP - has a p 
value of p=0.057 and a near fold doubling in CRSsNP compared to control samples.  A 
retrospective power calculation based on its data suggests a sample size of only slightly 
larger n=43 would be required to reach a significance level of p<0.05.  Such calculations only 
serve to highlight the need for a follow on larger study of mucosal lining fluid samples in CRS 
patients. 
A factor analysis was performed on the mucosal lining fluid mediators to investigate if the 13 
key CRSsNP mediators could be reduced into a smaller set of exploratory factors that 
account for most of the variance in the original variables.  Exploratory factor analysis is 
based on correlations of mediator scores and will not necessarily reflect functional relations.  
The process identified four factors to account for 83.3% of the variance (Table 9).  The first 
factor covers pro-inflammatory mediators, the second factor vascular inflammatory 
mediators, the third factor chemokine and growth factors and the fourth factor contains 
regulatory mediators.  A unifying factor analysis offers an insight into the relationship of 
mediators under the umbrella of ‘CRSsNP’ and such analyses may be helpful to allow us to 
move beyond the over simplistic phenotyping of CRS by the presence or absence of nasal 
polyps and in to more definitive endotypes as per Tomassen et al. (2016) 
4.5.5 Bioinformatics 
Data from the CRSsNP mucosal lining fluid swabs were entered into established 
bioinformatics database techniques to explore their interactions  Firstly the mediators were 
entered into WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) 
(http://www.webgestalt.org/) as per Wang et al (2013)  and Zhang et al (2005) to determine 
any disease and drug associations from the panel identified.  The top 15 statistically 
significant disease associations it returned included respiratory tract infections, 
inflammation, common cold, infection, sinusitis, nasal polyps and a variety of other 
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respiratory tract infection/inflammations (Table 10).  These WebGestalt disease associations 
provide a useful confirmation of the CRSsNP mucosal lining fluid mediators and the high 
return of related respiratory tract pathologies replicates the established unified airway 
hypothesis data (Giavina-Bianchi et al., 2016). 
WebGestalt also returns a list of associated drugs for the panel of mediators.  Four 
statistically significant associations were found: the corticosteroid dexamethasone, 
dinoprostone a prostaglandin E2, anakinra an IL-1 receptor antagonist, and immune globulin.  
Corticosteroids are widely used in CRS, though the other 3 drug associations offer interesting 
insights into potential pharmacological therapies.  Anakinra is a recombinant IL-1 
competitive receptor antagonist that blocks the pro-inflammatory actions of both IL-1α and 
IL-1β.  It differs from the circulating IL-1 receptor antagonist (IL-1RA) by the addition of a 
methionine residue at its amino terminus (Schett et al., 2016).   The potential anti-
inflammatory effects of IL-1RA have been investigated in trials in rheumatoid arthritis and a 
Cochrane systematic review has shown it to be safe and modestly efficacious (Mertens and 
Singh, 2009), though as yet there are no trials of its efficacy in respiratory tract disorders.  
Dinoprostone is a PGE2 prostaglandin that has its majority of clinical use currently in 
obstetrics.  PGE2 is generated by the metabolism of arachidonic acid via the enzyme 
cyclooxygenase and has been reported to have a role in modulating the inflammatory 
response in upper and lower airways (Machado-Carvalho et al., 2014), with reduced PGE2 
levels found throughout the airways in aspirin exacerbated respiratory disease.  PGE2 in the 
airways generates cyclic AMP via the prostanoid receptors, which results in overall negative 
regulation of the 5-lipoxygenase pathway and therefore less inflammatory airway 
leukotrienes.  A down regulation of prostanoid receptors has also been found in CRS patients 
(Perez-Novo et al., 2005), which may be a factor in the increased upper airway inflammation 
seen in these tissues.  The association with immune globulin is also interesting as there have 
been a number of cohort studies that have shown patients with refractory CRS to have a 
variety of immune deficiencies including common variable immune deficiency, selective IgA 
and IgG subclass deficiencies amongst others.  An open label trial of intravenous serum 
globulin has shown it can be a useful therapeutic adjunct in recalcitrant CRS (Ramesh et al., 
1997), although the trial was limited by a small sample size. 
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Differentially expressed mediators were also entered into the open access bioinformatics 
tools NetworkAnalyst ((http://www.networkanalyst.ca as per Xia et al in Nature Protocols 
(2015), GOstats Bioconductor Gene ontology and gplots Heatmap2 open source R package 
https://www.bioconductor.org/packages/devel/bioc/html/GOstats.html/)  as per Falcon and 
Gentleman (2007) and (Gregory R. Warnes et al., 2016). The results of the various biological 
pathways provide intuitive, graphical views of the myriad of interactions underlying CRSsNP 
samples with established biological processes.  From the illustrations in Figure 53 - Figure 56 
a summary of potential interactions of the differentially expressed mediators in CRSsNP can 
be obtained to guide further CRSsNP investigations.  Such comparative tools allow us to 
frame the novel, individual mediator results identified with the vast amount of 
bioinformatics data available on human health and disease. 
4.5.6 Quantitative RT-PCR replications  
Quantitative real time RT-PCR was used to investigate tissue biopsy specimens for mRNA of 
the thirteen differentially expressed CRSsNP sinonasal mucosal lining fluid mediators.  All 
five chemokine mediators identified by their protein samples in mucosal lining fluid could 
also be replicated at the mRNA level by qRT-PCR in their tissue biopsies (p<0.001-p<0.05).  
Similarly two of the three cytokine mediators seen in mucosal lining fluid could also be 
replicated at the mRNA level in tissue biopsies (Figure 59); interleukin 10 and interleukin 17 
(p<0.001).  However, differential expression of interleukin 6 mRNA in tissue biopsies was not 
replicated.  The lack of replication in tissue biopsies compared to mucosal fluid samples may 
infer that IL-6 is in fact not upregulated in tissue samples, or alternatively that due to the 
increased levels of IL-6 protein present in the mucosal lining fluid negative regulatory 
mechanisms of mRNA transcription are activated to reduce the amounts of IL-6 secreted.  
Only one of the three angiogenesis biomarkers, basic fibroblast growth factor, showed a 
statistically significant (p<0.05) upregulation in mRNA from CRSsNP tissue biopsies compared 
to controls.  Whilst both vascular injury mediators, Serum amyloid A (SAA) and Vascular cell 
adhesion molecule 1 (VCAM-1/CD106) showed increased mRNA levels in CRSsNP 
participants consistent with the mucosal lining fluid protein samples, neither reached 
statistical significance.  It would therefore appear that the mediators measured in the 
mucosal lining fluid are a reasonable indication, though not exact replication of the 
inflammatory mechanisms present in the parent tissues.  The closest resemblance between 
the mucosal fluid protein samples and tissue biopsy mRNA levels are seen in the chemotactic 
and pro-inflammatory mediators.   
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When the protein lysates from tissue biopsies are compared to mucosal swab protein levels 
the greatest parity is also seen with the chemokine and cytokine mediators (Figure 64) 
although the amounts measured are much greater in the tissue biopsies than the mucosal 
swabs (Figure 65).  Similarly if the amounts of mediators measured in mucosal swabs are 
compared to those in the epithelial cell and fibroblast samples there are minimal mediator 
protein levels present in the cellular samples (Figure 65). The low levels of mediator protein 
detected in the cellular samples are also confirmed in the mRNA expression in epithelial and 
fibroblast samples (Figure 60 - Figure 62).  In addition to the low levels of mediators 
measured in the epithelial and fibroblast samples there was markedly less differentiation 
between control and CRSsNP samples with only MIP-1α showing statistically significant 
upregulation in fibroblasts at the mRNA level (Figure 60) and IL-5 in epithelial cells and IL-1β 
in fibroblasts at the protein level (Figure 64) which questions how closely the isolated 
cultured primary cells may mirror their parent tissues of origin. There was also no significant 
difference in any of the mediators measured in serum between healthy controls and CRSsNP 
participants. 
4.5.7 Summary 
The Multiplex MSD electrochemiluminesce approach adopted has been a very helpful 
investigatory tool allowing more potential targets and mediators to be analysed than with 
individual ELISAs in the pilot work due to constraints on sample volume.  Multiplex and omic 
technologies yield vast quantities of data and are increasingly replacing some of the 
traditional techniques in health sciences research.  Here, a multiplex MSD V-PLEX Human 
Biomarker Kit is effectively a limited 40-plex protein array.  If 13 out of 40 mediators are 
differentially expressed in CRSsNP samples for mucosal lining fluid or 15 out of 40 tissue 
biopsy samples, the possibility of finding more CRS targets is optimistic.  It is beyond the 
scope of this project, though if future funding allows a proteomics approach to compare CRS 
tissues to look at a much greater sample of proteins may yield some very useful insights into 
the potential mechanisms in CRS.  
The multiplex approach utilised can potentially identify biomarkers for CRS, which would 
represent a very useful clinical adjunct.  The mucosal lining swab technique could offer an 
innovative way of investigating sinonasal disease, for example in a longitudinal study; by 
taking a swab at diagnosis, a repeat swab in a matched patient following medical treatment, 
similarly prior to and following surgical treatment and any revision procedures, and also at 
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different times of the day.  Data from such a study may be helpful in distinguishing different 
endotypes of CRS or predict response to medical or surgical treatment.  Such a study would 
need to have a much larger sample size due to heterogeneity of CRS patients with similar 
clinical phenotypes and offer the opportunity to discriminate between different CRS 
endotypes. 
4.6 Conclusion 
Within this chapter I have identified and refined a technique to measure the inflammatory 
micro-environment of the sinonasal cavities in CRSsNP and health.  A panel of mediators has 
been shown to discriminate CRSsNP participants from healthy controls based on this assay.  
These mucosal lining fluid sample mediators show significant overlap with analysis of tissue 
biopsy samples, though only a limited correlation with their matched isolated primary cells 
in culture.  Such non-invasive measures of the mucosal lining fluid of the sinonasal 
environment may well provide a useful clinical adjunct to monitoring disease in the nasal 
cavity when combined with clinical, endoscopic and radiological findings. 
The identification of mediators in the inflammatory environment in the sinonasal cavities is 
important when trying to replicate physiological conditions in the laboratory.  In the 
previous chapter, experiments with the commercially available nasal cell line RPMI 2650 
were discontinued as they did not appear responsive to a number of disease relevant 
stimuli, or  representative of primary human cells (Ball et al., 2015).  Work presented in this 
chapter has additionally questioned how reflective isolated primary epithelial and fibroblast 
cells are of either their parent tissue biopsies or mucosal lining fluid swab results from the 
sinonasal mucosa.  It may be that primary cells in conventional culture do not accurately 
represent the CRSsNP inflammatory processes present.  Therefore isolated cells will need 
further investigation to see if they can be effectively used to replicate and model 
inflammatory mechanisms in CRS tissues.  In the next chapter the cells’ transcriptome will be 
thoroughly investigated in CRSsNP and health and compared to matched tissue biopsy 
samples.  
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5 Results – Transcriptome analysis 
 
5.1 Specific aims & objectives 
The specific aims for this phase of research were to investigate the transcriptome (RNA 
transcripts in the cell, i.e. all of the genes that are being actively expressed) of CRSsNP and 
healthy control samples to identify if there are clusters of genes which are differentially 
expressed between the two patient groups.  Both patient derived primary cells and tissue 
biopsies were compared to determine firstly, if there are clusters of differentially expressed 
genes between the patient groups and, to assess how representative the primary cells are of 
their parent tissues. 
 
5.2 Scientific rationale for experimental approach 
Investigating the transcriptome of CRSsNP and healthy control samples allows a 
comprehensive assessment of a large number of target genes between the participant 
cohorts.  Histological assessment of tissue biopsy samples in chapter 3 demonstrated 
significant differences in the microscopic appearance of CRSsNP and healthy control tissues. 
These histological findings, combined with disease micro-environmental changes in the 
CRSsNP inflammatory environment established in chapter 4 predict differential gene 
expression in CRSsNP and control samples transcriptomes.  The comparison of both the 
CRSsNP and control tissue biopsy samples and their matched epithelial and fibroblast cells 
offers an analysis of healthy and CRSsNP tissues and their isolated cell populations.  Using 
microarrays and next generation RNA sequencing I sought to identify clusters of differential 
gene expression between CRSsNP and control samples and whether any differences are 
maintained between tissue biopsy and cellular samples as model systems.   
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5.3 Methods 
5.3.1 RNA extraction and quality control 
Total RNA was extracted from 1x106 cells from each sample using a Machery Nagel 
NucleoSpin RNA extraction kit as per manufacturer’s instructions.  Determination of the RNA 
yield and purity was performed on a nanodrop 2000 spectrophotometer (Nanodrop, USA) 
and the quality checked with an Agilent 2100 Expert Bioanalyser.  All RNA integrity number 
(RIN) scores were >8/10. 
5.3.2  Microarray procedure 
Microarray experiments were performed using the Illumina Bead Array HT12v4 to screen in 
excess of 47,231 gene probes per sample (Figure 66). The Illumina TotalPrep-96 RNA 
Amplification Kit was used to generate Biotin labelled (biotin-16-UTP), amplified cRNA 
starting from 200ng total RNA.  50 ng of the obtained biotinylated cRNA samples was 
hybridized onto the Illumina HumanHT-12 v4 as per manufacturer's instructions.  The 
samples were scanned using the Illumina iScan array scanner. There were no deviations from 
the Illumina protocol.  RNA labelling, amplification, and hybridization were performed by 
The Genome Centre at Barts and the London School of Medicine and Dentistry.  
 
Figure 66.  Schematic diagram of the Illumina Bead Array HT12v4.  Oligonucleotide probes of 
79 base pairs are attached to 3μm silica beads which self-assemble randomly into micro 
wells on the array chip using lithography on a silica slide.  Hybridised probes are then 
scanned with a laser and fluorescence is measured which generates the raw data files for 
each array.  Image adapted from (Illumina, 2016). 
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5.3.3 Microarray data analysis 
Prior to analysing my microarray data, I completed Dr C Gillespie & Dr S Cockell’ s R open 
source programming and Bioconductor course to learn how to write the command line code 
and perform analysis on my raw microarray data (http://bsu.ncl.ac.uk/support/courses).  All 
the code was written by myself in R and subsequently checked for accuracy and 
completeness by the Newcastle Bioinformatics Support Unit.  A copy of the code is included 
in the appendix and a summary of the methods follows here.   
The Illumina Human HT12v4 Expression BeadChip data was background corrected in Illumina 
Beadstudio.  Subsequent analysis proceeded using the lumi and limma packages in R 
(Bioconductor) (Du et al., 2008, Gentleman et al., 2004, Lin et al., 2008).  Variant 
Stabilisation Transformation and Robust Spline Normalisation were applied in lumi. Only 
probes with a detection p-value < 0.01 in at least one sample were considered valid for 
downstream analysis. Differential expression was detected using linear models and empirical 
Bayes statistics in limma.  A list of genes for each comparison was generated using a 
Benjamini Hochberg false discovery rate corrected p-value of 0.05 and a fold change of 1.5 
as cut-offs (Benjamini and Hochberg, 1995).   The raw data from the array has been 
deposited in the National Centre for Biotechnology Information Gene Expression Omnibus 
(NCBI GEO) (NCBI, 2015) public functional genomics data repository supporting Minimum 
Information About a Microarray Experiment (MIAME)-compliant data submissions (Brazma 
et al., 2001) (reference GSE69093). 
5.3.4 Quantitative real time RT-PCR 
Quantitative RT-PCR was used to replicate the findings of the microarray.  cDNA was 
prepared from  isolated RNA samples using the BIORAD iScript cDNA synthesis kit as per 
manufacturer’s instructions.  10ng of cDNA template was used per qRT-PCR reaction using 
SYBR Green JumpStart Taq Ready Mix on an Applied Biosystems 7500 Real-Time PCR System 
for 35 cycles.  1µl of forward and reverse primers (NFE2L3 - as identified from the microarray 
analysis, forward TCCCAGCATGAGGAAAATGA, reverse TTCTGCCTCCCAGTCAGGTTT (Korecka 
et al., 2013)) were supplied by Eurofins per reaction.  Expression levels of mRNA were 
normalised to those of the healthy controls for relative mRNA expression data.  Products 
formed in the qRT-PCR reactions were verified by 2% agarose gel electrophoresis and 
compared to a 100 base pair ladder. 
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5.3.5  Immunohistochemical staining 
Formalin fixed paraffin embedded tissue sections were produced from tissue biopsy 
samples.  Sections were de-waxed and rehydrated twice in Clearene followed by 100% and 
70% ethanol each for 5 minutes.  Antigen retrieval was performed in 1 mM EDTA at pH8 in a 
microwave at 700 watts for 15 minutes.  Non-specific binding was blocked using 5% bovine 
serum albumin in PBS with 0.2% Tween 20 (5% BSA PBST) at room temperature for 1 hour.  
To replicate the findings of the micro array and RT-PCR, anti NFE2L3 primary antibody (LSBio 
LS-B8066) at 1:200 dilution was incubated overnight at 4oC in 5% BSA PBST. TRITC 
conjugated secondary antibody (Sigma T6778) at 1:100 dilution was incubated in 5% BSA 
PBST at room temperature and in darkness.  Sections were counterstained and mounted 
with vectashield DAPI containing mounting medium (Vector laboratories H-1200).  Slides 
were imaged on a Nikon A1 using a Nikon Eclipse NI-E upright stand with a x20 0.75Na Plan 
Apo lens running Nikon elements 4.30.02.    
 
5.3.6 RNA sequencing procedure 
RNA sequencing was performed using the illumina HiSeq platform.  Library construction was 
performed using 1µg of RNA with the illumina TruSeq Stranded mRNA LT system as per 
manufacturer’s instructions.  Following library construction the libraries were assessed with 
an Agilent 2200 TapeStation (Agilent, US).  Libraries were then standardised, pooled and the 
finished pools were quantified again by quantitative PCR (qPCR) using the illumina 
sequencing library qPCR protocol prior to loading.  Libraries were loaded at 17pmol and run 
on the Illumina HiSeq 2500 with no deviations from the manufacturer’s protocol.  
Sequencing was completed using 3 flow cells of Rapid Run 75bp paired end sequencing with 
no deviations from the protocol.  RNA sequencing was completed by DBS Genomics within 
the School of Biological and Biomedical Sciences, Durham University. 
5.3.7 RNA sequencing data analysis 
RNA sequencing data was analysed using the standardised DESeq2 methodology for 
differential expression analysis of sequencing data (Love et al., 2014).  RNA sequencing  raw 
data in FASTQ file format was subject to quality control analysis using the Kraken toolset as 
per Davis et al. (2013) to remove low quality reads.  Subsequently FASTQ files were aligned 
to the Genome Reference Consortium Human Build 38 genome (Ensembl, 2016) using the 
splice junction mapper Tophat (Kim et al., 2016).  The outputted BAM files from Tophat were 
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then sorted and converted to SAM format using Samtools (Samtools, 2016).  The sorted SAM 
files were then used by HTSeq (Anders et al., 2015) to estimate gene counts. Gene counts 
were then fed into the R package DESeq2 and filtered to remove genes that did not have at 
least 1 count across the entire dataset. Once complete, gene counts were normalised and 
fitted to a generalised linear model and tested for significance using a Wald test.  Multiple 
hypothesis testing correction was carried out using the Benjamini and Hochberg 
methodology with a false discovery rate of 10% (Benjamini and Hochberg, 1995).  RNA 
sequencing data analysis was performed in combination with the Computational biology 
facility, School of Biological and Biomedical Sciences, Durham University, UK. 
5.3.7.1 RNA sequencing pathway analysis 
Following differential gene expression of the RNA sequencing data (5.3.7), pathway analysis 
was performed using the standardised Ingenuity Pathway Analysis program 
(www.ingenuity.com) as per Kramer et al. (2014).  Ingenuity Pathway Analysis is a software 
package for RNA sequencing data that uses differential expression data to generate 
functional outcomes and pathway analysis based on known biological pathways using a 
combination of public source data and a database of biological process findings extracted 
from the published literature. 
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5.4 Results 
5.4.1 Microarray data 
5.4.1.1 RNA quality control 
Total RNA was isolated from participant samples and its concentration and quality were 
measured using a nanodrop 2000 and Agilent 2100 Expert Bioanalyser.  High concentrations 
of high quality RNA without degradation suitable for subsequent microarray analysis were 
obtained.  The RNA quality control data is presented in Table 15 and a representative 
electrophoretogram trace is shown in Figure 67. 
 
 
Figure 67.  Example of RNA extraction quality control performed with an Agilent 2100 Expert 
Bioanalyser.  The RNA integrity number (RIN) is calculated from the electrophoretic trace of 
the RNA sample, including for the presence of degradation products and a score out of 10 is 
assigned.  In this sample a RIN score of 10 has been achieved. 
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Sample ID Conc (ng/ul) A260  A280  260/280  Bioanalyser RIN score 
PNEC-1 218.2 5.454 2.539 2.15 10 
PNEC-11 511.6 16.461 7.392 2.23 10 
PNEC-12 380 9.5 4.474 2.12 9.7 
PNEC-13 517.2 16.665 9.243 1.8 10 
PNEC-14 466.5 11.662 5.561 2.1 10 
PNEC-15 323 8.076 3.791 2.13 10 
PNEC-16 413.5 10.338 4.886 2.12 9.5 
PNEC-2 289.2 7.23 3.308 2.19 9.8 
PNEC-29 345.6 8.641 4.01 2.15 10 
PNEC-3 444.7 11.116 5.273 2.11 9.7 
PNEC-30 379.1 9.479 4.428 2.14 9.8 
PNEC-37 479.4 11.984 5.653 2.12 10 
PNEC-38 271.2 6.779 3.186 2.13 10 
PNEC-39 561 14.025 6.922 2.03 10 
PNEC-4 427.7 10.692 5.056 2.11 9.9 
PNEC-40 478.2 11.954 5.712 2.09 10 
PNEC-41 500.2 12.505 6.026 2.08 10 
PNEC-42 370.1 9.253 4.393 2.11 10 
PNEC-43 396 9.901 4.622 2.14 10 
PNEC-44 413.7 10.342 4.883 2.12 8.7 
PNEC-45 374.2 9.355 4.354 2.15 9.1 
PNEC-5 145.7 3.916 1.835 2.13 10 
PNEC-7 273.9 6.846 3.162 2.16 9.9 
PNEC-9 519.9 12.998 6.204 2.1 10 
PNF-11 238.8 5.969 2.762 2.16 10 
PNF-12 196.7 4.917 2.289 2.15 8.3 
PNF-13 333.6 8.341 3.827 2.18 9.1 
PNF-14 304.1 7.603 3.54 2.15 10 
PNF-15 475.7 11.892 5.653 2.1 10 
PNF-16 379.2 9.481 4.463 2.12 9.6 
PNF-2 465.6 11.64 5.208 2.24 10 
PNF-29 338.5 8.464 3.931 2.15 9.7 
PNF-3 150.6 3.765 1.748 2.15 9.2 
PNF-30 526.1 18.478 8.647 2.14 9.4 
PNF-37 437.1 10.927 5.113 2.14 10 
PNF-38 414.5 10.362 4.908 2.11 9 
PNF-4 318.2 7.954 3.704 2.15 10 
PNF-40 294.6 7.365 3.42 2.15 9.7 
PNF-41 636.2 15.905 7.39 2.15 10 
PNF-42 377.9 9.448 4.441 2.13 9.5 
PNF-43 666.8 16.669 7.919 2.1 10 
PNF-44 373.5 13.154 6.268 2.1 10 
PNF-45 630 15.751 7.322 2.15 10 
PNF-5 197.7 4.942 2.318 2.13 9.7 
PNF-6 263.1 6.578 3.063 2.15 10 
PNF-7 336.5 8.412 3.878 2.17 10 
PNF-8 276.7 6.917 3.244 2.13 8.8 
PNF-9 757.3 18.933 8.927 2.12 10 
 
Table 15. Table detailing concentrations of isolated RNA, 260 and 280 absorbance and RNA 
integrity number (RIN) score. 
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5.4.1.2 Microarray data transformation and normalisation 
Microarray data was obtained for 48 samples on 4 Illumina HT12v4 BeadArray chips with the 
raw data in IDAT files and chip layout information in SDF files.  The data was entered into 
Illumina GenomeStudio for background modified subtraction, a function based on in built 
random control probes within the BeadArrays.  From this process a sample probe profile of 
the raw data was created which contained for each of the 47,000 gene probes; the average 
signal, the detection p value, bead standard error and average number of beads.  As a result 
of the background modified subtraction, only 7 sample gene probes were excluded based on 
the control probes and the un-normalised background corrected fluorescence data was 
obtained (Figure 68). 
Variant stabilization transformation was performed on the background corrected data which 
utilises the within array technical replicates to improve differential expression reporting and 
reduce false positives (Lin et al., 2008, Kuhn et al., 2004).  Robust spline normalisation was 
used for between array chip normalisation to ensure values of intensity between different 
bead chip arrays have similar normalisation (Du and Gang Feng, 2016).  The results of 
transformation and normalisation of the raw fluorescence data are presented in Figure 69, 
and essentially ensures groups of arrays are comparable. 
5.4.1.3 Microarray quality control 
Quality control of microarray data was performed using the array QualityMetrics package to 
assess overall array quality and to diagnose batch effects.  Figure 70(a) shows a false colour 
heat map of the distances between epithelial cell arrays. The colour scale is chosen to cover 
the range of distances encountered in the dataset. Patterns in this plot can indicate 
clustering of the arrays either due to intended biological or unintended experimental factors 
(batch effects). The distance between two arrays is computed as the mean absolute 
difference between the data of the arrays (using the data from all probes without filtering). 
Outlier detection was performed by looking for arrays for which the sum of the distances to 
all other arrays was exceptionally large. One such array was detected, and is asterisked.  
A bar chart of the sum of distances to other arrays is shown in Figure 70(b), the outlier 
detection criterion from the previous heat map. The bars are shown in the original order of 
the arrays.  Based on the distribution of the values across all arrays, a threshold of 3.1 was 
determined, which is indicated by the vertical line.  The same array exceeded the threshold, 
was considered an outlier and therefore was excluded from the subsequent analysis. 
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A similar quality control analysis of the primary fibroblast arrays was performed and showed 
no outliers detected (Figure 78). 
 
Figure 68.  Raw fluorescence data from all microarrays density of intensity plot. 
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Figure 69.  Background corrected microarray data following Variant Stabilisation 
Transformation and Robust Spline Normalisation applied in lumi to ensure the groups of 
arrays are comparable. 
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Figure 70.  Array quality metrics quality control analysis of epithelial cell microarray data. (a) 
A false colour heat map of the distances between arrays. Patterns in the plot indicate 
clustering of the arrays due to either intended biological or unintended experimental factors 
(batch effects). The distance between two arrays is computed. Outlier detection was 
performed by looking for arrays for which the sum of the distances to all other arrays was 
exceptionally large. One such array was detected, asterisked.   
(b) Outlier detection for distances between arrays, a bar chart of the sum of distances to 
other arrays, the outlier detection criterion from the previous figure. The bars are shown in 
the original order of the arrays.  The same array exceeded the threshold, was considered an 
outlier and therefore was excluded from the subsequent analysis. 
 
(a) 
(b) 
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5.4.1.4 Microarray differential expression analysis 
The initial comprehensive microarray analysis was a hierarchical clustering to explore for 
differences in gene expressions between healthy controls (n=12) and CRSsNP patients 
(n=12).  Each gene starts in its own cluster and the most similar genes are merged according 
to the Euclidian distance similarity metric.  The similarity metrics are recalculated between 
the genes and the new cluster and the process is repeated until all genes are in a single 
cluster.  Hierarchical clustering analysis clearly separated samples based on their cell type, 
confirming the difference between epithelial and fibroblast samples.  The cluster analyses 
however did not significantly discriminate between healthy controls and CRSsNP participants 
as illustrated in the principal components plot (Figure 71) and cluster dendrogram (Figure 
72).  Figure 73 presents the Euclidian distance between all the pairs of samples in the study 
in a heat map, so the smaller the number, the more similar two arrays are to one another.  
Each array has a zero distance from itself, which represents the diagonal red stripe. 
 
Microarray analysis of isolated primary nasal epithelial cells was performed following 
Benjamini Hochberg correction for multiple hypothesis testing.  No significantly differential 
(>50% up or down) gene expression was found (Figure 76 & Figure 77).  Principal 
components analysis (Figure 74) and cluster dendrogram analysis (Figure 75) of primary 
nasal epithelial cells did not group cells between CRSsNP samples and healthy controls.  A 
similar comparison of fibroblast cells from control and CRSsNP participants identified one 
significantly differentially expressed gene (Figure 81, Figure 82 and Table 16), nuclear factor 
erythroid-derived 2-like 3 (NFE2L3, p= 0.000015, p= 0.0471 following multiple hypothesis 
testing correction).  NFE2L3 is a transcription factor with potential roles in inflammation that 
was 60% upregulated in CRSsNP fibroblast cells compared to healthy controls.  However, 
principal components analysis (Figure 79) and cluster dendrogram analysis (Figure 80) of 
primary nasal fibroblast cells did not group cells overall between CRSsNP samples and 
healthy controls. 
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Figure 71.  Principal components analysis plot of all arrays including cases (CRSsNP 
participants) vs controls for both primary nasal epithelial cells and primary nasal fibroblasts.  
The samples are principally separated on the basis of the cell type of origin, either epithelial 
or fibroblast rather than case (CRSsNP) or control. 
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Figure 72.  Dendrogram produced by hierarchical clustering of CRSsNP and healthy control 
gene samples.  Each gene starts in its own cluster and the most similar genes according to 
the Euclidian distance similarity metric are merged.  The similarity metrics are recalculated 
between the genes and the new cluster and the process is repeated until all genes are in a 
single cluster.  The samples are principally separated on the basis of the cell type of origin, 
either epithelial or fibroblast rather than case (CRSsNP) or control. 
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Figure 73.  Heat map representation of Euclidian distance data from all the primary nasal 
epithelial and fibroblast arrays. 
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Figure 74. Principal components analysis plot of all the primary nasal epithelial cells 
 
Figure 75.  Cluster Dendrogram of all the primary nasal epithelial cells 
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Figure 76.  XY scatter plot of all primary nasal epithelial cells.  Points outside of the two red 
lines represent genes that are more than 50% up or down regulated. 
 
Figure 77.  Volcano plot of all primary nasal epithelial cells.  Points outside of the two dashed 
vertical lines represent genes that are more than 50% up or down regulated.  No points are 
also below the dashed horizontal line demonstrating no statistically significant (p<0.05) 
differentially expressed genes following multiple hypothesis testing correction.
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Figure 78.  Array quality metrics quality control analysis of fibroblast microarray data. (a) A 
false colour heat map of the distances between arrays. Patterns in this plot can indicate 
clustering of the arrays either due to intended biological or unintended experimental factors 
(batch effects). The distance between two arrays is computed. Outlier detection was 
performed by looking for arrays for which the sum of the distances to all other arrays was 
exceptionally large. No outlier arrays were detected. 
(b) Outlier detection for distances between arrays - a bar chart of the sum of distances to 
other arrays, the outlier detection criterion from the previous figure. Based on the 
distribution of the values across all arrays, a threshold of 2.15 was determined, which is 
indicated by the vertical line. None of the arrays exceeded the threshold and was considered 
an outlier. 
(a) 
(b) 
 169 
 
Figure 79.  Principal components analysis plot of all the primary nasal fibroblasts 
 
Figure 80.  Cluster Dendrogram of all the primary nasal fibroblast cells 
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Figure 81.  XY scatter plot of all primary nasal fibroblast cells.  Points outside of the two red 
lines represent genes that are more than 50% up or down regulated. 
 
Figure 82.Isolated fibroblast cells volcano plot to identify any statistically significant 
differential gene expression between CRSsNP and control samples following Benjamini-
Hochberg multiple hypothesis testing correction.  Points outside the dashed vertical lines 
demonstrate either a 50% up or down regulation in gene expression.  Points above the 
dashed horizontal line show a statistically significant difference of greater than p<0.05.  
Points that satisfy both differential expression criteria and statistical significance have been 
coloured red.  In this instance one gene fulfils both criteria; NFE2L3.   
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5.4.2 Quantitative real time RT-PCR replication data 
 
Quantitative real time RT-PCR was used to replicate the microarray findings.  A statistically 
significant (p=0.0352) greater than two fold upregulation in the NFE2L3 gene in CRSsNP 
fibroblast cells was seen (Figure 83).  Figure 83(b) demonstrates an increase in NFE2L3 in 
CRSsNP epithelial cells compared to control cells, however this does not reach statistical 
significance (p=0.1980). 
  
 
Figure 83.  qRT-PCR replication of NFE2L3 gene expression between CRSsNP (n=12) and 
control fibroblasts (PNFs, n=12) and epithelial cells (PNECs, n=12).  Relative gene expression 
has been normalized to healthy control cells.  * = p<0.05. 
 
To corroborate the mainly negative findings from the microarray, qRT-PCR replications of 
fifteen primer pairs from the most differentially expressed microarray probes between 
CRSsNP (n=12) and control fibroblasts (n=12) and epithelial cells (n=12) were analysed.  
Although there were trends of increased expression of IL-6, CCL2, Interferon alpha-inducible 
protein 27 (IFI27) and Integrin beta-1 (ITGB1/CD29) in CRSsNP PNFs, none was significantly 
different consistent with the microarray.  Representative samples of these qRT-PCRs are 
shown in  
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Figure 84. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 84.  qRT-PCR replication of a sample of the 15 primer pairs from the most 
differentially expressed microarray probes between CRSsNP (n=12) and control fibroblasts 
(n=12) and epithelial cells (n=12).  Relative gene expression has been normalized to the level 
of the control fibroblasts (PNFs) and epithelial cells (PNECs).  In all cases no statistical 
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significance was identified (p>0.05). (IL-6 – interleukin 6, CCL2 - chemokine (C-C motif) ligand 
2, IFI27 - Interferon alpha-inducible protein 27, ITGB1 - Integrin beta-1, also known as CD29). 
5.4.3 Immunohistochemical replication data 
Fluorescent immunohistochemical staining of healthy control and CRSsNP tissue sections 
was then used to determine if there was any difference in the amounts of the NFE2L3 
transcription factor protein within the tissues.  Figure 85 shows typical examples of the 
expression of NFE2L3 in healthy control and CRSsNP tissue sections.  The greatest difference 
is demonstrated in the fibroblast rich lamina propria, with a smaller increase in the epithelial 
layer.  Quantitatively, there is an increase in staining highlighted by the increased signal from 
CRSsNP samples in agreement with the qRT-PCR PNEC and PNF replication data (Figure 84). 
 
Figure 85. Fluorescent immunohistochemical staining of CRSsNP and control tissue sections.  
Tissues have been stained with anti NFE2L3 primary antibody and TRITC conjugated 
secondary antibody (red).  Sections have been counterstained with DAPI nuclear staining 
(blue). (a) no primary control section (b) healthy control sample (c) CRS tissue sample.  
Magnification x40. 
5.4.4 RNA sequencing data 
Sequencing data was available for all of the cellular and tissue samples, however data for 
three of the tissue biopsy samples did not have sufficient read counts to be reliably used for 
differential expression testing.  Two CRSsNP tissue samples and one control tissue sample 
therefore had to be excluded, leaving 3 CRSsNP versus 4 healthy control tissue samples and 
5 CRSsNP versus 5 control epithelial and fibroblast cell samples.  A principal components 
analysis was first performed on all the RNA sequencing data and shows samples are 
principally separated dependent on their tissue or cell of origin (Figure 86).  The primary 
nasal epithelial cells are tightly clustered together and do not appear to show any 
segregation between CRSsNP and control samples.  The most separation between CRSsNP 
and control samples is seen in tissue biopsies, with primary nasal fibroblast samples showing 
some differentiation in CRSsNP and control samples.  Figure 87 presents the Euclidean 
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distance metrics for each of the samples in a heat map where the three distinct clusters of 
tissue biopsies, epithelial cells and fibroblasts can be seen.  The greatest differential 
expression can be seen within the tissue biopsy cluster. 
5.4.4.1   RNA sequencing differential gene expression analysis 
Differential expression analysis was performed using the DESeq2 package within 
Bioconductor as per (Love et al., 2014).  When CRSsNP tissue biopsies were compared to 
control tissue biopsies 239 genes were found to be significantly differentially expressed 
following multiple hypothesis testing correction.  An example of the most differentially 
expressed genes is presented in Table 17, with the complete list included in the appendix.  
Figure 88 presents the differentially expressed genes in an MA plot; where the log ratios of 
the gene measurements are called ‘M’ values represented on the vertical axis.  The mean 
average values of the measurements are called ‘A’ values and are represented on the 
horizontal axis.  Each point represents a single gene and those coloured red are significantly 
differentially expressed between CRSsNP and controls following multiple hypothesis testing 
correction. 
Using the fibroblast samples, 60 genes were found to be differentially expressed between 
CRSsNP and control samples as shown in Figure 89.  The most differentially expressed 
samples are listed in Table 18, with details of the complete list again presented in the 
appendix.  Similar to the microarray data, no genes were found to be significantly 
differentially expressed between CRSsNP and control primary nasal epithelial cells.  
5.4.4.1.1 Comparison of matched cellular and tissue samples 
Differential gene expression was also used to examine how similar or representative primary 
epithelial and fibroblast cells were of their matched parent tissue biopsies in both CRSsNP 
and health.  Figure 91 to Figure 94 present comparisons of CRSsNP and control tissue 
biopsies with matched isolated epithelial and fibroblast cells and show substantial 
differences in terms of differentially expressed genes (n=15,685-20,350). 
 
 176 
 
Figure 86.  Principal components analysis of primary nasal epithelial cell (PNEC), primary 
nasal fibroblast (PNF) and tissue biopsy (T) samples from both CRSsNP and healthy control 
cohorts.  The samples are principally separated dependent on their tissue or cell of origin, 
with some separation between CRSsNP and control tissue and PNF samples.   
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Figure 87.  Heat map representation of Euclidian distance data from primary nasal epithelial 
cell (PNEC), primary nasal fibroblast (PNF) and tissue biopsy (T) samples from both CRSsNP 
and healthy control cohorts.   
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Figure 88.  MA plot of RNA sequencing data comparing CRSsNP and control tissue biopsy 
samples.  The log ratios of the two measurements are called ‘M’ values represented on the 
vertical axis.  The mean average values of the measurements are called ‘A’ values and are 
represented on the horizontal axis.  Each point represents a single gene and those coloured 
red (n=239) are significantly differentially expressed between CRSsNP and controls following 
multiple hypothesis testing correction.  
Entrez Gene 
ID 
Associated 
Gene 
Name 
log2FoldChange p value Adjusted p 
value 
Chromosome 
NA IGLV3-1 5.015314 1.79E-06 0.003837 22 
931 MS4A1 4.699899 1.64E-08 0.000194 11 
93432 MGAM2 4.326691 0.000574 0.078833 7 
168620 BHLHA15 4.129225 4.91E-05 0.018631 7 
NA LINC00519 4.077802 0.000666 0.081632 14 
643 CXCR5 4.03579 4.75E-07 0.002074 11 
10563 CXCL13 4.020391 0.000385 0.063174 4 
Table 17.  Examples of the most significantly differentially expressed genes between CRSsNP 
and control tissue samples.  A complete list of differentially expressed genes has been 
included in the appendix. 
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Figure 89.  MA plot of RNA sequencing data comparing CRSsNP and control primary nasal 
fibroblast samples.  Each point represents a single gene and those coloured red (n=60) are 
significantly differentially expressed between CRSsNP and controls following multiple 
hypothesis testing correction.  
Entrez Gene 
ID 
Associated 
Gene 
Name 
log2FoldChange P value Adjusted  
p value 
Chromosome  
4316 MMP7 5.748825437 8.63E-06 0.0204119 11 
1439 CSF2RB 4.585301446 1.40E-07 0.0016593 22 
221476 PI16 4.464623102 6.19E-05 0.0511442 6 
4360 MRC1 4.050052797 1.25E-05 0.0229034 10 
56253 CRTAM 3.958263575 3.37E-05 0.0437037 11 
3553 IL1B 3.946288056 8.95E-05 0.0618933 2 
6289 SAA2 3.831654757 0.0001186 0.0669485 11 
Table 18.  Examples of the most significantly differentially expressed genes between CRSsNP 
and control fibroblast samples.  A complete list of differentially expressed genes has been 
included in the appendix.  
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Figure 90.  MA plot of RNA sequencing data comparing CRSsNP and control primary nasal 
epithelial cell samples.  Each point on the graph represents a single gene.  In this figure no 
points are coloured red as no significantly differentially expressed genes were identified 
between CRSsNP and controls following multiple hypothesis testing correction. 
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Figure 91.  MA plot of RNA sequencing data comparing control tissue samples with their 
isolated primary nasal epithelial cell samples.  Each point represents a single gene and those 
coloured red are significantly differentially expressed between control tissues and control 
epithelial cells following multiple hypothesis testing correction (n=18,223). 
 
Figure 92.  MA plot of RNA sequencing data comparing control tissue samples with their 
isolated primary nasal fibroblast samples.  Each point represents a single gene and those 
coloured red are significantly differentially expressed between control tissues and control 
fibroblast cells following multiple hypothesis testing correction (n=20,350). 
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Figure 93.  MA plot of RNA sequencing data comparing CRSsNP tissue samples with their 
isolated primary nasal epithelial cell samples.  Each point represents a single gene and those 
coloured red are significantly differentially expressed between control tissues and control 
epithelial cells following multiple hypothesis testing correction (n=15,685). 
 
Figure 94.  MA plot of RNA sequencing data comparing CRSsNP tissue samples with their 
isolated primary nasal fibroblast samples.  Each point represents a single gene and those 
coloured red are significantly differentially expressed between control tissues and control 
epithelial cells following multiple hypothesis testing correction (n=15,952).   
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5.4.4.2 RNA sequencing pathway analysis 
Differential gene expression data was available for tissue biopsy and primary nasal fibroblast 
samples allowing subsequent pathway analysis to be performed.  CRSsNP tissue samples 
demonstrated 239 and fibroblast samples 60 differentially expressed genes compared to 
their respective healthy control samples.  The differential expression ratios and adjusted p 
value from multiple hypothesis testing correction were entered into Ingenuity Pathway 
Analysis with standardised cut off thresholds (p<0.05 & fold change >2x) and returned 
pathway data consisting of:  
1. The most significant canonical pathways 
2. Associated diseases and biological functions 
3. Molecular and cellular functions 
4. Physiological System Development and Function 
Results for tissue samples and primary nasal fibroblasts are presented in Table 19 and Table 
20 respectively.  Within tissue biopsy samples the majority of pathways map to 
inflammatory and immune system functions, whereas isolated fibroblast cell samples appear 
related to oncological processes. 
The top five most significant pathways are presented in Table 19 and Table 20. Networks 
demonstrating the inter-relationships of the canonical pathways in tissue biopsy and 
fibroblast samples are presented in Figure 95 and Figure 96).  The representative figure for 
tissue biopsies (Figure 95) shows one main network of 19 inter-related inflammatory and 
immune pathways and one smaller network of 3 amino acid degradation pathways.  The 
comparative figure for primary nasal fibroblasts consists of three smaller pathways (Figure 
96), the largest of which contains 11 inter-related pathways with the most significant results 
mapped to bladder and ovarian cancer signalling.  An additional network of 8 related 
pathways is identified principally for polysaccharide biosynthesis and a smaller network of 4 
pathways regarding antigen presentation and macrophage migration inhibitory factor (MIF) 
immune regulation roles. 
 
 
    
 184 
Top Canonical Pathways 
Altered T Cell and B Cell Signalling in Rheumatoid Arthritis 
Systemic Lupus Erythematosus Signalling 
T Cell Receptor Signalling 
Tumoricidal Function of Hepatic Natural Killer Cells 
Communication between Innate and Adaptive Immune Cells 
 
Top Diseases and Biological Functions 
Inflammatory Response 
Cancer 
Haematological Disease 
Immunological Disease 
Organismal Injury and Abnormalities 
 
Molecular and Cellular Functions 
Cellular Development 
Cellular Growth and Proliferation 
Cell-To-Cell Signalling and Interaction 
Cell Death and Survival 
Cell Morphology 
 
Physiological System Development and Function 
Haematological System Development and Function 
Lymphoid Tissue Structure and Development 
Immune Cell Trafficking 
Humoral Immune Response 
Tissue Morphology 
Table 19.  Summary pathway analysis tables of differentially expressed CRSsNP tissue 
samples based on Ingenuity Pathway Analysis.  The top 5 canonical pathways, associated 
diseases and biological functions, molecular functions and physiological system functions are 
presented. 
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Figure 95.  Top networks identified with Ingenuity pathway analysis demonstrating inter-
related canonical pathways from CRSsNP tissue samples versus healthy controls.  The 
strongest red colour is associated with the most significantly associated pathways. 
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Top Canonical Pathways 
Bladder Cancer Signalling 
Ovarian Cancer Signalling 
Antigen Presentation 
Axonal Guidance Signalling 
HIF1α Signalling 
 
Top Diseases and Biological Functions 
Cancer 
Organismal Injury and Abnormalities 
Reproductive System Disease 
Endocrine System Disorders 
Gastrointestinal Disease 
 
Molecular and Cellular Functions 
Cellular Function and Maintenance 
Cellular Movement 
Cellular Growth and Proliferation 
Cellular Development 
Cell Morphology 
 
Physiological System Development and Function 
Haematological System Development and Function 
Behaviour 
Tissue Development 
Reproductive System Development and Function 
Embryonic Development 
Table 20.  Summary pathway analysis tables of differentially expressed CRSsNP primary nasal 
fibroblast samples based on Ingenuity Pathway Analysis.  The top 5 canonical pathways, 
associated diseases and biological functions, molecular functions and physiological system 
functions are presented. 
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Figure 96.  Top networks identified with Ingenuity pathway analysis demonstrating inter-
related canonical pathways from CRSsNP primary nasal fibroblast samples versus healthy 
controls.  The strongest red colour is associated with the most significantly associated 
pathways. 
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5.5 Discussion 
5.5.1 Microarray of epithelial and fibroblast cells 
Using the cohorts of carefully phenotyped CRSsNP patients and healthy control isolated cells 
from chapter 3, a genome wide microarray has been performed to look for differentially 
expressed CRSsNP genes as candidates for CRSsNP mechanistic studies.  Bioinformatics 
analysis of the microarray data has shown that the transcription factor NFE2L3 was 
significantly upregulated in component fibroblast cells from CRSsNP patients compared with 
healthy controls.  Somewhat surprisingly there was no significant difference in gene 
expression between CRSsNP & control epithelial cells (Figure 76 & Figure 77).  Quantitative 
real time RT-PCR replication with a series of candidate genes has replicated and confirmed 
the findings of the microarray analysis (Figure 83 - Figure 85).  Immunohistochemical staining 
of tissue biopsies for NFE2L3 protein further corroborated the micro array and RT-PCR 
findings. 
Nuclear factor erythroid-derived 2-like 3 (NFE2L3) belongs to the evolutionarily conserved 
Cap’n’Collar (CNC) protein subgroup of basic region-leucine transcription factors (Sykiotis 
and Bohmann, 2010).  It contains a 43 amino acid CNC domain specific to its DNA binding 
activity (Toki et al., 1997).  Cap’n’Collar transcription factors also contain a basic region 
leucine zipper motif (bZIP),enhancing DNA binding activity, and a leucine zipper motif for 
dimerization (Landschulz et al., 1988).  Cap’n’Collar transcription factors are obligate 
heterodimers functionally by forming complexes with jun proteins (Venugopal and Jaiswal, 
1998) and small musculoaponeurotic fibrosarcoma (Maf) proteins (Kobayashi et al., 1999, 
Itoh et al., 1995).  NFE2L3 expression has been investigated in a range of tissues, with the 
highest levels found in placental chorionic villi in the second and third trimester. Expression 
is also present in heart, lung, brain, kidney, pancreas, thymus, colon, spleen tissues and 
leukocytes (Kobayashi et al., 1999).  Biochemical, fractionation and immunofluorescence 
studies have identified three differentially migrating forms of NFE2L3; a slow A form found in 
the endoplasmic reticulum, an intermediate B form mainly found in the cytoplasm and fast C 
form mainly associated in the nucleus (Nouhi et al., 2007).  A hypothetical model has been 
proposed for the differentially migrating forms of NFE2L3 by Chevillard & Blank (2011) and is 
shown in Figure 97.  In summary, transcription of the NFE2L3 gene is dependent on a 
stimulus, such as tissue necrosis factor (TNF).  NFE2L3 mRNA in the nucleus is then 
translated into the B form of NFE2L3 in the cytosol.  The B form can then translocate to the 
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endoplasmic reticulum and following N-glycosylation becomes the A form of NFE2L3.  The A 
and B forms are converted into the active C form following cleavage at the N-terminal end 
which dimerise with Maf proteins to activate transcription at antioxidant response, stress 
response element and electrophile response element DNA binding sites.  The A, B and C 
forms are then proposed to be degraded through the conventional ubiquitin-proteasome 
pathway. 
 
 
Figure 97.  Hypothetical model of NFE2L3 regulation.   Adapted from (Chevillard and Blank, 
2011). 
 
Attempts have been made to study the physiological role of NFE2L3 in mouse knockout 
models.  Results from two independently generated NFE2L3 knockout models have 
produced mice that have been shown to grow normally, with no difference in development, 
blood chemistry, or haematological parameters (Derjuga et al., 2004, Kobayashi et al., 2004). 
The knock out mice are, however, more susceptible to inflammation (Witschi et al., 1989, 
Chevillard et al., 2010) and carcinogenesis (Chevillard et al., 2011, Willenbrock et al., 2006, 
Rhee et al., 2008).  NFE2L3 knockout mice are more susceptible to tobacco smoke 
carcinogen induced lymphomagenesis (Chevillard et al., 2011), from which the authors 
suggest a potential role of NFE2L3 in T-cell regulation. 
There is established evidence for a role of NFE2L3 in inflammation both in vitro and in vivo 
and via human genome wide association studies.  NFE2L3 is a member of a family of genes 
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that act as negative regulators of a collection of defensive genes in response to oxidative 
stress (Sankaranarayanan and Jaiswal, 2004, Jaiswal, 2004, Jaiswal, 2000).  Both NFE2L3 
protein and mRNA are upregulated in tissue culture by tumour necrosis factor and 
interferon-γ (Chenais et al., 2005, Kitaya et al., 2007), which are key Th1 cytokines in the 
pathophysiology of CRSsNP (Van Crombruggen et al., 2011).  NFE2L3 has been shown to be 
an important factor in murine models of oxidative lung injury (Chevillard et al., 2010, Paola 
and Cuzzocrea, 2007).  Genome wide association studies have also identified NFE2L3 being 
associated with the chronic inflammatory gynaecological condition endometriosis (Painter et 
al., 2011), obesity and diabetes (Heid et al., 2010).  Given the roles discussed it is therefore 
plausible that the transcription factor NFE2L3 may have a part to play in the complex chronic 
inflammation seen within the sinonasal cavity, though for this to be determined further 
work is required. 
In spite of the finding of upregulated NFE2L3 within sinonasal fibroblasts it is perhaps 
surprising that more differentially expressed genes were not identified between CRSsNP 
patients and healthy controls from primary cultures of their sinonasal epithelial and 
fibroblast cells.  Although the multiple hypothesis testing correction is strict, over 47,000 
different human probes were successfully screened for each sample.  The answer to this may 
lie in the patient selection, however as illustrated by the clinical, radiological and histological 
data in chapter 3 all patients were carefully phenotyped for CRSsNP.  The lack of 
differentially expressed genes may also be related to the fact that the cells studied were in 
fact quiescent cells grown in sterile tissue culture conditions, removed from the body and 
the complex environmental stimuli of the sinonasal cavity.  All cells were grown in tissue 
culture conditions, a sterile environment together with growth factors and antibiotics, to aid 
the successful proliferation of the primary human sinonasal cell lines established.  Both cell 
types used early passage cells of either P0 for epithelial cells and P1 for fibroblast cells rather 
than those that have undergone multiple cell divisions and trypsinisations in culture (Hughes 
et al., 2007, Almeida et al., 2016).  Within the cell culture, however, the presence of growth 
factors and antibiotics may have two fold effects.  Firstly, the sterile media with 
supplemental antibiotics removes the normal microenvironment of the sinonasal cavity, be 
it planktonic bacteria (Lee and Lane, 2011), viral (Hox et al., 2015) or biofilm (Foreman et al., 
2012, Aurora et al., 2013, Boase et al., 2013a) microbial stimulation.  Secondly the growth 
medium supplements to promote successful proliferation of primary cells in culture may 
provide supra-physiological stimulus for growth and cellular activity that over rides any 
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difference in gene expression between the healthy control and CRSsNP cells.  It is also worth 
commenting that a lack of major differences at the gene and RNA level does not always 
equate to a lack of difference at the functional level of the gene product i.e. the proteins 
translated from the individual genes and RNAs.  
Microarray technology has been used only relatively recently to study CRS, popularised in 
part following the suggestions of van Drunen et al. (2008).  The majority of published CRS 
microarray data has been derived from CRSwNP patient tissue biopsy samples.  One of the 
earliest published reports of microarrays in CRS used tissue biopsy samples from two 
patients with non-eosinophilic CRSwNP and two healthy controls (Payne et al., 2008).  From 
their small sample, 120 differentially expressed genes were identified using the same 
parameters as my microarray analysis with an absolute fold change cut off >1.5 and p<0.05, 
though no mention of multiple hypothesis testing correction methodology was made.  Of the 
120 differentially expressed genes, 58 were up-regulated and 62 down-regulated, with the 
largest clusters of genes upregulated concerned with Gene Ontology biological process 
categories of cell communication, and cell growth/maintenance.  Payne et al. also identified 
that a number of genes traditionally associated with CRS showed trends of differential 
expression, but did not reach statistical significance.  The same authors also identified 
upregulation of genes associated with fibrosis and fibroblast migration such as Tenascin-C, a 
pro-inflammatory extracellular matrix glycoprotein, and stem cell factor.  The main limitation 
of this early report is the small sample size of 2 per group, which is important in a disease 
with the heterogeneity of CRS.  The small sample size was probably in part due to financial 
constraints since the cost of microarrays was significantly higher at the time Payne’s initial 
exploratory study was carried out. 
Subsequently Frączek et al. (2013) published a microarray analysis of 15 cases of CRSwNP 
and 8 control samples.  The microarray technology used in this report was a focused array to 
investigate a panel of 14,500 genes with 580 genes related to the NF-κB transcription factor.  
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of 
transcription factors involved in regulating many normal physiological processes including 
immune and inflammatory responses, growth and development.  Differential expression 
analysis between the CRSwNP and control groups identified 25 genes with >2 fold 
upregulation and 19 genes with decreased expression, although again no mention was made 
regarding the methodology of multiple hypothesis testing correction.  In agreement with 
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Payne et al., Tenascin-C was found to be upregulated in CRSwNP samples - along with a list 
of genes without any clear functional relationship, with the exception of 4 chemokines.  No 
functional analysis of the differentially regulated genes was performed such as Gene 
Ontology biological processes (GO BP), KEGG pathway (Kyoto Encyclopaedia of Genes and 
Genomes) or wikipathways to explain or hypothesise the consequences of altered 
expression. 
Linke et al. (2013) investigated inferior turbinate and nasal polyp tissue samples from 6 
CRSwNP patients using Agilent human genome 44K DNA microarrays to analyse over 43,000 
human genes.  The DNA microarray was used with the principal aim of evaluating 
quantitative differences in STAT3 (signal transducer and activator of transcription 3) mRNA 
between the nasal polyps and inferior turbinates as internal controls.  STAT3 was chosen as a 
phosphokinase with key roles in cell cycle signalling regulation and is responsive to 
numerous cytokines and ligands.  No comparison with external healthy control tissue was 
made, however.  Microarray data was appropriately analysed using the Rosetta Revolver 
gene differential expression analysis (Weng et al., 2006).  The authors reported no 
quantitative difference in amounts of STAT3 mRNA between turbinate and polyp from 
matched participants, with a mean fold change of 0.99 (SD 0.23).  Unfortunately no mention 
was made regarding the remainder of the human genome data measured by the 
microarrays. 
In another early CRS microarray study, Orlandi et al (2007) analysed nasal polyp tissue biopsy 
samples from four patients with allergic fungal sinusitis (defined by - nasal polyposis, 
eosinophilic mucin, histological or culture based detection of fungus and immunological 
evidence of type I hypersensitivity) and three patients with eosinophilic mucin rhinosinusitis 
(defined by - nasal polyposis, eosinophilic mucin and absence of fungus).  Microarray 
analysis was performed using glass based arrays with 6912 specific gene probes.  The nasal 
polyp tissue samples were compared to universal human reference RNA, a commercial 
product consisting of a mix of 14 cell lines from different human tissues – rather than 
healthy control nasal tissue.  From data within chapter 3 it has been shown that there is only 
one commercially available nasal cell line which has limited resemblance to primary human 
cells (Ball et al., 2015), so perhaps the choice of universal reference RNA as a control may 
not be appropriate. 
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More recently Liu et al (2015) compared nasal polyp tissue biopsies from 30 CRSwNP 
patients and tissue biopsies from 16 healthy control patients having a septoplasty procedure 
due to a bent nasal septum (partition) between the two nostrils.  The authors used a 
SuperArray Bioscience extracellular matrix and adhesion molecule microarray with 
differential expression levels between polyp tissue and control tissue cut off set at two fold 
change and p<0.05.  Following careful reading of the supplementary online technical details 
however, only tissue biopsies from 2 CRSwNP patients and 2 controls were subject to 
microarray analysis.  A total of 27 differentially expressed genes were identified, with 19 
being upregulated and 8 downregulated.  Their most significant finding reported was the 
upregulation of osteopontin, known also as T lymphocyte activation 1.  Osteopontin was 
discovered in bone as a matrix protein (Cantor and Shinohara, 2009) and has also been 
identified in most immune cells (Shinohara et al., 2006) with numerous roles in the 
pathogenesis of inflammatory, immune and fibrotic processes.  Osteopontin is involved in 
both Th1 and Th2 pro inflammatory mechanisms (Cho et al., 2009, Konno et al., 2011) and as 
a result monoclonal blocking antibodies have been developed in an attempt 
pharmacologically to modify pathological inflammation.  The safety, pharmacokinetic and 
pharmacodynamic data of osteopontin inhibitors was first shown in a cohort of patients with 
rheumatoid arthritis (Boumans et al., 2012), though it failed to demonstrate significant 
clinical improvements in arthritis patients.  Osteopontin inhibitors have subsequently 
received attention in the respiratory literature (Gela et al., 2016) and may represent possible 
future candidates for therapeutic trials in sinonasal and lower respiratory tract disease. 
The published literature harnessing microarray experiments in CRS has thus far typically 
used RNA generated from nasal polyp tissue biopsy samples.  The results presented in this 
chapter are to the best of my knowledge the first study to utilise microarrays to compare the 
component nasal epithelial and fibroblast cells in CRSsNP and health.  The aim of 
investigating the isolated patient derived epithelial and fibroblast cells was two-fold; firstly 
to separate the epithelial and fibroblast cells from the recruited immune cells in CRSsNP and 
secondly to identify clusters of differentially expressed genes that could be used in 
subsequent future cellular CRS mechanistic studies.  Reflecting on the results of the 
microarray data I have generated it appears that primary patient derived epithelial and 
fibroblast CRSsNP cells have not shown major differences when compared to healthy 
controls.  This was an unexpected result and prompted a more in depth next generation RNA 
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sequencing experiment to compare the whole transcriptome between matched tissue, 
epithelial and fibroblast cells from both CRSsNP and healthy controls. 
5.5.2 RNA sequencing of matched biopsy and cellular samples 
To investigate the low number of differentially expressed primary nasal epithelial and 
fibroblast gene targets identified by microarray, a next generation RNA sequencing 
transcriptome analysis of the parent tissue biopsies and their matched epithelial and 
fibroblast cells was performed.  RNA sequencing, unlike microarrays is not limited by the 
number of pre-determined probes on an array but instead reads the sequence of RNA 
present in the samples and maps this to a reference genome.  As a result the number of 
genes that can be measured is significantly greater and similarly the dynamic range of 
expression levels for which genes can be measured is much larger than microarrays.  
Moreover, RNA sequencing has been proven to be highly accurate and reproducible 
compared with quantitative RT-PCR (Nagalakshmi et al., 2008, Mortazavi et al., 2008, 
Cloonan et al., 2008).  Such an analysis generates vast amounts of data requiring extensive 
analysis which will extend beyond the completion of this thesis.  No studies using RNA 
sequencing have thus far been performed in the published sinonasal literature.  The primary 
RNA sequencing analysis has shown some interesting observations between CRSsNP and 
control samples.  Firstly, in agreement with the microarray and qRT-PCR analysis, no 
significantly differentially expressed genes have been identified between CRSsNP and control 
primary nasal epithelial cells.  Consistent findings across two different transcriptomics 
platforms suggest that there is no difference to be found in the transcriptome of my CRSsNP 
and control primary nasal epithelial cells.  In comparison, 239 genes have been found to be 
significantly differentially expressed between CRSsNP and control tissue biopsy samples 
(Figure 88).  Such variation between epithelial cells and their matched parent tissue biopsies 
suggests that a difference between CRSsNP and health is not reflected in the primary 
cultures of epithelial cells.  To investigate further how closely patient derived primary nasal 
cells match their parent tissues a direct comparison was made between primary nasal 
epithelial cells and their matched parent tissue biopsies.  The initial MA plot analyses show 
extensive numbers (n=15,685-20,350) of significantly differentially expressed genes in both 
CRSsNP and control tissues with their respective primary epithelial cells (Figure 91 and 
Figure 93).  The combination of findings presented from the microarray and RNA sequencing 
data in this chapter suggests that in this cohort of patients, isolated primary nasal epithelial 
cells are not representative of their matched tissue biopsies for studying CRSsNP.  Efforts 
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were made to carefully phenotype and culture primary nasal epithelial cells, for example 
using only early cultures at P0 without trypsinisations or splitting of cells.  However, it 
appears that in spite of this phenotyping the pathological features of CRSsNP visible in the 
histological sections in chapter 3 are not reflected in differences in gene expression of 
isolated epithelial cells.  Epithelial cells were grown in submerged culture on laboratory 
plastic ware with epithelial growth supplements as is standard in laboratory tissue culture.  
The combination of these factors may well underlie such a loss of differentiation between 
CRSsNP and health.      
In addition to looking at differential expression of genes between CRSsNP and healthy 
controls it is possible to use the extensive established data available on biological functions 
to perform functional pathway analysis.  Although a list of up or down regulated genes 
provides very detailed information of molecular changes in the transcriptome it can be 
difficult to make functional sense of all the RNA changes.  Furthermore, most genes typically 
have many different context-dependent functions and act very differently in isolation 
compared to within biological pathways and organisms (Werner, 2008).  As a result powerful 
bioinformatics methods have been developed to resolve lists of differentially expressed 
genes into functionally relevant information.  A schematic illustration of such methods is 
presented in Figure 98.  
 
 
Figure 98.  Schematic of how differential expression data from RNA sequencing and 
microarrays can be used to compile pathways and regulatory networks based on known 
biological information.  Image adapted from (Werner, 2008) and (Goodwin et al., 2016). 
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For the RNA sequencing presented in this chapter I have used the software package 
Ingenuity Pathway Analysis as per Kramer et al. (2014).  Ingenuity pathway analysis is a web 
based software package for analysing RNA sequencing data that utilises the vast amount of 
publically available biological knowledge on genes, proteins, diseases and drugs.  In addition 
to this publically available information such as the Gene Ontology (GO) and KEGG (Kyoto 
Encyclopaedia of Genes and Genomes) databases, Ingenuity pathway analysis is also 
continuously updated from published literature by a dedicated team of research scientists.  
One of the drawbacks of using an alternate database such as KEGG or GOstats is related to 
how current the biological information is.  KEGG became a subscription predominant service 
from 2011 following a change in its funding structure.  As a result the last free release data 
which supplies many packages including GO stats is approximately five years out of date.     
Ingenuity pathway analysis has the additional advantage that it is not a command line code 
based package, but instead uses a windows interface.  This makes it much more user 
friendly, for example than the code written to analyse the microarray data (see appendix). 
The use of Ingenuity pathway analysis on my sequencing data has identified a series of 
functional pathways and networks for both CRSsNP tissue biopsies and primary nasal 
fibroblasts.  Within tissue biopsies the most significant associations are seen in inflammatory 
and immune functions (Table 19 and Figure 95), similar to the multiplex MSD 
electrochemiluminescence disease micro-environment findings from chapter 4 and 
immunohistochemical images in chapter 3.  Primary nasal fibroblast samples also generated 
functional pathways based on their differential expression, although the pathways identified 
differed significantly from those generated for tissue biopsy samples (Table 20 and Figure 
96), with the top two canonical pathways identified as bladder and ovarian cancer signalling.  
Such a difference in the pathways observed, together with the extensive numbers of 
significantly differentially expressed genes between tissue biopsy samples and their matched 
fibroblasts implies that my cohort of primary nasal fibroblasts may not be the optimum 
model with which to study CRSsNP.  
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5.6 Conclusion 
In conclusion, within this chapter two separate transcriptomics approaches have been 
utilised in microarrays and RNA sequencing to analyse CRSsNP samples.   
 Neither microarrays nor RNA sequencing showed any significant differences between CRSsNP 
and healthy control primary nasal epithelial cells, therefore it is recommended they should 
not be utilised in further work to model CRSsNP.   
 Primary nasal fibroblasts show some significant differences between CRSsNP and healthy 
controls although these changes do not appear reflective of those seen in their matched 
tissue biopsies and their further use to model CRSsNP in their current state is at least 
questionable.   
 Tissue biopsies, when compared with RNA sequencing show the most significant changes 
between CRSsNP and health.  Furthermore, functional pathway analysis shows alteration of 
predominantly immune and inflammatory pathways consistent with the histological data and 
disease microenvironment data obtained within this thesis.  My further work should and will 
be directed principally by these tissue biopsy samples and will utilise the additional potential 
of the RNA sequencing data to obtain the maximal information from this novel resource for 
CRSsNP pathophysiology.    
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6 Thesis summary 
A detailed discussion of the results presented in this thesis has so far been included within 
chapters 3, 4 and 5.  In this section I shall provide a brief summary of the major findings and 
conclusions from my thesis and outline my plans for future work. 
Chronic rhinosinusitis (CRS) continues to pose a therapeutic challenge for patients and 
clinicians alike.  Our current therapeutic options mean that many patients require surgery 
when pharmacological treatment fails; however, the relatively high post-surgical recurrence 
rate further underlines the inadequacy of medical treatments - since CRS remains principally 
a medical rather than a surgical disease.  A more in depth understanding of CRS 
pathophysiology will ultimately lead to better treatments.  In an effort to address this 
knowledge gap I prospectively recruited a carefully phenotyped cohort of CRS patients 
without nasal polyps and healthy control participants with their associated clinical symptom 
scores.  My cohorts were subject to a detailed histological assessment of sinonasal tissue 
biopsy sections using tinctorial stains, immunohistochemistry and electron microscopy to 
investigate their disease status.  I analysed the microbiological environment of the 
participants’ sinonasal cavities with conventional microbiological culture and a microbiome 
approach.  Additionally, I developed a novel non-invasive measure of the sinonasal 
inflammatory microenvironment.  By using a standardised 210mm2 piece of clinical grade 
hydrophilic filter paper strip, a mucosal lining fluid sample, has helped obtain information on 
the inflammatory environment of the nasal mucosa.  Placed alongside the sinonasal mucosa 
it has been used to collect mucosal lining fluid i.e. mucus in continuity with the epithelial 
mucosa.  Characterising this fluid using a panel of human proteins and cytokines, a group of 
13 mediators has been shown to discriminate between control and CRS without nasal polyp 
participants.  Such an assay would be valuable in the clinic, improving on our current 
symptom and endoscopic based assessment.  This mucosal lining fluid strip has the potential 
to give a measure of the ‘inflammatory score’ of CRS, both as a diagnostic aid and as a 
means of monitoring disease activity.  Additionally, further mucosal lining strip analysis may 
lead to the development of biomarkers to help stratify patient’s therapeutic interventions. 
My mucosal lining fluid assay is very much in its infancy, however, and I have identified in 
this thesis a number of important limitations when it is applied in a heterogeneous condition 
such as CRS.  For this reason, much of the previous work has focussed on CRS with nasal 
polyposis – but my intention was to tackle the more diverse and even less well understood 
 199 
non polypoid chronic sinusitis.  Only once I have had the opportunity to control for key 
demographic variables (notably age, gender, cigarette smoking) in both normal and diseased 
individuals will I be in a position to attempt to stratify different inflammatory subtypes of 
CRS without nasal polyps.  
Despite the constraints of the sample size feasible within a PhD timescale, my results have 
shown some significant differences in CRS without nasal polyposis in terms of upregulated 
mucosal chemokines and cytokines, notably MIP-1 alpha, MIP-1beta, MCP-4, TARC, eotaxin 
3, IL-6, IL-10 and IL-17.  Correlating these discriminant mediators with symptom scores of 
rhinological disease severity suggests that MIP-1 alpha and MIP-1 beta appear the most 
promising candidates for CRS disease severity – which can be the initial focus of my future 
investigations.  These studies are very timely, given the increasing emergence of targeted 
biological therapies in inflammatory conditions of the airways. 
In short, the potential of such a measure to help look after patients with sinonasal disease 
clearly merits further exploration.  I intend to seek funding for a more detailed longitudinal 
study investigating mucosal lining fluid measurements in a much larger cohort of CRS with 
and without nasal polyp patients and controls.  I propose to take measurements 
longitudinally from diagnosis through disease flare ups, in response to medical treatment, 
surgical procedures and at different times of the day to investigate the intra individual 
variability of mucosal lining fluid scores.  Such a study will also need careful assessment of 
the whole respiratory tract including for the presence of respiratory diseases such as asthma 
and related conditions.  The possible use of nasal and respiratory nitric oxide measurements 
could also be incorporated to complement the mucosal lining fluid measurement.  
Throughout the thesis I have sought to compare findings in vivo with those in my respective 
study tissue biopsies and isolated primary cells.  My aim was to see if primary patient-
derived epithelial and fibroblast cells could be used to model CRS disease in the laboratory.  
Furthermore, information gained from in vivo and tissue biopsy studies could serve to make 
any in vitro cellular studies more representative of the sinonasal environment in health and 
disease.  The present work has highlighted, however, some key deficiencies in my 
hypotheses.  I have discovered that primary patient-derived cells - epithelial cells especially – 
differ significantly in terms of their inflammatory profile and transcriptome.  This may be a 
reflection of how they are isolated, though I suspect it is more to do with the process of cell 
culture.  Although the cells have been very recently isolated from participants’ sinonasal 
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cavities, rather than being grown in a complex mucosal environment, they are proliferating 
on laboratory plastic ware with numerous potent primary cell media supplements. 
My short term plans therefore do not include continuing investigation with these primary 
cells.  Instead I wish to focus my attention on CRS tissue biopsies to investigate the 
upregulated inflammatory pathways identified from bioinformatics analysis of the tissue 
transcriptome data – the first report of RNA sequencing technology in the field.  In addition, I 
shall consider newer, more sophisticated tissue culture systems such as tissue slice or 3D cell 
culture, where for example a fresh tissue biopsy is sectioned very thinly with an 
ultramicrotome and bathed in a continuous supply of fresh media to mimic capillary flow.  In 
such a system all the component cells are present to more accurately model the tissue 
situation in vivo.  However, one challenge from such a system would be to isolate individual 
cell types in an effort to determine their precise functions.  Bearing this in mind, 
complimentary laser capture microdissection of tissue sections and subsequent molecular 
analysis of the dissected cells with quantitative RT-PCR or RNA sequencing data may be 
useful. 
In conclusion, the phenotyped CRS and control samples generated in this thesis have 
provided a detailed comparison of the histological, disease micro-environment and 
transcriptome of chronic rhinosinusitis without nasal polyps.  Cellular models, both 
immortalised cell lines and primary patient-derived cells do not convincingly provide 
representative models of CRS and further work should be directed towards isolated tissue 
biopsy specimens. 
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7 Appendix  
7.1 Appendix 1 – Publications, presentations and personal development 
 
7.1.1 Publications 
 Complications of rhinosinusitis. Ball SL, Carrie S. British Medical Journal. 2016 Feb 
26;352:i795.  
 The Role of the Fibroblast in Inflammatory Upper Airway Conditions. Ball SL, Mann DA, 
Wilson JA, Fisher AJ.  American Journal of Pathology. 2016 Feb;186(2):225-33. Review. 
 Thymoma complicated by deep vein thrombosis of the arm. Ball SL, Cocks HC.  
BMJ Case Rep. 2015 Dec 21;2015. pii: bcr2015213404  
 Pott's puffy tumour: a forgotten diagnosis. Ball SL, Carrie S. BMJ Case Rep. 2015 Sep 29;2015. 
pii: bcr2015211099.  
 How Reliable Are Sino-Nasal Cell Lines for Studying the Pathophysiology of Chronic 
Rhinosinusitis? Stephen Ball, Monika Suwara, Lee Borthwick, Janet Wilson, Derek Mann & 
Andrew Fisher. Annals of Otology, Rhinology & Laryngology 2015.  
 The use of phenol as a topical anaesthetic for the tympanic membrane.  Ball SL.  
Clinical Otolaryngology. 2015 Oct;40(5):506..  
 Anatomy of a swallow. Ball SL, Arullendran P. British Medical Journal. 2015 Jul 13;351:h3494.  
 Pharyngeal angiosarcoma following multimodal treatment for oropharyngeal squamous cell 
carcinoma.  Stephen Ball, Foon Ng Kee Kwong, Fergus Young & Andrew Robson. The Annals 
of the Royal College of Surgeons 2014 Mar;96(2):e5-6. 
 Complications of Bone Anchored Hearing Aids. Stephen Ball & Ian Johnson. The 
Otolaryngologist 2014;7(3)146-50. 
 Scott Brown’s Otolaryngology, Head & Neck Surgery, 8th Edition. Stephen Ball & Sean 
Carrie.  Text book chapter: Complications of Rhinosinusitis co-authored & in press. CRC press. 
 Are pro-inflammatory fibroblasts the driving force in chronic rhinosinusitis? 
Stephen L Ball, Anthony De Soyza, Andrew Fisher, Derek Mann & Janet A Wilson.  (2012) 
Clinical Otolaryngology July:37(Suppl.1):1-2.   
 
7.1.2 Prizes 
 European Rhinological Society.  Junior member travelling Fellowship, 2016  
 Royal Society of Medicine, Section of Laryngology & Rhinology: Ian Mackay Essay prize, 
2014.  Osteitis – the modern theory of sinusitis.  
 Munro-Black Research Prize. Northern Region ENT Surgery research prize, 2014. 
 Royal Society of Medicine, Section of Laryngology & Rhinology.  Annual short paper prize, 
2013. 
7.1.3 Presentations 
 European Rhinology Society 26th Congress in conjunction with the 35th International 
Symposium of Infection & Allergy of the Nose, Stockholm June 2016. 
 British Rhinological Society, Leeds May 2016 
 British Academic Conference in Otolaryngology, Liverpool 8-10th July 2015 
 British Rhinological Society, Manchester May 2015 
 European Rhinology Society 25th Congress in conjunction with the 32nd International 
Symposium of Infection & Allergy of the Nose, Amsterdam June 2014. 
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 British Rhinological Society, Norwich May 2014 
 European Respiratory Society, Lung Science Conference, Estoril March 2014. 
 British Society of Academic Otolaryngology March 2014. 
 Royal Society of Medicine, Section of Laryngology & Rhinology February 2013. 
 
7.1.4 Papers in submission/preparation 
 Transcriptome analysis of tissue biopsies, epithelial and fibroblast cells in Chronic 
rhinosinusitis. 
 Sinonasal mucosal lining fluid analysis – a ‘biosignature’ for CRS. 
 Sinonasal disease- a consequence of autonomic imbalance?  Yao A, Wilson JA & Ball SL. 
 A Review of Periorbital Cellulitis Protocols in the United Kingdom.  Okwonko A, Carrie S & Ball 
SL. 
 15 years and 100 cases of paediatric intracranial suppuration. 
 
7.1.5 Clinical trials  
I am a Principal Investigator on a £745,355 NIHR (National Institute for Health Research) 
funded phase 3 randomised controlled trial; TOPPITS (Trial Of Proton Pump Inhibitors in 
Throat Symptoms) www.toppits.co.uk. 
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7.2 Appendix 2 – R Studio code for microarray analysis 
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7.3 Appendix 3 – Mucosal lining fluid non-parametric correlations 
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7.4 Appendix 4 - Sino-Nasal Outcome Test-22 Questionnaire v4 
Below you will find a list of symptoms and social/emotional consequences of your nasal 
disorder. We would like to know more about these problems and would appreciate you 
answering the following question to the best of your ability. There are no right or wrong 
answers, and only you can provide us with this information. Please rate your problems, as 
they have been over the past two weeks. Thank you for your participation. 
 
Considering how severe the 
problem is when you experience it 
and how frequently it happens, 
please rate each item below  
No 
problem 
Very mild 
problem 
Mild or 
slight 
problem 
Moderate 
problem 
Severe 
problem 
Problem 
as bad as 
it can be 
1. Need to blow nose 0 
 
1 2 3 4 5 
2. Sneezing 0 
 
1 2 3 4 5 
3. Runny nose 0 
 
1 2 3 4 5 
4. Cough 0 
 
1 2 3 4 5 
5. Post nasal discharge (dripping at 
the back of your nose) 
0 1 2 3 4 5 
6. Thick nasal discharge 0 
 
1 2 3 4 5 
7. Ear fullness 0 
 
1 2 3 4 5 
8. Dizziness 0 
 
1 2 3 4 5 
9. Ear pain/pressure 0 
 
1 2 3 4 5 
10. Facial pain/pressure 0 
 
1 2 3 4 5 
11. Difficulty falling asleep 0 
 
1 2 3 4 5 
12. Waking up at night 0 
 
1 2 3 4 5 
13. Lack of a good night’s sleep 0 
 
1 2 3 4 5 
14. Waking up tired 0 
 
1 2 3 4 5 
15. Fatigue during the day 0 
 
1 2 3 4 5 
16. Reduced productivity 0 
 
1 2 3 4 5 
17. Reduced concentration 0 
 
1 2 3 4 5 
18. Frustrated/restless/irritable 0 
 
1 2 3 4 5 
19. Sad 0 
 
1 2 3 4 5 
20. Embarrassed 0 
 
1 2 3 4 5 
21. Sense of taste/smell 0 
 
1 2 3 4 5 
22. Blockage/congestion of nose 0 
 
1 2 3 4 5 
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7.5 Appendix 5 – Sample Patient information sheet 
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7.6 Appendix 6 – Sample participant consent form 
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7.7 Appendix 7 – Participant look up sheet 
 
 
Study identifier Patient identifier 
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7.8 Appendix 8 – Ethical approval 
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7.9 Appendix 9 – Newcastle Hospitals NHS Trust R&D Approvals 
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